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Thursday 22th May  
Time Schedule Speaker Page 
08.30 – 09.00 Congress Opening 
 Themed Session. Lower Urinary Tract Tumors  
09.00 - 09.30 Introduction by Chair Medical Oncology Deborah Knapp 14 
09.30 - 10.00 Radiotherapy of LUT Tumors Susan LaRue 22 
10.00 – 10.30 Coffee Break 
10.30 – 11.45 Surgery and Interventional Urology Lynetta Freeman & 
Deborah Knapp 
25 
11.45 - 12.00 Summary by Chair Deborah Knapp 
12.00 - 12.10 Definitive high-dose hypo-fractionated total pelvic irradiation with simultaneous 
boost in canine urinary CCT: a feasibility study and first clinical experiences    
Mario Dolera 
 
44 
12.10 - 12.20 Expression of cell cycle regulators proteins (14-3-3σ & p53), and vimentin in canine 
transitional cell carcinoma of the urinary bladder 
Alejandro Suárez-
Bonnet 
45 
12.20-12.30 Retrospective data analysis in a cohort of dogs with lower urinary tract tumours 
treated with advanced surgery 
Giorgio Romanelli 46 
12.30 - 12.45 Discussion  
12.45 – 14.00 Poster Session with invited lunch by ESVONC 
14.00 – 14.12 Transcriptomic analysis identified up-regulation of solute carrier transporters and 
UDP glucuronosyltransferases in dogs with aggressive cutaneous mast cell tumors. 
Mery Giantin 47 
14.12 - 14.24 
 
The neutrophil to lymphocyte and albumin to globulin ratios as biomarkers 
predicting the histopathological grade of canine mast cell tumours. 
Michael 
Macfarlane 
48 
14.24 – 14.36 Comparison of Ki67 and mitotic index (MI) for predicting outcome in canine mast 
cell tumours (MCT) 
James Warland 
 
49 
14.36 – 14.48 Insights into Cox-2 dependent pathways in canine mast cell tumours: a role for 
microvascularization and tumoural proliferation 
Hugo Gregório 
 
50 
14.48 – 15.00 MicroRNA profiling of archival tumour biopsies for the discovery of new 
biomarkers for canine metastatic cutaneous mast cell tumours 
Sara Verganti 
 
51 
15.00 – 15.15 The evaluation of Progression Free Survival with masitinib incorporation into first 
line and rescue treatment protocols in 147 dogs with mast cell neoplasia                     
Invited clinical abstract 
Gerry Polton 52 
15.15 - 15.27 
 
A European multicentre pilot study to evaluate the combination of toceranib, 
lomustine and prednisolone for non-resectable or recurrent canine mast cell 
tumours 
Spela Bavcar 
 
53 
15.27 – 15.39 Clinical relevance of simultaneous histopathological grading of canine cutaneous 
mast cell tumors at first presentation: a retrospective study on 386 cases 
Roberta Ferrari 54 
15.40 – 16.10 Coffee Break 
16.10 – 16.22 Radiotherapy in the treatment of 52 canine genitourinary carcinomas. preliminary 
results of a multi-institutional retrospective study 
Irina Gramer 
 
55 
16.22– 16.34 Response to toceranib in dogs with measurable, unresectable, recurrent or 
metastatic mammary carcinomas 
Francesca Gattino 
 
56 
16.34 – 16.46 Interrogating the Inflammasome in Canine Inflammatory Mammary Cancer Teresa Raposo 57 
16.46 – 16.58 The presence of the short form of ron/stk transcript is a prognostic factor of poor 
outcome in feline mammary carcinomas 
Lorella Maniscalco 
 
58 
16.58 – 17.10 Gadolinium neutron capture therapy for III stage malignant oral melanoma in 34 
dogs 
Ksenia Lisitskaya 59 
17.10 – 17.22 An open-label phase 1 dose-escalation clinical trial to determine the maximally 
tolerated dose and dose-limiting toxicities of a single intravenous gemcitabine 
administration in dogs with advanced solid tumors 
Laura Beatrice 
 
60 
17.22 - 17.34 Outcome in Dogs with Stage IIIb Anal Sac Adenocarcinoma Treated with Coarse 
Fractionated Radiation Therapy  
Valeria Meier 61 
18.00 Welcome Reception at Spanish Riding School, Sponsored by Merial  
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Friday 23rd May 
Time Schedule Speaker Page 
09.00  - 09.12 Clinical outcome, IHC features and potential treatment targets in feline histiocytic 
disorders: a retrospective, multinstitutional study  
 Elisabetta Tregliari 62 
09.12 – 09.24 Assessment of infiltrating lymphocytes in histiocytic sarcoma of the flat coated 
retriever: a comparison of different locations 
Aleksandra 
Marcinowska  
63 
09.24 – 09.36 Gene expression profiling in localized and dissiminated histiocytic sarcomas in the 
predisposed Flatcoated Retriever dog 
Kim Boerkamp  64 
09.36 – 09.48 Identification of pancreatic neuroendocrine cancer stem cells 
Winner Basic Science Award Dutch Animal Cancer Foundantion 
Laurien Feenstra 65 
09.48 – 10.03 Response of canine intranasal tumors to a COX-2 inhibitor (Meloxicam) alone, and 
in combination with hypofractionated radiation therapy   
Martin Kessler 66 
10.03 – 10.15 Hematologic abnormalities in canine diffuse large B cell lymphoma: what we have 
found in a group of 37 dogs 
Joaquim Henriques 67 
10.15 – 10.45 Coffee Break 
10.45 – 10.57 ABC-transporter expression in canine multicentric lymphoma Maurice Zandvliet  68 
10.57 – 11.09 Prognostic significance of ki67 evaluated by flow cytometry in dogs with high grade 
B-cell lymphoma 
Alessia Poggi  69 
11.09 – 11.21 P-H2AX as a marker of genomic instability in dog with lymphoma undergoing 
chemotherapy: preliminary study 
Francois Serres 70 
11.21 – 11.33 Progression Free Survival of dogs with high-grade T-cell lymphoma, treated with L-
CHOP or CCNU-L-CHOP-based protocols as first-line therapy 
Malgorzata 
Ossowska  
71 
11.33 - 11.45 Characterization of stem cell markers in canine B-cell lymphoma  Wen Liu  72 
11.45 - 12.00 Characteristics and outcome of 17 cases of canine lymphoma with aberrant 
immunophenotype                   
Invited clinical abstract 
Chiara Leo  
 
73 
12.00 – 12.30 Radiation Oncology Add-on Presentation Carla Rohrer-Bley  
12.30 – 14.30 
Lunch on your own 
EU Canine Lymphoma Network meeting during lunch 
14.30 – 15.30 Keynote Speaker. Targeted Therapy.  
Sponsored by Novartis               
Gerald Prager  40 
15.30 – 16.00 Coffee Break 
16.00 – 16.12 Concurrent T zone and B cell lymphoma in 7 dogs Paul  Avery  74 
16.12 – 16.24 Genetic heterogeneity of canine DLBCL by Oligonucleotide Array CGH Arianna Aricò 75 
16.24 – 16.36 Expression of Bcl-2 and Ki-67 in 45 feline non-Hodgkin lymphomas   Ricardo Felisberto 76 
16.36 – 16.48 Results of PEG-L-asparaginase (Oncaspar®) incorporation in a modified COP-
protocol, or added to prednisolone, for the treatment of high-grade lymphoma in 
cats 
Ada Krupa 77 
17.00 - 18.00 ESVONC Annual General Meeting 
19.00 Gala Dinner at Palais Ferstel 
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Saturday 24th May  
Time Schedule Speaker Page 
 Themed Session . Melanoma  
09.00 Introduction by Chair Susan Larue 
09.05 – 09.25 Melanoma Behaviour and Biology  David Vail 28 
09.25 – 09.45 Review of Surgery and traditional / palliative treatment Susan Larue 30 
09.45 – 10.30 New Treatment strategies: vaccine, targeted, radiotherapy, etc. David Vail & 
Susan Larue 
32 
10.30 – 11.00 Coffee Break 
11.00 – 11.30 Genetic aspects – canine melanoma as a model for Human Catherine  André 36 
11.30 – 11.50 Comparative aspects grey horse melanoma Sabine Brandt 37 
11.50 – 12.00 Summary by Chair Susan Larue 
12.00 – 12.30 Discussion 
12.30 – 14.00 Lunch on your own 
14.00 – 14.10 Krakow 2015 Presentation 
14.10 – 14.30 Summary of EU Canine Lymphoma Network meeting 
14.30 – 14.42 Canine Melanoma Treated with Autologous Dendritic Cell-Based Vaccines in 10 
dogs 
Thomas Grammel 78 
14.42 – 14.54 Advantages and limitations of different hybrid imaging methods in veterinary 
oncology with a special emphasis on staging and restaging canine melanoma 
cases.   
Lajos Balogh  79 
14.54 – 15.06 Coarse fractionated radiation therapy for the treatment of microscopic canine 
soft tissue sarcoma  
Valerie Poirier 80 
15.06 – 15.21 Canine meningioma. Comparison of palliative therapy, surgery and stereotactic 
radiosurgery    
Invited clinical abstract 
Mario Dolera 81 
15.21 - 15.33 Colloid gold nanoparticles conjunct with doxorubicin for feline injection-site 
sarcomas treatment - new preclinical oncological studies 
Katarzyna 
Zabielska 
82 
15.33 – 16.00 Coffee Break 
16.00 – 16.15 Coarse Fractionated Radiotherapy for Canine Soft Tissue Sarcoma. A 
Retrospective Study of 97 Cases Treated with 5x6Gy 
Carla Rohrer Bley  
 
83 
16.15 – 16.27 Generation and characterisation of an EGFP-HMGA2 in vitro model for canine 
prostate cancer  
Saskia Willenbrock 84 
16.27 – 16.39 Vaccination with virus-like particles induces long lasting protection from 
experimentally induced sarkoid- like tumours in horses 
Edmund Hainisch 85 
16.39 – 17.00 Targeting multiple oncogenes simultaneously improves response to therapy and 
circumvents acquired resistance to single target tyrosine kinase inhibitors 
Gurå Bergkvist  86 
17.00 Closing Ceremony 
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POSTERS Presenter Page 
Adrenal tumours with vascular invasion: stereotactic hypofractionated volume modulated arc 
radiotherapy (VMAT) in 10 dogs 
Mario Dolera 89 
Rabbits thymoma: optimisation of image-guided dynamic IMRT set up Mario Dolera 90 
Efficacy of external beam radiation comparing to gadolinium neutron capture therapy radiation for 
dogs with III stage malignant oral melanoma 
Ksenia Lisitskaya 91 
Generation and Validation of a Gene Expression Signature for Metastasis in Canine Soft Tissue 
Sarcomas 
Marlene Hauck 92 
The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic 
effects on canine cancer cell lines and cancer stem cells in vitro 
Lisa Pang  93 
Long term tolerance in dogs with selected neoplasia undergoing continuous low dose 
chemotherapy: results in 75 dogs 
Francois Serres 94 
Chromosome preparation from canine whole blood and tumor cells Florenza Lueder 
Ripoli   
95 
Is prognosis better than we thought?! - A retrospective analysis of 40 canine gingival squamous cell 
carcinomas receiving radical surgery 
Sandra Kuehnel 96 
Treatment of canine mast cell tumors with radiotherapy, toceranib, chlorambucil and prednisone Mario Dolera 97 
Molecular characterization of canine mammary tumours: the role of miRs and mRNAs as 
biomarkers in the metastatic transition 
Alexandra 
Fernandes  
98 
Efficacy and side effects of radiation therapy in comparison with radiation therapy and 
temozolomide in the treatment of canine malignant melanoma 
Laura Marconato 99 
Treatment of advanced canine MCT with Palladia® (toceranib phosphate) Aaron Harper 100 
ERBB2 oncogene DNA copy number, mRNA and protein expression studies in cat mammary 
tumours 
Claudia Baptista 101 
High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural 
inflammatory infiltrate in canine mammary tumours 
Maria Carvalho  102 
PCR for Antigen Receptor Gene Rearrangement as an Adjunct Tool in the Characterisation of IBD Sabine Essler 103 
Evaluation of COX-2 and MDR1 expressions in canine mammary gland tumours Peter Vajdovich 104 
Establishment of a molecular screening system for claudin-gene expression in canine neoplasias and 
characterisation of claudin-gene expression in canine cell lines and canine mammary tissue samples 
Susanne Hammer 105 
First patient cohort of canine nasosinal tumors treated with radiotherapy at the university of 
veterinary medicine vienna 
Miriam Kleiter 106 
Evaluation of thermography as a clinical prognostic factor in canine mast cell tumors Samanta Rios Melo 107 
Canine Diffuse Large B Cell Lymphoma. serology status for canine Herpesvirus (cHV) infection and 
survival analysis 
Joaquim Henriques 108 
Evaluation of survival time and efficacy of radiation therapy with chemotherapy for dogs with II 
stage osteosarcoma 
Ksenia Lisitskaya 109 
Second cancer incidence in patients treated with electrochemotherapy Ron Lowe 110 
Intra-operative Electrochemotherapy in Canine Mast Cell Tumor: Retrospective Study of 34 Cases Jennifer Ostrand 
Freytag 
111 
Canine Diffuse Large B cell Lymphoma- Survival analysis on 23 patients treated with CHOP 19 week 
protocol 
Joaquim Henriques 112 
Retrospective Evaluation of Canine Urinary Bladder Cancer (2009 – 2013) Julia Matera 113 
Definition of a Ki-67 threshold for canine B-cell lymphoma Catherine Ibisch 114 
Toceranib phosphate, cyclophosphamide and prednisone as a rescue protocol in canine 
multicentric lymphoma 
Juan Borrego 115 
Prospective study of toceranib phosphate (Palladia®) in feline mammary tumors Juan Borrego 116 
Cyclooxygenase-2 expression in equine cutaneous neoplasms Felisbina Queiroga 117 
Biological characterization and sensitivity to metformin of cancer stem-like cells from canine 
osteosarcoma cell lines 
Alessandra Ratto 118 
P-cadherin expression as a hallmark of malignancy in feline mammary tumours Ana Figueira 119 
Effects of toceranib phosphate on canine osteosarcoma cell lines Raquel Sánchez-
Céspedes 
120 
Apoptosis and proliferation in canine mammary tumors Maria Carvalho 121 
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Inhibition of telomerase in canine sarcoma cell lines reduces tumor cell viability Theresa Kreilmeier 122 
Evaluation of patent blue dye for sentinel lymph node identification in canine mammary tumours Catherine Ibisch 123 
Factors and transporters affecting 5-ALA PDT in tumor-bearing cats Bernadett Szabó 124 
Toceranib and COX2 inhibitor as palliative treatment or adjuvant to conservative surgery in dogs 
with oral melanoma 
Victor Domingo 125 
Hematology results of dogs with lymphoma at initial presentation Barbara Rütgen 126 
c-Kit immunoexpression pattern in melanotic and amelanotic canine oral melanomas Maria Zaidan Dagli 127 
Quality of life evaluation in cancer patients using the HHHHHMM® scale Ana Mendonça 128 
Epidemiology of canine mammary tumours: individual risk factors and similarities to human breast 
cancer 
Marta Vascellari 129 
Squamous Cell Carcinoma in Cat: Retrospective Study of 32 cases of head and neck localization Margarida Vale 130 
Electrochemotherapy in canine squamous cell carcinoma (SCC) disseminated in medial abdomen 
and pelvic limbs: Case Report 
Marcelo Monte 
Mór Rangel 
131 
Oxidative Status in Feline Malignant Mammary Tumours Ana Figueira 132 
 
 
Published only Author Page 
Clinical outcomes of different treatment combinations in canine melanoma patients in Hungary  Lajos Balogh  134 
Long term efficacy of metronomic oral therapy in a case of non-resectable sublingual SCC Ignacio Lopez 135 
Adjuvant Treatment with Toceranib Phosphate and Metronomic Chemotherapy on a Cat with 
Aggressive Mammary tumour 
C. M. Suarez 
Santana 
136 
Electrochemotherapy as alternative treatment in a lower eyelid carcinoma in a cat Carmen Iole 
Grande 
137 
Complete remission of a primary unresectable high grade hemangiosarcoma in a dog treated with 
VAC and antiangiogenic therapy 
Cristina Rizkallal 138 
Multiple hair follicular melanocytoma in a dog Alejandro Suárez-
Bonnet  
139 
Local recurrence control of a large ectopic thyroid adenocarcinoma in a dog using metronomic 
therapy alone 
E Rodriguez Grau-
Bassas 
140 
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Dear colleagues and friends, 
 
Welcome to the annual ESVONC congress being held for the first time in Vienna! 
We will, as has been the case for the past many years, have a great program with state of 
the art information from different fields of veterinary and comparative oncology. 
The main focus of the congress is, as always, to put together the recent knowledge on basic 
sciences and clinical oncology. 
As you already know, based on the remarks of last year’s questionnaire, we have decided to 
pursue with two items, that were really appreciated in the last congress in Lisbon: first, the 
themed sessions with a focus on lower urinary tract tumors on Thursday and melanoma on 
Saturday; second, there will be  invited clinical abstracts, selected by our scientific 
committee. 
 
The local committee, headed by Miriam Kleiter, has the tremendous responsibility to 
organize, along with our ESVONC team, this academic program that is top of the world as 
well as a great social program in this wonderful town! Don’t miss it! 
You know that ESVONC Annual congress is a place not only for scientific meeting but also for 
social gatherings and sharings: the venue will be at the splendid Palais Niederösterreich, the 
Welcome Reception will be in the Spanish Riding School! 
On Friday evening, we will organize our annual gala dinner in the Palais Ferstel. 
 
And I can promise you one thing: all these nice people working for this congress and these 
well organized things will contribute to make for everyone of you and us, some  
« Happy congress Days » ! 
 
ESVONC President Frederique Ponce and the ESVONC team   
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    Subway station congress venue: HERRENGASSE 
 
 
 
 
 
4 min, 350 m 
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Our Sponsors 
 
Without our sponsors it would be impossible to organise a conference like this! 
On behalf of ESVONC, the Congress Committee wishes to express sincere gratitude. 
 
To all Delegates – Please visit our sponsors and thank them personally!! 
Platinum Sponsor: Merial  
Merial is a world-leading, innovation-driven animal health company, 
providing a comprehensive range of products to enhance the health, 
well-being and performance of a wide range of animals. 
Merial employs around 6,200 people and operates in more than 150 
countries worldwide with close to €2 billion of sales in 2013. Merial is 
a Sanofi company.   
For more information, please see  www.Merial.com  
 
Gold Sponsor: Zoetis  
Zoetis, formerly a business unit of Pfizer, is a global animal health 
company, dedicated to supporting its customers and their 
businesses in ever better ways. Building on 60 years of experience, 
we have become a world leader in discovery, development, 
manufacture and             marketing of veterinary medicine and 
medicines. 
  For more information, please see www.zoetis.com  
 
Bronze Sponsor: AB Science  
AB Science is a young biotechnology company that specializes in 
developing targeted drugs for high medical need indications, such as 
cancer, chronic inflammatory diseases and neurodegenerative 
disorders. Masitinib is the most advanced drug in the AB Science 
pipeline and received the first ever anticancer license for dogs by EMA 
in 2008. It is available under the name Masivet® for Veterinary use all 
over Europe and Kinavet in the United States. 
The approval relates to non-resectable mast cell tumor grade 2 and 3. 
The  clinical study which led to the licensure was one of the largest in  
veterinary oncology with more than 200 dogs. Worldwide, more than 
15 000 dogs have been treated so far with Masivet®/Kinavet some of  
            them. For more than 5 years. 
 
            For more information, please see www.ab-science.com  
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Novartis Animal Health is a leader in developing new and better ways to prevent and treat diseases 
in pets, farm animals and farmed fish. Our innovative, high-quality medicines contribute to the 
quality of life, health and welfare of animals around the world. 
      
For more information, please see www.novartis.com 
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Disclaimer 
Although every effort to ensure that the information available in these proceedings is 
factually correct, the Congress Committee does not accept liability for any errors or 
omissions. The Congress Committee does not endorse or accept any liability for views and 
opinions expressed in any of the text or advertisements or any of the associated websites. 
 
 
 
Scientific Abstracts 
The abstracts as published in these proceedings have not been subjected to extensive peer-
review and therefore should not be quoted in publications. The abstracts may be considered 
as Personal Communications and referenced as such, with permission of the individual 
authors. Copyrights of the material belong exclusively to the authors and may not be 
reproduced without their permission. 
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Themed session 
LOWER URINARY TRACT TUMOURS 
 
     Deborah W. Knapp, DVM, MS, Dipl. ACVIM 
 
Department of Veterinary Clinical Sciences 
Dolores L. McCall Professor of Comparative Oncology 
Director, Purdue Comparative Oncology Program 
Co-Section Head, Oncology 
 
Purdue University College of Veterinary Medicine 
West Lafayette, IN, USA 
 
Presentation, Behavior, Medical Therapies and Interventional Urology Applications 
 
Canine Urinary Bladder Tumors   
Urinary bladder cancer accounts for approximately 2% of all reported malignancies in the dog.1 
With >100 million pet dogs worldwide, even uncommon forms of cancer affect tens of thousands of 
dogs each year. Invasive transitional cell carcinoma (TCC), also referred to as urothelial carcinoma, is 
the most common form of canine urinary bladder cancer.1,2 Most TCCs are intermediate- to high-
grade papillary infiltrative tumors.1,2 Low grade superficial TCC, which is common in humans, is rare 
in dogs. Some of the most exciting work in canine TCC, however, is comparative oncology research 
that is expected to positively impact the outlook for dogs and humans with invasive bladder cancer. 
Other bladder tumors in dogs include squamous cell carcinoma, adenocarcinoma, undifferentiated 
carcinoma, rhabdomyosarcoma, lymphoma, hemangiosarcoma, fibroma, and other mesenchymal 
tumors.1 This discussion will focus on invasive, high grade TCC.  
 
TCC is most often located in the trigone region of the bladder. Papillary lesions and a thickened 
bladder wall are common and can lead to partial or complete urinary tract obstruction. TCC of the 
bladder has been reported to also involve the urethra in 56% of dogs and the prostate in 29% of male 
dogs.3 Nodal and/or distant metastases are present in ~15% of dogs at diagnosis and 50-60% of dogs 
at death.3 Following World Health Organization (WHO) criteria for staging canine bladder tumors4, 
approximately 75% of dogs have T2 tumors, and 25% of dogs have T3 tumors.3 
 
The etiology of canine TCC is multifactorial. Risk factors include exposure to older-generation flea 
control products and lawn chemicals, obesity, possibly cyclophosphamide exposure, female gender, 
and strong breed-associated risk.1 In a recently updated analysis of cases in the Veterinary Medical 
Data Base (university based veterinary hospitals in the United States and Canada), breeds of dogs 
with significantly higher TCC risk compared to mixed breed dogs included: Scottish Terrier (OR 21.1, 
95% CI 16.3-27.5), Eskimo Dog (OR 6.6, 95% CI 3.3-13.0), Shetland Sheepdog (OR  6.0, 95% CI 4.8-
7.7), West Highland White Terrier (OR 5.8, 95% CI 4.2-8.1), Keeshond (OR 4.3, 95% CI 2.2-8.1), 
Samoyed (OR 3.43, 95% CI 1.8-6.5), and Beagle (OR 3.1, 95% CI 2.3-4.1) (unpublished data, Moore 
and Knapp, 2014). The female:male ratio of dogs with TCC has been reported to range from 1.71:1 to 
1.95:1.1 TCC risk is higher in neutered dogs than in intact dogs of both sexes, although the reason for 
this has not been determined.1,5  A positive finding from a case control study in Scottish Terriers was 
that dogs that ate vegetables at least three times a week, along with their normal diet had a reduced 
risk of TCC (OR, 0.30, 95% CI 0.01-0.97, p <0.001).6 The specific type of vegetable with the most 
benefit could not be determined, but carrots, given as treats, were the most frequently fed vegetable 
in the study. 
 
The most common clinical signs in dogs with TCC are hematuria, stranguria, and frequent urination.1 
These same clinical signs, however, are more often associated with urinary tract infection, and can 
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also occur with urolithiasis and other bladder conditions. Many conditions can also mimic TCC in 
regards to abnormal epithelial cells in urine, and mass lesions within the urinary tract. Differential 
diagnoses include other neoplasia, chronic cystitis, polypoid cystitis, granulomatous 
cystitis/urethritis, calculi, and others. It is important to distinguish non-TCC conditions from TCC 
because the treatment and prognosis differ considerably and depend on the condition present. 
A definitive diagnosis of TCC is made through histopathologic examination. In poorly differentiated 
carcinomas, immunohistochemistry for uroplakin III (UPIII) can be helpful in distinguishing TCC from 
other carcinomas.7 Methods for obtaining tissue for histopathologic diagnosis include cystotomy, 
cystoscopy, and traumatic catheterization. These biopsy techniques are discussed under the surgery 
section and below under interventional urology. When obtaining a biopsy of suspected TCC, care 
should be taken to avoid seeding the tumor. In a recent report, 24 of 544 dogs with TCC evaluated at 
the Purdue University Veterinary Teaching Hospital (PUVTH), had spread of TCC to the abdominal 
wall.8 TCC in the abdominal wall developed significantly more often in dogs that had undergone 
cystotomy (18/177,10.2%) than in those that had not (6/367,1.6%). Once detected in the abdominal 
wall, the TCC grew aggressively and did not respond to medical treatments. The median survival after 
detection of the abdominal wall TCC in the 24 dogs was 57 days (range 0-324 days). The report also 
demonstrated that TCC can, albeit uncommonly, spread to the abdominal wall via lymphatics. With 
the poor outlook for dogs with abdominal wall TCC, every effort should be made to avoid seeding the 
tumor. Percutaneous biopsy methods and cystocentesis should be avoided if TCC is suspected.  
 
Common clinical signs in dogs with TCC include hematuria, dysuria, pollakiuria, and, less commonly, 
lameness caused by bone metastasis or hypertrophic osteopathy.1 Urinary tract signs may be present 
for weeks to months and may resolve temporarily with antibiotic therapy. In dogs with TCC, a 
physical examination with rectal examination, may (or may not) reveal thickened urethra, 
enlargement of iliac lymph nodes, and sometimes a mass in the bladder or a distended bladder.  
 
In dogs with confirmed or suspected TCC, evaluation should include an assessment of overall health 
(CBC, serum biochemistry profile, urinalysis,  urine culture) and staging of the cancer (thoracic 
radiography, abdominal ultrasonography, and urinary tract imaging). To avoid the risk of seeding TCC 
through cystocentesis, urine may be collected by free catch or catheterization. If a catheter is to be 
passed, care must be taken to avoid penetrating the diseased bladder or urethral wall. Common sites 
of metastases detected with thoracic radiography and abdominal ultrasonography include lymph 
nodes, liver, and lungs, although metastases can occur in other areas as well including skin and 
bone.1,9  
 
Urinary tract imaging is used to assess the TCC location for potential surgical intervention and to map 
and measure TCC masses in order to subsequently determine response to medical therapy. Mapping 
TCC in the bladder, proximal urethra, and prostate can be accomplished by cystosonography, 
cystography, or computed tomography (CT).1,10,11 Regardless of the imaging technique used, to 
accurately track response to therapy it is important to follow a consistent protocol from visit to visit 
for bladder distension, patient positioning, equipment, and operator.  
 
The treatment of TCC can include surgery, medical therapy, and radiation therapy. Although the 
trigonal location of TCC in dogs usually precludes surgical excision, surgery may be indicated for one 
or more of the following reasons: (1) to obtain tissue for diagnosis, (2) to attempt to remove the TCC 
within the bladder if lesions are away from the trigone, and (3) to maintain or restore urine flow. 
These are discussed more in the surgery section notes by Dr. Freeman.  In the uncommon cases in 
which all gross TCC can be surgically removed, it appears helpful to place the dogs on a 
cyclooxygenase (COX) inhibitor to reduce the risk of recurrence from residual microscopic disease or 
from new primary tumors that form due to the field effect.1 In a small series of 9 dogs in which all 
gross TCC was removed, and then the dogs were treated with deracoxib (3 mg/kg daily), the median 
survival was 749 days (range, 231 to 2,581 days).1  Early reports of radiation therapy to treat TCC 
were not encouraging due to side effects, but new technology and growing expertise are improving 
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the application of radiation therapy to dogs with TCC. This is discussed more in the radiation therapy 
section by Dr. Larue.  
Systemic medical therapy is the mainstay of TCC treatment in dogs and usually consists of 
chemotherapy, COX inhibitors (nonselective COX inhibitors and COX-2 inhibitors), and combinations 
of these.1  Although medical therapy is not usually curative, several different drugs can lead to 
remission or stable disease of TCC, and most therapies are well tolerated. Resistance to one drug 
does not necessarily imply resistance to other drugs. Some of the best results are seen in dogs that 
sequentially receive multiple different treatment protocols over the course of their disease. The 
approach used at the PUVTH is to obtain baseline measurements of the TCC masses, to initiate a 
starting treatment, to monitor the response to that treatment at 4-8 week intervals, and to continue 
that treatment as long as the TCC is controlled, side effects are acceptable, and quality of life is good. 
If cancer progression or unacceptable toxicity occurs, then a different treatment is instituted. 
Subsequent treatment changes are based on tumor response and treatment tolerability. By following 
this approach, TCC growth can be controlled in approximately 75% of dogs, the quality of life is 
usually very good, and median survival times can extend beyond a year. Although it could be 
tempting to simultaneously combine multiple chemotherapy agents in dogs with TCC, the benefit of 
this has not been determined, and the potential development of resistance to multiple drugs at the 
same time could limit subsequent therapy options. 
 
Medical treatments that have been used commonly in dogs with TCC include: (1) single-agent COX 
inhibitor, (2) mitoxantrone combined with a COX inhibitor, and more recently (3) vinblastine with or 
without a COX inhibitor.1 The COX inhibitor that has been used most frequently in dogs with TCC is 
the nonselective COX inhibitor, piroxicam.1 Updated results of piroxicam treatment (0.3 mg/kg once 
daily) indicate a 20% remission rate with most being partial remissions, and 60% stable disease (lack 
of remission or progression) rate. Median survival times with single agent piroxicam are typically in 
the 6-7 month range with a minority of dogs living years after diagnosis. Quality of life is usually 
maintained or improved with piroxicam, although it is important for dog owners to observe the dog 
for potential side effects. The most common side effect which has been observed in approximately 
15% of treated dogs, is GI irritation. If vomiting, melena, and anorexia occur, piroxicam should be 
withdrawn and supportive care provided as needed until the toxicity resolves. In these cases, it may 
be safest to switch to a COX-2 inhibitor if further COX inhibitor treatment is indicated. COX-2 
inhibitors also have activity against TCC with reported activity of deracoxib, firocoxib, and others in 
dogs.1,12,13 The remission rate appears similar between COX-2 inhibitors and piroxicam, although 
complete remissions have been reported with piroxicam, but not with the COX-2 inhibitors to date.  
 
Two of the most commonly used chemotherapy protocols in dogs with TCC are mitoxantrone 
combined with piroxicam, and vinblastine (alone or in combination with piroxicam).11,14 In a study of 
55 dogs with TCC treated with mitoxantrone and piroxicam, 35% of dogs had remission with minimal 
toxicity, and the median survival was 291 days.14 In a study of 28 dogs treated with vinblastine, 36% 
of dogs had partial remission, and 50% had stable disease.11 Most dogs had failed other therapies 
when vinblastine was initiated, and the median survival from the start of vinblastine until death was 
147 days. Data analyses are pending of a followup study in which dogs with TCC were randomized to 
receive vinblastine followed by piroxicam vs vinblastine given concurrently with piroxicam.  
 
An alternative approach for the conservative management of TCC is metronomic chemotherapy with 
leukeran (4 mg/m2 per day orally).15 Of 31 dogs with TCC, of which 29 had failed prior therapy, tumor 
control (1 partial remission, 20 stable disease) was accomplished in 70% of dogs.  The median 
survival time from the start of chlorambucil to death was 221 days (range 7-747 days). Toxicoses 
were minimal with only one dog discontinuing therapy due to toxicity.  
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There are multiple other drugs that have antitumor activity against canine TCC. The platinum agents, 
cisplatin and carboplatin, appear more active (remission rates 40-70% when combined with COX 
inhibitors) than mitoxantrone and vinblastine.1 The reason the platinum agents are not used more 
often or used as front line treatment is because of undesirable side effects including bone marrow 
suppression, prolonged anorexia, other GI toxicity, and renal toxicity (cisplatin). Similarly, intravesical 
mitomycin C in dogs with TCC has resulted in remission and good tumor control, but in some dogs 
the drug is systemically absorbed.16 This unpredictable absorption results in severe systemic toxicity 
including bone marrow and GI toxicity. Other systemic therapies including doxorubicin and 
gemcitabine in combination with COX inhibitors have also been reported to have activity in dogs with 
TCC.17,18   
 
In addition to treating the cancer, it is important to monitor dogs with TCC for secondary urinary 
tract infections and to treat those appropriately based on culture and sensitivity. The emergence of 
highly resistant bacteria is posing an important and life threatening outcome in dogs with TCC.  
 
Feline Urinary Bladder Tumors 
Bladder cancer is rarely reported in cats. A report of 27 bladder tumors in cats included 15 
carcinomas, 5 benign mesenchymal tumors, 5 malignant mesenchymal tumors, and 2 lymphomas.19 
Most cats were elderly, and included 20 male and 7 female cats. A series of 20 cats with TCC included 
13 neutered male and 7 spayed female cats (median age 15.2 years).20 A series of 15 cats with TCC 
examined at the PUVTH in recent years included 6 neutered male and 9 spayed female cats (median 
age 13 years, range 4-18 years).1 Clinical signs in cats with TCC are similar to those in dogs 
(hematuria, stranguria, pollakiuria). Concurrent urinary tract infection is common, being reported in 
75% of cats in the published study20 and 67% of cats at the PUVTH. Regional and distant metastasis of 
feline TCC is clearly possible, but the metastatic rate has not been defined. The optimal treatment for 
bladder tumors in cats remains to be defined.  
 
Canine Prostate Cancer 
Prostate cancer is typically a disease of older dogs and can affect neutered and intact dogs.21 In broad 
terms, prostate cancer in dogs usually occurs in one of 3 forms: (1) TCC arising from prostatic duct 
epithelium, (2) adenocarcinoma that is clinically apparent and problematic, and (3) prostatic 
intraepithelial neoplasia (PIN) which is usually subclinical. TCC in the prostate is typically treated 
similarly to TCC in the bladder and urethra, although the response, as compared to TCC in the 
bladder, is not yet well defined. High grade PIN is an accepted precursor to prostate carcinoma in 
men, however, many men with PIN (especially if not high grade) do not progress to clinically relevant 
cancer. Step sectioning of the prostates from dogs with no evidence of prostatic disease who were 
euthanized for other reasons, revealed PIN, including some with high grade PIN.22 It is not known if 
these lesions would have progressed had the dogs not died of other causes. The prognosis for dogs 
that present with clinically problematic prostatic adenocarcinoma is poor. Canine prostatic 
adenocarcinoma is associated with a high metastatic rate including spread to bones, and poor 
response to traditional chemotherapy. Palliative care could include COX inhibitors and metronomic 
chemotherapy. Prostate cancer is very rarely detected in cats, and the optimal treatment has not 
been defined.   
 
Interventional Urology Applications for Lower Urinary Tract Tumors 
Interventional urology refers to image-guided, non-surgical procedures to correct or to provide 
accommodation for problematic urologic conditions. In regards to lower urinary tract tumors, this 
most often includes cystoscopic inspection and biopsy, and the non-surgical placement of urethral 
stents. Laser tumor resection techniques utilized in humans, have been described in dogs, but do 
involve potentially serious risks as discussed below. An interventional urologic approach to the 
placement of ureteral stents (i.e. insertion of ureteral stents via cystoscopy) could be considered, 
although technical challenges in small dogs and poor to absent visualization of the ureteral orifice 
due to the trigonal tumor, make this approach very challenging, if not impossible in some cases.   
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Cystoscopy provides the opportunity to visually inspect the urethra and bladder, and to obtain 
biopsies in a noninvasive method.23 The location of the tumor, distance from the trigone (which 
could allow subsequent surgery), and the extent of impingement of the tumor on ureteral orifices 
and urethra can be assessed. Small diameter flexible scopes are used in male dogs, and rigid scopes 
are generally used in female dogs. With the small size of cystoscopic biopsies, diligence in collecting 
sufficient tissue for diagnosis is crucial. Placing tissue samples in a histology cassette prior to 
processing helps prevent loss of small samples. In a report of 92 dogs, diagnostic samples were 
obtained by cystoscopy in 96% of female dogs and 65% of male dogs that ultimately had 
hisotopathologically diagnosed TCC.23 The more recent use of a wire basket designed to capture 
stones during cystoscopy allows collection of larger tissue samples and has increased the yield of 
diagnostic biopsy samples, especially in male dogs. Traumatic catheterization to collect tissues for 
diagnosis can also be performed, although samples collected by this method are usually small and 
the diagnostic quality varies considerably from case to case. Percutaneous biopsy methods can lead 
to tumor seeding and are best avoided. 
 
Urethral obstruction from TCC will rapidly become fatal if not relieved. Procedures to relieve or 
bypass urethral obstruction include the placement of a cystostomy tube, or the placement of a 
urethral stent. The placement of cystostomy tubes is discussed in the notes on surgery. The 
advantages of urethral stents over cystostomy tubes are stents can be placed non-surgically with 
fluoroscopic guidance, and there are not any external components of stents for the dog to chew out. 
Currently, the most commonly used urethral stents are self-expanding nitinol mesh stents. These 
come in covered and uncovered designs. For the covered stents, the mesh in the middle of the stent 
is covered in order to theoretically reduce the growth of tumor through the stent mesh once it is 
placed. The ends of the covered stents are uncovered in order to engage the tissues to hold the stent 
in place. Problems with migration of covered stents, however, has led to increased use of uncovered 
stents. The uncovered stents appear more likely to stay in place, and tumor growth through the 
stents has only rarely been observed.  
 
Briefly, for the placement of a urethral stent24, the dog is placed under general anesthesia. A 
measuring catheter is placed in the colon and positioned parallel to the area of suspected urethral 
obstruction.   
A flexible tipped urologic hydrophilic guide wire is inserted up the urethra into the bladder.  
An appropriately sized vascular sheath (7 to 10 Fr) is placed over the guide wire. Iodinated contrast 
mixed 50/50 with sterile saline is infused into the bladder to achieve moderate bladder distention.  
 A retrograde positive contrast urethrogram is then performed with fluoroscopy to identify the area 
of urethral obstruction.  In female dogs, the vascular access sheath is withdrawn through the urethra 
during retrograde infusion of iodinated contrast agent to attempt to obtain maximal urethra 
distension and determine length and width measurements of the urethra.  The colonic measuring 
catheter, which has 10 radiopaque bands at 1-cm intervals, is visualized on the urethrogram next to 
the urethra in order to determine the length of obstruction caused by the tumor mass, the length of 
the urethra measured from trigone to papilla in female dogs, and the widest diameter of urethra 
adjacent to the obstruction.   
The width of the stent is selected to be at least 10% larger than the widest diameter of the urethra 
adjacent to the obstruction. When possible, the length of the stent is selected to allow 0.5 to 1 cm of 
the stent to be in contact with normal tissue proximal and distal to the obstruction. For female dogs 
with the entire urethra involved with neoplasia, the length of the stent is chosen with the goal to 
stent approximately 67% of the urethra, but to stent no more than 75% of the length of the urethra. 
Once the appropriately sized stent has been selected, the stent is placed over the guidewire, 
positioned across the obstruction, and deployed with fluoroscopic guidance. After stenting, the 
bladder is manually expressed to ensure urethral patency, and the dog observed several hours in the 
hospital.  
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The outcome of dogs with TCC with urethral stents has been reported in 2 recent publications. The 
first included 19 dogs at the PUVTH.24 Eleven dogs had already received medical therapy for their TCC 
at the time of obstruction. Urethral obstruction was successfully relieved in 17 of 19 dogs. In one of 
the dogs, the urethral obstruction was so severe that a guidewire (nor stent) could be advanced up 
the urethra. 
 In another dog, tumor compression caused collapse of the stent shortly after stent placement. 
Survival in the 17 dogs following successful stent placement ranged from 2-366 days (median 78 
days). All 17 dogs received some form of medical therapy for the TCC after stent placement. The dog 
who died after 2 days had a severe adverse event to chemotherapy. A survey of the owners of dogs 
who had stents placed indicated that 16 of the 17 owners were satisfied with the outcome and 
would recommend stent placement to others. Although urethral stent placement is expected to be 
lifesaving in the vast majority of dogs, complications can occur. In the 19 dogs, complications 
included incontinence (39% of dogs), reobstruction from continued growth of urethral neoplasia 
(17%), acute reobstruction (5.5%), and stent migration (11%). Stent migration in 2 dogs was thought 
to be due to suboptimal stent size selection in one dog, and dramatic tumor shrink due to medical 
therapy in the other dog. The optimal tumor for successful stent placement appears to be one in 
which normal urethral tissue is present on either end of the tumor where the stent can be securely 
anchored. It is postulated that dogs with stents that only cover a small part of the urethra are less 
likely to experience incontinence than dogs with tumors requiring longer stents, but this has not 
been proven in studies to date. Similarly, the potential added risk of infection in dogs with stents has 
not been studied to date. It has been noted that extending the stent into the vagina should be 
avoided due to discomfort caused by the stent in that location.  
 
In a another report, the outcome of 42 dogs with obstructive carcinoma who underwent urethral 
stent (self-expanding metallic stent) placement was summarized.25 Relief of urethral obstruction was 
accomplished in 41 of 42 dogs (97.6%) dogs. In one dog, the stent migrated into the bladder after 
being deployed. Following stent placement, incontinence of varying severity occurred in 6 of 23 male 
and 5 of 19 female dogs. The median survival after stent placement was 78 days (range 7-536 days). 
Survival appeared longer (median 251 days, range 8-536 days) in the dogs treated with COX 
inhibitors before, and chemotherapy after, stent placement.  
 
Another “non-surgical” approach reported to address urethral tumors is laser tumor resection. Pet 
owners may inquire about transurethral resection because they are aware of this approach in human 
bladder cancer patients. What most pet owners do not recognize, however, is this approach is most 
often applied to superficial tumors in humans where it is possible to resect the lesions without 
penetrating the bladder wall. Unfortunately, TCC in most dogs is invasive into the bladder wall.  
A procedure has been reported in which the investigators attempted to use ultrasound to guide 
endoscopic diode laser ablation of TCC.26 Using this and similar approaches, the main risk of laser 
resection of TCC in dogs remains bladder perforation. The value of laser resection has not been well 
defined as dogs in previous reports were receiving multi-modality treatment, and it is not possible to 
know which component(s) of the treatment could have been beneficial.  At our institution, laser 
procedures are limited to carefully selected cases in which a “ball valve” type lesion clearly 
protruding into the lumen can be resected without substantial risk of perforation of the bladder or 
urethra.  
 
Progress in Bladder Cancer Management 
TCC has become a highly “treatable” cancer in dogs, and the outlook for dogs in regards to length 
and quality of life continues to improve. TCC, however, is rarely curable. Research in the prevention, 
early detection and intervention, and better therapies for TCC must continue. Tens of thousands of 
people also die from invasive bladder cancer worldwide each year. Experimentally-induced bladder 
tumors in animals for research do not sufficiently mimic the human condition. This means research in 
ESVONC, Vienna 2014 - 20 - 
dogs with naturally-occurring TCC is all the more important to improve the outlook for humans, as 
well as for dogs facing invasive bladder cancer.27 
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Radiotherapy for Lower Urinary Tract Tumors  
 
Canine urogenital tumors present a therapeutic challenge.  Curative surgery is often not an option 
because of tumor location.  Traditional fractionated radiation therapy is associated with severe acute 
intestinal toxicity. Chemotherapy and palliative radiation therapy can improve clinical signs, but 
duration of response is limited.  Limited information is available on novel techniques such as local 
chemotherapeutic infusions or photodynamic therapy.  Recent technological advances in the fields of 
radiation oncology and minimally invasive surgery have provided promising new options for the 
treatment and management of these cancers.  This lecture discuss focus on the application of specific 
technologies, such as intensity modulated radiation therapy (IMRT), image guided radiation therapy 
(IGRT), dynamic adaptive radiation therapy (DART) and stereotactic radiation therapy (SRT) for 
treatment of tumors of the bladder, prostate and urethra.  We will also discuss management of 
radiation/tumor effects with stenting of the ureter and urethra.  
 
Treatment of tumors of the bladder, urethra and prostate 
Tumors of the lower urinary tract make up 2% of all canine cancers, and it is speculated that with the 
increased availability of ultrasound and computed tomography that clinical diagnosis is becoming 
more common. Transitional cell carcinoma of the bladder is the most frequently encountered tumor 
histologic type.   Key to treating urinary tract tumors with radiation therapy is determining the 
location and extent of the tumor. The trigone of the bladder is the most common location although 
the entire bladder can be involved. Disease extension from the bladder to the urethra is seen in over 
50% of patients while extension to the prostate occurs in almost 30% of male patients.  Nodal (15%) 
and distant (14%) metastases can be present at initial presentation but is as high as 50% at the time 
of euthanasia.  Therefore, accurate staging is of great importance.  Confirmed or suspected regional 
lymph nodes should be treated. Other tumor types observed in this region include squamous cell 
carcinoma, adenocarcinoma, undifferentiated carcinoma, rhabdomyosarcoma, lymphoma, 
hemangiosarcoma, fibroma and other sarcomas.  Tumor histology does not impact radiation 
prescription because radiation dose is always limited by normal tissue tolerance.  However histologic 
type is extremely important in selecting the most appropriate post radiation chemotherapy regimen. 
Treatment with radiation therapy is technically challenging for a number of reasons.  The bladder 
varies in size and location based not only on urine volume but on rectal content. (1)  In addition, the 
target tissues move relative to the bony landmarks identifiable using standard port film techniques.  
Therefore when using a traditional radiation therapy technique such as three dimensional conformal 
radiation therapy (3D-CRT), the radiation treatment field necessary to include the tumor plus 
microscopic extension, (called the clinical target volume, or CTV) must be enlarged to take this 
variation into account.(2)  This expanded radiation field is called the planning target volume (PTV). 
Adjacent normal tissue structures, such as the colon, rectum and intestines, are unnecessarily 
exposed to high doses of radiation, resulting in acute GI toxicity and consequential late effects. (3)  
This problem is exacerbated when disease has spread to regional nodes, further increasing the 
volume of tissue treated. 
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Technological Advances 
Improvements in radiation oncology technology have vastly improved the ability to safely and 
effectively treat urinary tract tumors. Intensity Modulated Radiation Therapy (IMRT) controls the 
intensity of each beam through motorized collimator leaves (MLC) that move during treatment, 
allowing the dose to be sculpted around important normal structures.  This technique requires a 
specific treatment planning system that uses inverse planning. Inverse planning requires that the 
various tumor structures  
(Gross tumor volume [GTV], CTV and PTV) as well as critical normal tissue structures be identified.  
This is achieved by outlining (contouring) each structure of interest on each slice of the CT scan.  
Dose objectives for each structure are entered, and a sophisticated algorithm attempts to meet all 
objectives.  The 2 major benefits associated with IMRT are: 1) Dose to adjacent normal tissue 
structures can be minimized, dramatically reducing acute effects and 2) Radiation dose to the tumor 
can be increased, improving the probability of tumor control.  Both of these benefits were realized 
when IMRT became the standard of care for prostatic tumors in men.   
Image guided radiation therapy (IGRT) is another key component in the treatment of urinary tract 
tumors in dogs.  IGRT utilizes imaging systems built into the therapeutic accelerator to confirm the 
location of the target immediately prior to treatment.   For tumors that are firmly associated with 
boney structures, such as brain tumors and nasal tumors, orthogonal radiographs taken at treatment 
can be compared, using intrinsic software, to the digitally reconstructed radiographs (DRRs) from the 
treatment plan. For bladder and prostate cancers, a more advanced imaging technique, such as a 
cone beam CT (CBCT) is required.  Prior to treatment, a CBCT is acquired and compared in 3 
dimensions, to the CT used for the radiation treatment planning.  IGRT allows the oncologist to 
confirm the location of the treatment target.  The importance of this is that it allows a substantial 
decrease in the size of the PTV expansion, drastically decreasing the amount of normal tissues in the 
field.(1)   
Dynamic Adaptive Radiation Therapy (DART) is a technique where the patient’s CBCT is evaluated 
each day before treatment to determine size/location of bladder.  Based on previous work by Nieset 
(2), variations in bladder size/location can be predicted.  With DART, a “small”, “medium” and “large” 
bladder plan is created.   
Intensity Modulated Image Guided Radiation Therapy (IG/IMRT) combines the dose precision of 
IMRT with daily CBCT to minimize the PTV expansion.  Twenty-one client owned dogs with tumors of 
the lower urinary tract were treated with IG/IMRT.(4) Primary tumors were located in the prostate 
(10), urinary bladder (9) or urethra (2). 54 to 58 Gy was administered in 20 daily fractions.  Grade I 
and II GI toxicoses were observed in 33 and 5% of the dogs, respectively.  Four dogs had late grad 3 
GI or GU toxicosis.  Median event-free survival was 317 days, and median survival was 654 days.  The 
protocol was well tolerated and resulted in superior survival times compared to previous reports in 
the literature.  
Stereotactic Radiation Therapy (SRT) is another new technology that may have applications for 
tumors limited to the prostate or urethra.  It is unlikely that this technique can be safely applied to 
the bladder.  Bladders are not tolerant of large doses per fraction and because of variations in 
size/location of bladders, it is difficult to target with the precision that is required for SRT to be 
successful.   
SRT involves the use of high doses per fraction but overcomes the radiobiological limitations with 
stereotactially verified positioning and treatment delivery techniques that leave a minimal volume of 
normal tissue in the high dose area.  Stereotactic radiation therapy, by definition, requires: 1) a 
tumor for targeting (not microscopic disease); 2)  treatment planning and administration that will 
provide a dramatic dose drop off between the tumor and the surrounding normal tissue structures; 
and 3) a method of stereotactically verifying patient positioning.  The result is that normal late 
responding tissue structures are spared through dose avoidance rather than by administering small 
doses per fraction.   
The normal tissue structures still receive dose, and the dose per fraction is higher than for traditional 
radiation therapy.  This technique is appealing because only 1-5 fractions of radiation are required 
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and treatments are generally well tolerated by the patient.  Normal tissue tolerance for important 
regional late responding tissues have been well defined. (5)  A major concern about SRT is that most 
canine urogenital tumors are transitional cell carcinomas.  Unlike adenocarcinomas, these may not 
be restricted to the prostate.  For tumors that seem restricted to prostate or urethra, we still 
recommend obtaining a cystoscopic biopsy of the bladder. the bladder even if it has a normal 
appearance.   
 
 
Conclusions 
The new renaissance in radiation oncology has introduced exciting technologies that may benefit 
canine and feline patients with urinary tract tumors.  It is important that progress in this area be 
documented.  Determining normal tissue tolerance of organs at risk is crucial to the development of 
optimal radiation therapy protocols.  Minimally invasive procedures such as ureteral, urethral and 
rectal stents will become increasingly important as patients live longer and develop mild to moderate 
toxicities.  As local tumor control improves, it is also critical that a chemotherapy protocols are 
carefully evaluated for efficacy.    
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Fractionated Radiation Therapy Protocols Using Cone-Beam Computed Tomography. Veterinary 
Radiology & Ultrasound 51(2), 235. 2009.  
2. Nieset JR, Harmon JF, LaRue SM. Use of cone-beam computed tomography to characterize daily 
urinary bladder variations during fractionated radiotherapy for canine bladder cancer. 
Vet.Radiol.Ultrasound 2011;52:580-8. 
3. Anderson CR, McNiel EA, Gillette EL, Powers BE, LaRue SM. Late complications of pelvic 
irradiation in 16 dogs. Vet.Radiol.Ultrasound 2002;43:187-92. 
4. Nolan MW, Kogan L, Griffin LR et al. Intensity-modulated and image-guided radiation therapy for 
treatment of genitourinary carcinomas in dogs. J.Vet.Intern.Med. 2012;26:987-95. 
5. Nolan MW, Ehrhart EJ, Wasserman T, LaRue SM. Dose tolerance limits for stereotactic body 
radiotherapy in the dog pelvis. Proceedings of the Annual Meeting of the American College of 
Veterinary Radiology , 95. 10-20-2012.  
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Oncologic “Surgery” of the Lower Urinary Tract 
 
Classic surgery for cancer involving the urinary system is biopsy and extirpation.  This lecture will 
discuss the traditional and the emerging technologies in treating or palliating cancer of the urinary 
system. 
Laparoscopic-assisted cystotomy  
To obtain a diagnostic sample in cases where less invasive means such as traumatic catheterization 
and cystoscopic biopsy are unsuccessful, a laparoscopic-assisted cystotomy may be indicated.  In this 
approach, the urinary bladder is visualized with a laparoscope and, through a small opening in the 
body wall, the bladder surface is exteriorized and stabilized with stay sutures.  A threaded trocar is 
placed into the bladder and a cystoscope is used to visualize the inside of the bladder and obtain 
biopsy samples.   
If the bladder is large enough, a 5 mm scope and alligator forceps or biopsy cup forceps may be used 
through the single port.  Special care is taken to minimize urine spillage and to prevent 
contamination of the body wall with biopsy samples to prevent tumor seeding of the incision sites.  
To my knowledge, none of the tumor seeding cases described previously by Dr. Knapp occurred with 
minimally invasive surgery.  When diagnosis is confirmed, medical therapy ensues. 
Cystostomy tubes 
In the past, we placed cystotomy tubes for palliative management of tumors involving the urethra, 
but these have been replaced by urethral stents.   
Partial cystectomy 
For small tumors of the bladder apex, partial cystectomy may be considered for removal of gross 
disease.  However, many surgeons are hesitant to pursue this approach for fear of tumor regrowth 
from microscopic disease.  When we attempt these operations, our goal is to obtain a 1 cm margin 
around the gross disease, and animals are placed on COX inhibitors postoperatively.  The bladder is 
exteriorized through a caudal midline laparotomy and is packed off with laparotomy sponges.  With 
the bladder distended with urine and the mass palpable at the apex, a series of stay sutures are 
placed in the bladder in grossly normal tissue at least 1 cm from the mass, further if possible.  These 
stay sutures will then be used to handle the bladder reconstruction once the tumor is removed.  The 
mass is then excised and the bladder is closed with a simple interrupted suture pattern.  If possible, 
the suture line is then oversewn with an inverting Cushings pattern.  The bladder will be very small, 
and the animal will appear to be incontinent after surgery.  These signs will improve with time as 
bladder capacity is restored.  
 
When tumor invades or occludes the ureter, obstruction leads to hydronephrosis and impaired renal 
function.  In the past, unilateral ureteral obstruction might have been treated by 
ureteronephrectomy.  Today, our goal is to maintain function of both kidneys for as long as possible.  
Recently, techniques adapted from interventional urology have created additional options for 
treatment of local disease.   
Ureteral stenting 
TCC involving the trigone can be treated with ureteral stents.   Prior to surgery, VD radiographs are 
obtained with a marker catheter to estimate the stent length that will be needed.  The distance from 
the renal pelvis to the trigone is measured.  Chose a stent that is longer than the measurement 
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because in most cases, the dilated ureter will have become tortuous and is much longer than what is 
measured.  The stents can be placed by approaching the ureteral orifice from the bladder.  In cases of 
extensive disease, it can be very difficult to identify the ureteral orifice and that precludes a 
cystoscopic approach.  A cystotomy is then performed on the ventral surface of the bladder and is 
extensive to offer visualization of the trigone area.  If a normal ureteral orifice can be identified, it is 
helpful to temporarily place a 3 fr red rubber feeding tube into that orifice to assist with determining 
the local of the opening of the abnormal ureter.  A 0.035” floppy guide wire is used to probe the 
region to identify the ureteral opening.  Once the ureter is accessed with the guide wire, a C-arm is 
then used to track the advancement of the guide wire to the renal pelvis.  The urethral catheter is 
then advanced over the guide wire so that a coil remains in the renal pelvis as the guide wire is 
removed.  C-arm images confirm the proper location of the ureteral stent. 
 
For mass hard lesions involving the distal ureter that can’t be accessed from the bladder, one 
approach is to drill through the mass with a renal access needle from the ureter to inside the bladder 
and then pass the guide wire through the needle into the ureter.  Although there is a potential 
concern for leakage of urine from the needle stick in the ureter, this was not an issue in the single 
case in which this approach was used.  The ureter can also be approached by passing a renal trocar 
needle percutaneously into the renal pelvis using CT or US guidance.  When the pelvis is accessed, a 
sample is withdrawn for culture, and a contrast study is performed.  Through the needle, the guide 
wire is passed and directed caudally to the ureter. The guide wire is then advanced through the area 
of the ureteral obstruction to emerge inside the bladder.  The needle is then removed.  When 
combined with cystotomy, the ureteral stent is then passed over the guide wire and coiled in the 
renal pelvis.   By creating access through the renal parenchyma, the risk of urine leakage is less. 
 
In experienced hands, an IR approach may be used for antegrade placement of a ureteral stent.  
Renal access is obtained using a combination of US and CT guidance to place the renal trocar needle 
in the renal pelvis.  A contrast study is performed and a guide wire is passed through the needle, 
down the ureter, into the bladder, and out the urethra to obtain “thru-and-thru” access.  A sheath is 
passed retrograde over the guide wire to the renal pelvis and a second guide wire is then passed in a 
retrograde manner.  The first guide wire maintains access at all times and the second guide wire is 
used for passage of the stent.   After the stent is coiled in the renal pelvis, a push catheter is then 
used to deploy the distal coils in the urinary bladder.  When the stent is properly placed, the thru-
and-thru guide wire is removed.  If disease extends to the urethra, urethral stenting can be 
performed in addition to the ureteral stenting, as discussed by Dr. Knapp. 
 
Subcutaneous Ureteral Bypass (SUB) 
An emerging therapy, initially developed for management of feline ureteral obstruction due to 
ureterolithiasis,  is being used in selected cases for palliative management of ureteral obstruction 
due to tumor. 
 
The SUB system is a combination of a nephrostomy tube and a cystostomy tube, connected via a port 
that is implanted in the subcutaneous tissues of the ventral abdominal wall.  The system is placed 
surgically, using C-arm guidance.  Access to the renal pelvis is obtained with a needle and the 
nephrostomy component is placed.  A cuff on the outside of the catheter is secured to the surface of 
the kidney with surgical adhesive.  Attention is then directed to the bladder and a purse-string suture 
is placed in the bladder and a cystostomy tube is placed via a needle in the center of the pursestring.  
The suture is tied, and a similar cuff is adhered to the surface of the bladder with surgical adhesive 
and 4 sutures.  The tubing from the nephrostomy catheter and from the cystostomy tube are then 
tunneled through the body wall and connected to a port that is placed in the subcutaneous tissue.  
The port is secured to the external sheath of the rectus abdominis muscle with 4 sutures.  Secure 
attachment is achieved with “boots” that are advanced over the outside of the catheter.  Unilateral 
or bilateral SUBS can be placed.  A port with 3 connectors is available to accept 2 nephrostomy tubes 
and 1 cystotostomy tube.  There has been limited experience with total extirpation of the bladder 
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and placement of the “cystostomy tube” into the urethra.   This renders the animal incontinent, but 
most animals with this stage of disease are incontinent already. 
 
IR Chemoembolization/ Chemotherapy 
Interventional radiology techniques are being explored for local delivery of chemotherapy agents 
directly to tumors with the goal of delivering a much higher dose to the tumor that can be achieved 
with systemic chemotherapy.   To access the prostate, Dr. Weisse uses vascular access of the femoral 
artery,  
a series of guide wires and microcatheters that are passed to directly access the blood supply to the 
tumor.  Chemotherapy is delivered locally to the tumor.  At this point, it is unknown whether 
combining the chemotherapy with beads or embolic therapy may be useful.  And it is unknown 
whether it is better to access the blood supply from both the right and left arteries as a single or 
staged approach. 
 
While some of these advanced surgical techniques may seem “extreme”, when combined with 
medical management, the animal’s life may be prolonged.  When the quality of life is acceptable to 
the owner, these new therapies may represent options for continued management of tumors of the 
lower urinary tract. 
 
1. Freeman LJ. Operative laparoscopy. In. Moore AH, Ragni RA, eds. Clinical Manual of Small Animal 
Endosurgery. West Sussex, England. Wiley-Blackwell; 2012.135-167. 
2. Lipscomb JV.  Bladder.  In Karen M. Tobias & Spencer A Johnston, eds.  Veterinary Surgery Small 
Animal.  Elsevier Saunders, St. Louis, 2012, pp 1978-1992. 
3. Berent AC1, Weisse C, Beal MW, Brown DC, Todd K, Bagley D.  Use of indwelling, double-pigtail 
stents for treatment of malignant ureteral obstruction in dogs. 12 cases (2006-2009).  J Am Vet 
Med Assoc. 2011 Apr 15;238(8).1017-25.  
4. Horowitz C1, Berent A, Weisse C, Langston C, Bagley D. Predictors of outcome for cats with 
ureteral obstructions after interventional management using ureteral stents or a subcutaneous 
ureteral bypass device. J Feline Med Surg. 2013 Dec;15(12).1052-62.  
5. Boston S1, Singh A. Total Cystectomy for Treatment of Transitional Cell Carcinoma of the Urethra 
and Bladder Trigone in a Dog. Vet Surg. 2014 Jan 16.  
6. Smith KA1, Kim HS. Semin Oncol. Interventional radiology and image-guided medicine. 
interventional oncology. 2011 Feb;38(1).151-62. 
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Melanoma: Behaviour and Biology 
 
In dogs, tumors of melanocytes (cells that produce melanin) represent an extremely varied biological 
spectrum of disease, from the benign melanocytoma to the highly aggressive mucosal melanoma of 
the oral cavity.  The varied presentation and biology often leads to confusion in diagnosis, prognosis 
(table 1) and treatment of this spectrum of diseases.  Until we in veterinary oncology advance our 
understanding of basic genetic and molecular drivers of the varied types encountered, we will remain 
simplistic in our approach to a disease that requires a more individualized approach to treatment. 
 
As in humans, there exist 3 general categories of melanoma: 1) Cutaneous melanoma, the most 
common form in humans and the second most common form in dogs, 2) Mucosal Melanoma, the 
most common malignant form in dogs is rare in people, and 3) Ocular melanoma, a relatively rare 
presentation in dogs and cats.  
 
In humans, a significant majority of malignant melanomas are linked to exposure to ultraviolet rays 
from the sun. In dogs, most malignant melanomas occur in areas not exposed to sunlight and 
therefore the etiology is likely a combination of genetic and environmental factors unrelated to UV 
exposure.   
In humans, alterations in cell signaling pathways are commonly implicated, in particular those of the 
MAP-kinase signaling pathway. BRAF and NRAS mutations are common in cutaneous melanoma in 
humans but are rare in mucosal melanoma. Similarly, in oral mucosal melanoma of dogs BRAF 
mutations have not been identified and NRAS mutations are rare as are PTEN mutations. C-kit 
mutations are quite common in humans with oral mucosal melanoma and while KIT expression is 
common in mucosal melanoma of dogs, activating c-kit mutations have not been clearly identified in 
canine mucosal melanomas. Most but not all oral mucosal melanomas in dogs have aggressive 
biology’s characterized by high metastatic rates and poor outcomes. Up to 10% of oral mucosal 
melanomas in dogs are benign (similar to blue nevi) and can be cured with surgery – this benign 
variety is typically smaller (< 2cm), deeply pigmented, with a low or absent mitotic index and lack 
surface ulceration.  
 
Some excellent recent reviews and large compilations of canine melanomas with histologic and 
genetic characterization have recently been published (Simpson 2013, Gillard 2013, Smedley 2011, 
Esplin 2008) and have begun the much needed work of characterizing the genetic and pathologic 
subtypes of melanoma in dogs that is a necessary prerequisite to rational and more individualized 
treatment strategies for dogs with aggressive melanomas.   Nearly all melanoma specimens from 
humans are subjected to genetic testing such that proper treatment recommendations can be made.  
 
ESVONC, Vienna 2014 - 29 - 
Table 1. Known or suspected prognostic factors identified in canine melanoma.  
 
Factor Comment 
Location Tumors arising from haired skin are generally benign. Oral mucosal 
nail bed, footpad locations are generally malignant. Ocular 
melanomas of eyelid, limbal and uveal structures are usually benign. 
Histology Histologic criteria of malignant versus benign is predictive of 
biologic behavior. Determination based primarily on the mitotic 
index; however, nuclear atypia, lymphatic invasion and degree of 
pigmentation may also be prognostic.  
Clinical stage Visceral metastasis is a negative factor.  Nodal metastasis is likely 
negative, however definitive data lacking. 
Infiltration/invasion Deep infiltration and bone lysis negative for oral melanoma and 
invasion beyond dermis is negative for cutaneous melanoma 
Tumor cell proliferation 
rate 
Immunohistochemical (e.g., MIB-1/Ki67, PCNA) techniques that 
measure proliferation shown to be prognostic.  Only modestly more 
predictive than simple histology and mitotic index. 
DNA ploidy Prominent G2/M peaks predictive for malignant behavior. No more 
predictive than simple light microscopy, therefore not cost 
effective. 
 
 
Gillard et al. (2013). Naturally occurring melanomas in dogs as models for non-UV pathways of 
human melanomas. Pigment Cell Melanoma Res, 27, 90-102. Doi:10.1111/pcmr.12170 
Simpson et al. (2013). Sporadic naturally occurring melanoma in dogs as a preclinical model for 
human melanoma. Pigment Cell Melanoma Res, 27, 37-47. Doi:10.1111/pcmr.12185 
Smedley et al. (2011). Immunohistochemical Diagnosis of canine oral amelanotic melanocytic 
neoplasms. Vet Path, 48, 32040. Doi:10.1177/0300985810387447  
Smedley et al. (2011). Prognostic markers for canine melanocytic neoplasms: A comparative review 
of the literature and goals for future investigations 
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Melanoma: Review of Treatment with Surgery and Traditional/Coarsely 
fractionated/ Palliative Radiation Therapy 
 
Malignant melanoma is the most common oral tumor in dogs and is associated with a high rate of 
regional and distant metastasis. (1)  Tumor size is prognostic; regardless of treatment stage I tumors 
(≤ 2 cm) have better long term survival than larger tumors. Most dogs will succumb to metastatic 
disease.  However, the local tumor will generally impact quality of life sooner than metastatic 
disease, so local disease should be addressed. Surgical excision and/or radiation therapy provide the 
best options for controling loco-regional disease.  
Thorough staging is recommended before treatment and should include CBC and platelet count, 
biochemical profile, urinalysis, thoracic radiographs (3 views), and local node assessment and 
cytology.  Interestingly, nodes should be aspirated whether enlarged or normal is size; in a study of 
100 dogs with melanoma, 40% had local nodal metastasis when not lymphadenomegally was 
present.(2) Abdominal ultrasound should be considered for evaluation of visceral metastasis.  
 
Complete surgical excision is the most effective local treatment option, and there are a variety of 
innovative surgical options, depending on tumor location.  Although “wide margins” are advocated, 
little outcome based information exists regarding surgical or radiation margin width.  Wide margins 
of 2-3 cm have been advocated, but some surgeons feel that 1-2 cm is adequate.  Rostral tumors may 
be diagnosed earlier than caudal tumors because they are easier seen by the client, improving the 
likelyhood of complete excision.  Caudal tumors may be larger and more invasive by the time of 
diagnosis, making surgery more challenging.  Advanced imaging, such as CT, PET/CT or MRI as well as 
complete oral inspection should always be performed before excision of caudally located tumors so 
the extent of disease can be established and the surgery planned ahead of time.  Incomplete excision 
of subclinical disease still provides a benefit to the patient, because radiation therapy is more 
effective when treating microscopic melanoma.  The role of chemotherapy for gross of microscopic 
disease is unclear.      
 
Radiation therapy has been used for many years for the treatment of oral melanoma.(3)  Aggressive 
fractionated protocols have provided good tumor control, however their use must be weighed 
against the acute radiation effects and the probability of early metastatic spread.  Currently, 
aggressive protocols are used for patients who have tumors with good prognostic indicators.  In one 
study, 38 dogs with oral melanoma without evidence of metastasis were treated with 48 Gy 
delivered in 4 Gy fractions on a Monday-Wednesday-Friday schedule.(4) The median PFS was 17.8 
months for all dogs and was stage dependent; for T1 tumors, it was 38 months; for T2 tumors, 11.7 
months, and for T3 tumors, 12 months. Melanomas are believed to have a low α/β ratio, so higher 
doses of radiation per fraction are believed to improve response rates for melanoma. Coarsely 
fractionated protocols have more merit than for other types of oral tumors.  A retrospective study of 
140 dogs, most of which had regional or distant metastasis at presentation.(5) Coarsely fractionated 
(9 to 10 Gy weekly fractions to a total dose of 30 to 36 Gy) and conventionally fractionated (2 to 4 Gy 
fractions to as high as 45 Gy or more) protocols were used with or without surgery or chemotherapy. 
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The median times to first event and survival were 5 and 7 months, respectively. Tumor recurrence 
was the first event in only 27% of the dogs, with new metastases or death accounting for the other 
63%.  In 39 dogs with incompletely resected oral melanoma treated with coarsely fractionated 
radiation therapy plus platinum-based chemotherapy, the median survival time was 363 days.(6) The 
dogs received 6 weekly fractions of 6 Gy, with cisplatin (10 to 30 mg/m2) or carboplatin (90 mg/m2) 
administered 1 hour before irradiation. Fifteen percent of the dogs failed locally, and the median 
time to metastasis was 311 days. Palliative therapy can be used in the face of gross tumor.  Bleeding 
and odor can be temporarily abated.   
 
Treatment toxicity depends on the time-dose-fractionation of the protocol and the specific normal 
structures in the treatment field.  For oral melanomas, this can include the skin, nasal cavity, and 
eyes. The major acute complication associated with radiation treatment of the oral cavity is 
mucositis.  Mucositis always occurs to some degree in patients that have received irradiation to the 
oral cavity, pharynx, and/or esophagus.  Mucositis typically begins during the second week of therapy 
and reaches a maximum severity during or shortly after the last week of therapy. Clinical signs 
include thickened saliva and tenderness of the mouth. These patients occasionally become reluctant 
to eat or drink and require supportive care. Low-salt foods are more palatable and less irritating to 
the oral mucosa than regular commercial diets. Oral mucositis should subside 1-2 weeks after 
therapy.  Late complications of radiation specific to the oral cavity include, osteoradionecrosis, 
xerostomia and oronasal fistula development.  Xerostomia (dryness of the mouth due to salivary 
dysfunction) is a common complication in human patients undergoing radiation therapy of the head 
and neck region. Osteoradionecrosis, or development of non-vital bone susceptible to pathologic 
fracture after radiotherapy, is an uncommon complication that can occur in any bone in a radiation 
field, typically years after treatment.  The mandible is the most susceptible bone to 
osteoradionecrosis but as with most late effects, the risk can be minimized by administering 
radiation in lower dose per fraction.  Oronasal fisutla development after radiation is rare unless the 
hard or soft palate has been disrupted by an aggressive tumor or oral surgery.   
 
 
 1.  Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog:  a retrospective survey of 
361 cases. J Am Vet Med Assoc 1979;175:567-71. 
 2.  Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral 
malignant melanoma: 100 cases (1987-2001). J.Am.Vet.Med.Assoc. 2003;222:1234-6. 
 3.  Pommer A.  X-ray Therapy in Veterinary Medicine. In: Brandly CA, Jungher EL. Advances in 
Veterinary Science Academic Press, 1958:98-136. 
 4.  Theon AP, Rodriquez C, Madewell BR. Analysis of prognostic factors and patterns of failure in 
dogs with malignant oral tumors treated with megavoltage irradiation. Journal of the American 
Veterinary Medical Association 1997;210:778-84. 
 5.  Proulx DR, Ruslander DM, Dodge RK et al. A retrospective analysis of 140 dogs with oral 
melanoma treated with external beam radiation. Veterinary Radiology & Ultrasound 
2003;44:352-9. 
 6.  Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by 
hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). Journal of 
Veterinary Internal Medicine 2003;17:96-101. 
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Melanoma: New Treatment Strategies 
 
The mainstay of local melanoma therapy in dogs remains surgical excision and/or radiation therapy.  
Depending on the location and malignant potential of a particular lesion, surgery alone can lead to 
cure or long-term control. However, a significant proportion of oral mucosal and subungual 
melanomas have metastatic potential and effective systemic therapies are essential for the 
management of biologically aggressive lesions. Unfortunately, malignant melanoma in dogs and 
humans is notoriously resistant to standard cytotoxic chemotherapy. Currently, considerable 
variability in reported progression-free and overall survival exist for dogs following excision and is 
consistent with the unpredictability of the disease with our current level of characterization. The 
varied outcomes reported combined with little correlative information regarding potential prognostic 
and predictive factors make outcome comparisons of surgery and additional adjuvant therapies 
difficult. Most canine therapeutic studies include insufficient numbers for adequate statistical power 
and fewer compare treatment protocols in a randomized prospective fashion.   In addition, staging, 
inclusion and response criteria vary considerably between the treatment groups.  Therefore, 
evaluations of efficacy between the various treatments are subject to bias, making direct 
comparisons difficult and indeed precarious.   
 
Nearly all melanoma specimens from humans are subjected to genetic testing such that proper 
treatment recommendations can be made.   Our understanding of the genetic and molecular players 
in canine melanoma is increasing but is still limited and is a necessary prerequisite to rational and 
more individualized treatment strategies for dogs with aggressive melanomas.  Table 2 presents 
some of the current novel therapeutic approaches and potential therapeutic targets under 
investigation in veterinary oncology – these will be discussed during this presentation. Much of the 
activity currently involves immunomodulatory therapies designed to stimulate a clinically relevant 
immune response to melanoma.  Vaccine technologies are a particularly active area of research, 
however we are still in relative infancy in our understanding of the immune system and the 
mechanisms by which tumors avoid immune attack.  Vaccines strategies that are combined with the 
immunomodulation of tolerance such as CTLA4 inhibition (ipilimumab) and PD-1/PD-1L inhibitors are 
currently showing promise in human trials and will likely become important in the future in 
veterinary medicine. 
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Table 2. Novel therapeutic approaches/targets under evaluation for canine malignant melanoma 
either with in vitro and/or in vitro data  
 
Small molecule 
inhibitors 
 NFKB inhibition (e.g., Bortezomib) – in vitro/vivo 
 Bcl-2 inhibition (e.g., ABT-737) – in vitro 
 Heat shock protein inhibition (e.g., STA-1474) – in vivo 
 NK-1R inhibition (e.g., maropitant) – in vitro/vivo 
 KIT inhibition (e.g., masitinab, toceranib) – in vitro/vivo 
 IGF-1, JAK1, PDGF inhibitors - in vitro/vivo 
 RACK1 – in vivo 
 AKT, mTOR - in vitro 
Immunomodulation  Nonspecific immunomodulators (e.g., L-MTP-PE, imiquimod  
             IL-12, AdCD40L) – in vitro/vivo 
 Antitumor vaccines (e.g., DNA vaccines, whole cell vaccines,  
            cytokine enhanced vaccines, electrogene transfer, dendritic   
             cell vaccines) - in vitro/vivo 
 Radiation/immunomodulation combinations - in vitro/vivo 
 Methods of breaking tolerance – (e.g., Treg depletion, CTLA4      
             blockade, antiPD-1/PD-1L) - in vitro/vivo 
siRNA, oncomirs 
(microRNA) 
 siRNA targeting surviving – in vitro 
 anti-oncogenic microRNA tumor suppressors -  in vitro 
Oncolytic viruses   Oncolytic vaccinia virus – in vitro  
Cox-2 inhibitors  in vitro/vivo 
Other novel targets  Leptin 
 Cadherins 
 Fascin-1 
 MMP9 
 Chondroitin sulfate proteoglycan-4 
 
Bergman et al. (2013). Melanoma. In Withrow, Vail & Page (eds). Small Animal Clinical Oncology. 
Pp321-334. St. Louis, MO, Elsevier. 
Campagne et al. (2013). Canine melanoma diagnosis: RACK1 as a potential biological marker. Vet 
Path, 50, 1083-1090. DOI:10.1177/0300985813490754. 
Coyner and Loeffler. (2011). Topical imiquimod in the treatment of two cutaneous melanocytomas in 
a dog. Vet Derm 23, 145-e31. DOI: 10.1111/j.1365-3164.2011.01000 
Docampo et al. (2011). Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix 
metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines. Am J Vet Res, 72, 
1087-1096. DOI:10.2460/ajvr.72.8.1087 
Finocchiaro and Glikin. (2012). Cytokine-enhanced vaccine and suicide gene therapy as surgery 
adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Canc Gene Therapy, 
19, 852-861. 
Gentschev et al. (2013) Characterization and evaluation of a new oncolytic vaccinia virus strain 
LIVP6.1.1 for canine cancer therapy. Bioenineered, 4, 84-89. DOI:10.4161/bioe.2242 
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Greene et al. (2013). Expression of leptin and iNOS in oral melanomas in dogs. J Vet Intern Med 27, 
1278-1282. DOI:10.1111/jvim.12169. 
Grosenbaugh et al. (2011). Safety and efficacy of a xenogeneic DNA vaccine encoding for human 
tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of 
the primary tumor. Am J Vet Res 72, 1631-1638. 
Han et al. (2013). Alteration in E-cadherin/B-catenin expression in canine melanotic tumors. ˆVet 
Pathol, 50, 274-280. DOI:10.1177/0300985812457792. 
Impellizeri et al. (2012). Electro-gene-transfer as a new tool for cancer immunotherapy in animals. 
Vet Comp Onolc, DOI: 10.1111/vco.12006, epub 
Ito et al. (2013). The proteasome inhibitor bortezomib inhibits the growth of canine malignant 
melanoma cells in vitro and in vivo. Veterinary J, 198, 577-582. 
Kent et al. (2009). Activation of the AKT and mammalian target of rapamycin pathways and the 
inhibitory effects of rapamycin on those pathways in canine malignant melanoma cells.Am J Vet Res, 
70, 263-269. DOI:10.2460/ajvr.70.2.263. 
London et al. (2011). Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor 
ganetespib in dogs with spontaneous cancer. PlosONE , e27018. doi:10.1371/journal.pone.0027018 
Mayayo et al. (2011). Chondroitin sulfate proteoglycan-4: a biomarker and potential 
immunotherapeutic target for canine malignant melanoma. Vet J, 190, e26-30. 
DOI:10.1016/j.tvhjl.2011.02.020 
Moriyama et al. (2010). Small interfering RNA (siRNA) against the survivin gene increases apoptosis in 
a canine melanoma cell lineJ Vet Med Sci, 72, 1643-1646. 
Noguchi et al. (2011). MicroRNAs as tumor suppressors in canine and human melanoma cells and as 
a prognostic factor in canine melanomas. Vet Comp Onc, 11, 113-123. DOI: 10.1111/j.1476-
5829.2011.00306.x 
Ottnod et al. (2013). A retrospective analysis of the efficacy of Oncept vaccine for the adjunct 
treatment of canine oral malignant melanoma. Vet Comp Oncol, DOI: 10.1111/vco.12057, epub 
Pavlin et al. (2012). IL-12 based gene therapy in veterinary medicine. J Transl Med 10, 234-245 
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Melanomas spontaneously occur in dogs, as in humans, due to genetic and environmental factors.  
The availability of dog breeds, presenting different melanoma type predispositions, considered as 
genetic isolates, should considerably simplify the search of the genetic causes of melanomas.  
To characterize their homologies and differences with human melanoma types, we obtained 
epidemiological data from 2350 melanocytic tumours from veterinary histopathology laboratories 
and we analyzed in depth epidemiological, clinical and histopathological data from 150 canine 
melanocytic tumours. We found that melanomas occur in the same anatomical locations than 
humans and interestingly, specific dog breeds present higher risk to develop oral or cutaneous 
melanoma, strongly reflecting genetic predispositions. We then proposed a histogenetic 
classification, based on the human classification and showed that canine melanomas appear good 
natural models for different human melanoma types, especially for the non-UV pathways of human 
melanomas, specifically acral and mucosal melanomas.  
 
We collected over 500 blood samples and 250 melanoma tumour /healthy samples from oral and 
cutaneous melanomas in high-risk dog breeds. Our first results show that oral melanomas present 
low frequency of somatic mutations in NRAS and PTEN genes, while no mutation have been found in 
the BRAF gene. The finding of mutations in the same genes as in human melanoma subtypes, and 
even, at the human hotspot sites, opens the field for specific targeted clinical trials in dogs. We 
expect genetic and epidemiological approaches to reveal genetic and environmental events involved 
in dog melanomas, considering each canine melanoma subtype in its predisposed breed as a piece of 
the complex human melanoma puzzle. Dogs thus represent invaluable models to identify novel 
genes, especially in the non-UV pathways, participating to the development of new therapies, which 
can benefit both human and veterinary medicine. 
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Comparative aspects of grey horse melanoma 
In humans, melanomas are mostly aggressive melanocytic skin tumours, which metastasise to other 
organs and are usually lethal when left untreated at an early stage. In dogs, melanoma disease 
accounts for up to 7% of all skin tumours. Whilst lesions arising from haired skin are usually 
associated with a good prognosis, lesions affecting the oral cavity or mucocutaneous junctions show 
a high tendency for rapid progression and metastasis. Feline melanomas are rare, mainly involve the 
eye or eyelid and at these sites are behaviourally more malignant than dermal melanomas.  
A particular scenario is encountered in horses. Malignancy of the lesions rather seems to depend on 
the coat colour than the site of affection. In solid-coloured horses, melanomas are rare, yet show a 
highly aggressive behaviour. In contrast, grey horses frequently develop cutaneous melanomas and 
internal pigment cell tumours, especially during the second half of their life. It is estimated that up to 
80% of grey horses older than 15 years develop melanomas. As a unique feature, grey horse 
melanomas are frequently encapsulated and thus poorly vascularised. As a consequence, metastasis 
of such lesions is retarded or inhibited. Gene analyses have allowed to assign the grey phenotype to 
a 350 kb region of equine chromosome 25. This region comprises the gene coding for syntaxin 17 
(STX17). Southern blot analysis of non-grey versus grey horse DNA has revealed the presence of a 4.6 
kb duplication in STX17 intron 6 of the latter.  This duplication (D) was detected in both alleles of 
homozygous (D/D), yet only one allele of heterozygous grey horses (D/-), thus strongly suggesting a 
direct association of the duplication with the grey phenotype. Screening of 472 homozygous, and 255 
heterozygous grey horses as well as 131 non-grey individuals fully confirmed this assumption. 
Remarkably, it could be shown that the incidence of melanoma significantly correlated with the D/D 
genotype, i.e. homozygous grey horses. 
Currently, there is no universally effective therapy to cure melanoma disease. Treatment methods 
include the use of chemotherapeutics, radiotherapy, immune-modulators and gene expression 
suppressors. Difficulty to treat malignant melanoma in domestic animals and man is due to the fact 
that many aspects of disease initiation and progression still remain to be elucidated. 
An important step towards the development of an effective, targeted therapy against melanoma is 
the reliable identification of key regulatory factors in the progression of the disease. This can be 
achieved via gene expression profiling and mutation analyses.  
Microarray-based expression profiling has revealed novel pathways in the transformation of human 
melanocytes to malignant melanoma. DNA microarray technology is also used as a powerful 
predictive diagnostic tool for clinical applications. The European Organisation for Research and 
Treatment of Cancer (EORTC) has analysed 83 primary melanoma samples for a correlation between 
gene expression profile and clinical outcome. Using class comparison and prediction algorithms, a 
signature of 254 genes could be identified to act as an accurate indicator for 4-year distant 
metastasis-free survival. Another recent study used molecular profiling as a tool to predict the clinical 
outcome in patients suffering from stage III melanoma, which previously was not possible by any 
other means. For this, RNA was isolated from lymph node sections of 29 patients and subjected to 
oligonucleotide array analysis. A predictive score algorithm that was based on the expression of a 
subset of 21 genes could be accurately applied to distinguish patients with good from those with 
poor prognosis.  
In horses, microarray technology has been used thus far to study the biological mechanisms involved 
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in the development of common, papillomavirus-induced skin tumours termed sarcoids, revealing 
deregulated transcription of a broad range of genes, including MMP-1, TLR4, MHC-I, and CD68. 
Thanks to second generation-sequencing technologies, i.e. RNAseq, it has recently become feasible 
to quickly and inexpensively analyse transcriptomes, exomes, and complete genomes isolated from 
cancer samples. 
We have used this method to analyse the transcriptomes of grey horse intact skin versus melanoma 
and primary melanoma cells derived from the same individuals. Methodologically, tumour and skin 
samples have been obtained with the owners’ written consent from affected grey horses and 
processed immediately. RNA has been isolated from collected tissue and cell material using an 
RNeasy Mini kit (Qiagen, Hilden, Germany). Then, a protocol that effectively amplifies non-ribosomal 
RNA molecules with lengths greater than 50 nucleotides (nts), including polyadenylated and non-
polyadenylated transcripts, has been applied. Finally, RNAseq analysis was carried out by commercial 
partner BGI in Hong Kong.  
Ongoing analysis of obtained data has so far revealed deregulated intratumoural transcription for 
over 2000 genes. Deregulated genes have been assigned to functional clusters, i.e. cell proliferation 
and apoptosis, angiogenesis, cell adhesion, motility and integrity, inflammation and immunity, as to 
determine deregulation-affected biological pathways. Genes with significantly upregulated 
transcription included e.g. melanoma marker genes that have already been identified in human 
melanoma, such as MAGE (melanoma antigen), MITF (microphthalmia-associated transcription 
factor), PMEL17 (aka Silv, gp100; pre-melanosome protein 17), or TYRP1 (tyrosinase-related protein 
1). As already described for human and animal tumours, and most notably equine sarcoids, 
upregulation of MMP1 (matrix metalloproteinase 1) has been noted for equine melanoma tissue and 
cells. This is not surprising in so far as this proteinase lyses the extracellular matrix and thus 
promotes metastatic processes. Increased transcription has also been observed for collagen-
degrading MMP9. Detected MMP1 and MMP9 overexpression has been confirmed on mRNA and 
protein level for additional melanoma (n=9), skin (n=8) and cell samples by quantitative RT-PCR, 
immunohistochemistry (IHC) and immunofluorescence (IF). 
Particular attention is currently paid to the recorded tumour-associated overexpression of CD68 
mRNA. CD68 is a glycoprotein that is typically expressed by monocytes/macrophages and thus 
regarded as specific marker for these cells. Accordingly, traditional immunological detection of 
monocytes/macrophages is carried out using anti-CD68 antibodies. Based on this type of assay, 
different human studies came to the conclusion that macrophages predominantly invade progressive 
cancers. Consequently, presence of tumour-associated macrophages, so called TAMs, is commonly 
correlated with poor prognosis.  
On this basis, the observed upregulation of CD68 transcription in grey horse melanoma was initially 
attributed to the intratumoural presence of TAMs. However, it seemed rather absurd to correlate 
this finding with poor prognosis since the CD68-positive tumour material was mainly derived from 
semi-quiescent encapsulated nodules. Conventional RT-PCR from additional tissue and cell RNA 
material revealed the presence of CD68 transcripts in melanoma tissue and monocyte/macrophage-
free primary equine melanoma cell lines. To verify this unexpected finding, we then analysed 
melanoma tissue sections by IHC. In addition, primary melanoma cell lines were analysed by IF using 
green fluorescently labelled anti-CD68 and red fluorescently labelled anti-melanoma (S100) 
antibodies. IHC revealed CD68-positive cells that were morphologically identified as tumour cells. IF 
showed co-localization of CD68 and S100 for a high percentage of tumour cells, providing conclusive 
evidence of equine melanoma cells expressing CD68 protein.  
Although first descriptions of CD68 date from the 1980th, its function is still largely unknown. 
However, there are indications for CD68 having a key role in phagocytosis. This led us to assess the 
phagocytic potential of CD68+ primary melanoma cells. As shown by FACS analysis, these cells were 
able to engulf green fluorescently-labelled latex beads.  
We hence conclude that grey horse melanoma cells express CD68 glycoprotein, and by this, are 
phagocytic cells. In depth investigations are required to elucidate the tumour biological impact of this 
phenomenon. Together with the finding of CD68 upregulation in equine sarcoid cells reported by 
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Prof. Nasir and her group (Glasgow, UK), our findings are indicative for CD68 representing a 
phagocytosis rather than a monocyte/macrophage marker. We hypothesize that CD68 is expressed 
by different types of cancer cells in different species. Our current work focusses on testing this 
hypothesis and investigating the pathobiological role of CD68 expression by cancer cells.  
For references: please contact S. Brandt (sabine.brandt@vetmeduni.ac.at) 
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Targeted Therapies in the Treatment of Human Cancers 
 
The introduction of targeted therapies, especially monoclonal antibodies, have revolutionized the 
treatment of human cancer. When in the late 90’s trastuzumab as one of the first antibodies in the 
treatment of Her-2 positive breast cancer was introduced into the clinics (Hudis, 2007). Thus, a so far 
worse prognostic marker became a druggable target and improved progression as well as overall 
survival of the patients. Targeting tumor cells soon led to introduction of further antibodies against 
other members of the EGFR-family, such as cetuximab and panitumumab(Van et al., 2009; Douillard 
et al., 2010). Beside antibodies directly targeting tumor cells, the microenvironment has soon 
become the focus of therapeutic intervention. Thus, anti-VEGF targeting antibodies (Hurwitz et al., 
2004) as well as genetic engineered anti-VEGF traps (Tabernero J, 2012) are in routine use for certain 
types of cancer such as those originating from colon, lung or kidney. 
 
However, recent advances in our understanding of the intricate molecular mechanisms for malignant 
transformation and the aberrant control of complementary pathways have presented a much more 
complex set of challenges for the diagnostic and therapeutic disciplines than originally anticipated. 
Based on these advances, medical oncology has started to enter an era of individualized medicine 
where treatment selection for each cancer patient is becoming individualized or customized. For 
example, anti-EGFR antibodies in the treatment of colorectal cancer requires a genetic unaltered 
subsequent signaling pathway. A somatic RAS-gene mutation frequency of approximately 55% in all 
metastasized colorectal cancers prevents the application of a treatment option in this disease. Thus, 
mCRC requires a baseline gene mutations analysis to stratify the right patient for the right treatment. 
Notably, RAS-mutated mCRC patients, who received an anti-EGFR plus chemotherapy treatment, had 
a significant shorter progression-free survival as those patients who were treated with chemotherapy 
only (Douillard et al., 2013). 
 
A tailored treatment is based on molecular and genetic characterization of the tumors including 
biomarker technology, which allow us to align the most appropriate treatment according to the 
patient's disease. Although there is a general acceptance towards such an individualized approach 
thereby stratifying and subgrouping patients to improve the quality of clinical care in oncology, 
molecular profiling has just started to assist prediction. 
 
Thus, several excellent demonstrations of the utility of prognostic and/or predictive biomarkers have 
emerged over the past decade.  
Currently introduced novel targeted agents in the treatment of cancer are approved for a certain 
subtype of cancer rather than for an individually diagnosed druggable target or for an entire signaling 
pathway. Therefore, there is increasing evidence that an extension of treatment protocols focusing 
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at molecular profile-based treatment decisions is needed thus generating a scientific rationale for an 
individualized treatment approach. 
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Oral presentations 
 
The Wim Misdorp Award aims to encourage members in the earlier years of their career in veterinary 
oncology to pursue a period of scientific investigation in the field of veterinary oncology. 
 
The award is to recognize outstanding contributions to the knowledge related to pathogenesis, 
diagnosis, therapy, prevention, or control of animal tumour-diseases. It is given once yearly at the 
ESVONC Annual General meeting to a veterinarian based upon his/her written abstract and oral 
presentation of scientific data at the meeting. In addition to a Certificate this award covers the travel 
and registration costs for the author to attend the Veterinary Cancer Society Annual Congress in 
the USA and to present their work. 
 
The Wim Misdorp Award is sponsored by Novartis. 
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Introduction 
Lower urinary tract transitional cell carcinoma (CCT) pose challenge in order to the appropriate 
radiotherapy (RT) regimen. Organs at risk (OARs) within the irradiation field (ureters, rectum) are 
limiting factor in dose escalation. The primary aim of this study was to evaluate the technical 
feasibility of hight-dose hypo-fractionated dynamic IMRT in not-resectable lower urinary CCT 
affected dogs. The secondary goal was to evaluate the toxicity and the efficacy of the RT regimens. 
Materials and Methods 
Three dogs with lower urinary tract CCT were treated with definitive high-dose hypo-fractionated RT 
with VMAT technique. Volume treatment definition include the gross tumor (GTV), the PTV1 
(GTV+3mm), limphatics (PTV2), the entire bladder, prostate in males and uretra (PTV3), the entire 
pelvis except the rectal volume (PTV4). Dose prescriptions were 40 Gy to PTV1, 38 Gy to PTV2, 34 Gy 
to the PTV3, 30 Gy to the PTV4, in 6 fractions on alternate days. Piroxicam was subministered to all 
dogs. Serial clinical and CT/MRI examination were performed. Disease control and toxicity effects 
were evaluated according to RECIST and VRTOG criteria. 
Results 
Three T2N0M0 vescical CCT were treated. Prescription goals were obtained in all three cases with 
V95%>95% and V107%>2%. During follow up (mean 6 months) one partial response and two 
complete response were obtained. Two grade I cystitis developed. Non rectal toxicity was 
recognized. 
Conclusions 
Initial experiences with the RT regimen adopted indicate a feasibility and effectiveness in canine 
lower urinary canine CCT. Longer follow up and larger series are needed. 
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Introduction 
Canine TCC shows striking similarity to human bladder cancer, however little is known of the 
molecules implicated in canine TCC. The aims of our study was to dilucidate if there are alterations in 
the expression of molecules especially intricated in cancer development as the tumor suppressors 
p53 and 14-3-3σ and also vimentin.   
Materials and Methods 
Nineteen canine bladder tumours cases and 2 normal bladder tissues were retrieved from our tissue 
archives. All samples had been fixed in 10% neutral buffered formalin and embedded in paraffin wax. 
Monoclonal antibodies against 14-3-3σ, p53 and vimentin and the EnVision™ immunohistochemical 
technique were employed. The reactions observed were semicuantitatively analyzed.  
Results 
Expression of 14-3-3σ was decreased in 53% of cases, p53 protein was over-expressed in 26% of 
cases and vimentin was neo-expressed in 21% of cases. Vascular invasion was observed in three 
cases and showed moderate to strong staining of both 14-3-3σ and vimentin.  
Conclusions 
The pattern of expression of 14-3-3σ indicates a probable role in the carcinogenesis and invasion 
mechanisms of canine TCC. The expression of vimentin in infiltrative cells reflexes the acquisition of 
an epithelial-mesenchimal transition that could lead to greater likelihood of metastasis. Finally, p53 
appears to contribute to develop TCC with high frequency than previously thought.
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Introduction  
Surgery has a limited role in treatment of canine lower urinary tract tumours. In human medicine, 
invasive bladder transitional cell carcinoma (TCC) is treated by means of radical cystectomy followed, 
in most of the cases, by reconstruction with an ileal orthotopic neobladder. The aim of this study was 
to evaluate similar techniques in dogs. 
Materials and Methods  
Records of dogs with bladder and urethral TCCs diagnosed between 2005 and 2013 were identified. 
Dogs with histologic diagnosis of a primary lower urinary tract TCC treated with total or subtotal 
cystectomy or isolated urethrectomy were included. Surgical treatment consisted in urethrectomy 
and cystovaginal anastomosis (CVA), radical cystectomy and ureterovaginal anastomosis (UVA), 
radical cystectomy and ureterourethral anastomosis (UUA), and trigonal resection (TR). 
Results  
Eleven dogs were included. Nine purebred dogs and 2 cross breed dogs (10 females, one male), 
between 9 and 13 years of age (mean 10.2) were identified. Median body weight was 10.5 kg (range 
4-37 kg).      Three dogs were treated by CVA, 3 by UVA, 4 by UUA and 1 using TR. Three dogs 
received adjuvant chemotherapy. Survival time ranged between 7 days and 20 months (mean 6.45 
months, median 3.5 months). Three dogs died for unrelated causes 14, 14 and 20 months after 
surgery respectively and one dog is still alive 6 months after surgery. 
Conclusions 
Our experience with complete cystectomy was good in terms of clinical outcome, although most of 
the patients died because of metastatic disease. Chemotherapy did not seem to improve survival in 
our cases. 
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Introduction 
The last decade has witnessed significant advances in personalized treatments as a result of genomic 
analysis and targeted drug therapies. In the present study, the transcriptome of dogs that had died 
because of mast cell tumors (MCTs) was characterized to identify a fingerprint having significant 
influence on cancer risk assessment, prognosis determination and treatment selection. 
Materials and Methods 
The transcriptome of 7 biopsies obtained from dogs with histologically-confirmed, surgically-
removed MCT, treated with chemotherapy, and dead for MCT-related causes, was characterized by 
using Agilent Canine V2 4x44k DNA microarray, and compared with 40 samples obtained from dogs 
with histologically-confirmed, surgically-removed MCT that were alive after ~2 years of follow-up. 
Among the differentially expressed genes, 11 transcripts were chosen to validate DNA microarray 
results by qPCR and, then, their mRNA levels were measured in a cohort of 22 independent MCTs. 
Results 
Statistical analysis identified a total of 377 differentially expressed genes (FDR 5%). The functional 
annotation analysis provided evidence of drug metabolism, steroid metabolism and cell cycle 
pathways; particularly, members of solute carrier transporter (SLC) and UDP glucuronosyltransferase 
(UGT) gene families were identified as targets. The Principal Component Analysis of the 22 cohort 
MCTs identified two separate clusters, and one of these referred to 4 dogs that had died due to MCT. 
Conclusions 
SLCs and UGTs have been recently recognized in human cancer as important key factors in tumor 
progression and chemo-resistance. An in-depth analysis of their role in aggressive MCT might be 
useful in perspectives.  
 
Supporting grants: RC IZSVE 04/10 
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Introduction 
Canine mast cell tumours (MCTs) are variable in their biological behaviour and treatment decisions 
depend heavily on the histopathological grade. Biomarkers such as neutrophil to lymphocyte ratio 
(NLR) and albumin to globulin ratio (AGR) are used to predict biological behaviour of human 
neoplasms, but have not been widely studied in dogs. 
Materials and Methods 
A retrospective analysis of all dogs presenting to our hospital with MCTs from 2009-2014 was 
performed. Inclusion criteria were haematology and/or biochemistry results, a histopathological 
specimen and no steroid therapy or surgery within the last 60 days. Cutaneous MCTs were regraded 
if necessary using the two tier system proposed by Kiupel. 
Results 
Forty nine patients were included in the study (11 high grade, 38 low grade tumours). Receiver 
operator characteristic curve analyses was performed. These produced areas under the curve, 
representing the predictive ability of parameter, of 0.86 for NLR and 0.63 for AGR. The most suitable 
cut-off point for NLR was 8.7 (sensitivity 73%; specificity 97%). This value correctly classifying the 
largest proportion of tumours (92%). Neither AGR nor any individual parameter was found to have a 
useful a cut off value.           NLR of low (5.59) and high grade (10.5) tumours were compared using a 
Mann-Whitney test which showed a significant difference between groups (p=0.0003). 
Conclusions 
An NLR cut-off of 8.7 can be used alongside existing prognostic tools (appearance, location etc.) to 
help to predict the likely grade of a canine mast cell tumour. This biomarker could therefore be used 
to guide treatment decisions prior to obtaining a histopathological diagnosis. 
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Introduction 
Ki67 and MI scoring are independent predictors of survival in canine MCT, but often conflict making 
clinical decisions difficult. The study aims were to assess how closely they correlate and which more 
accurately predicts survival. 
Materials and Methods 
Dogs with MCT, with MI & Ki67 scoring, from three UK referral hospitals were retrospectively 
analysed. Ki67 analysis used the cut-off provided by the laboratory. Correlation of Ki67 and MI were 
assessed and Kaplan Meier survival analysis compared by Ki67 and MI scores. 
Results 
163 dogs were included. 57 dogs died, 37 due to MCT, 126 were censored (alive or dead of other 
causes).Using numeric Ki67 data with a quoted 1.8% cut-off (134), correlation between Ki67 and MI 
was good (Pearson’s coefficient = 0.758); agreement using Ki67 cut-offs was poor (Cohen’s kappa 
0.214 (MI≥5)). Using established reference values, high Ki67 was sensitive at predicting MCT related 
death (86.5%), but poorly specific (57.9%). MI≥5 was poorly sensitive (43.2%) but highly specific 
(94.4%). ROC analysis established MI≥2 as a superior cut-off, providing 75.7% sensitivity and 80.2% 
specificity. Ki67 produced a significant survival difference within the MI<2 group (p=0.009) but this is 
unlikely to be clinically significant. Ki67 score did not predict survival in tumours with MI≥2. 
Conclusions 
MI≥5 accurately predicted death but many dogs with MI<5 succumbed to MCT. Low Ki67 accurately 
predicted survival but high Ki67 was not necessarily a poor prognostic indicator. A lower MI cut-off 
(2) seemed more accurate, but created an unpredictable intermediate level (MI 2-5), where Ki67 did 
not provide further prognostic information.     
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Introduction 
Mast cell tumours (MCTs) are among the most common cutaneous neoplasms in dogs and have a 
highly variable clinical behavior leading to the need of finding markers with potential as therapeutic 
targets. The overexpression of COX-2 seems to play a key role in MCTs, having being described an 
association between high Cox-2 immunoexpression and the histological grade of malignancy. In order 
to contribute to the understanding of the role of Cox-2 in MCTs, three main pathways were 
investigated: angiogenesis (by CD31 and VEGF expression), tumour cell proliferation (by Ki-67 
antigen) and the inflammatory microenvironment (T-lymphocyte and macrophages). 
Materials and Methods 
Fifty (50) MCTs were included (15 grade I, 17 grade II and 18 grade III), and submitted to immuno-
histochemical staining for detection of the following markers (COX-2, Ki-67, CD31, CD3 and MAC387). 
Results 
High COX-2 immunoexpression revealed a statistically significant association with histological grade  
(P = 0,002); CD31 (P = 0.0018); Ki-67 (P = 0.008); but not with macrophages and CD3+ T-lymphocytes. 
COX-2 was also positively correlated with CD31 (r = 0.334; P = 0.029) and Ki-67 proliferative index  
(r = 0.359; P = 0.011). 
Conclusions 
In this study, MCTs with high Cox-2 immunostaining presented predominantly an elevated 
histological grade of malignancy, a higher number of microvessels and a high proliferative index 
comparatively to tumours with low Cox-2 immunoexpression. Present results support the hypothesis 
that some of the underlying pathways involved in its biological aggressiveness including those related 
to angiogenesis and tumor proliferation might be related with COX-2-dependent mechanisms. 
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Introduction 
Mast cell tumours (MCT) are the most common canine cutaneous malignancy. Histological grade and 
proliferative markers are used as prognostic indicators but limitations exist. MicroRNAs are post-
transcriptional regulators of gene expression. They have key roles in all phases of cancer 
development and are dysregulated in numerous human cancers. The aim of this study was to 
evaluate microRNA profiling of cutaneous MCTs of dogs in order to potentially stratify patients with 
metastatic and non-metastatic disease. 
Materials and Methods 
Total RNA was isolated from 20 formalin-fixed, paraffin-embedded surgical biopsies of 
chemotherapy-naïve primary canine cutaneous MCTs with known outcome (10 metastatic and 10 
non-metastatic). Metastatic patients had proven local and/or distant spread of disease. RNAs were 
labelled with Hy3 and hybridised to miRCURY LNA 7th generation microRNA (human, mouse & rat) 
microarrays. Background-subtracted hybridisation signal intensities were log2-transformed, and 
between array loess normalisation performed. MicroRNAs showing differences in expression 
between metastatic and non-metastatic MCTs were identified by T-test. P values were adjusted for 
multiple testing by application of a permutation test. 
Results 
Fourteen microRNAs displayed statistically significant differential expression (Pd increased 
expression in the metastatic MCTs). Reverse transcription-quantitative PCR was used to validate the 
differential expression of 6 of the 14 microRNAs which displayed the largest fold differences in 
expression. 
Conclusions 
This preliminary investigation suggests that microRNAs may be useful as markers for predicting the 
aggressive clinical behavior of cutaneous MCTs in dogs, and may indeed have a role in the regulation 
of canine MCT metastasis. 
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Introduction 
The goal of this retrospective study was to assess Progression Free Survival (PFS) of masitinib-
incorporated treatment protocols in dogs with mast cell tumours (MCTs), co-analyzing tumour grade, 
metastasis status, remission rate and previous surgery. 
Materials and Methods 
Data (01/12/2008-01/01/2014) were collected from two veterinary oncology centres (NL&UK). MCTs, 
either surgically unmanageable, and/or with high metastatic risk or already metastasized were 
included and divided in cutaneous grade 1-2-3, subcutaneous (SQ) and other locations (OL). The first-
line and rescue protocols masitinib-sole (MS), masitinib-prednisolone (MP), and masitinib-
prednisolone-chemotherapy (MPC) were analyzed, using multivariate Cox-regression method. 
Adverse events were recorded according to VCOG-CTCAE v1.1. 
Results 
147 dogs were enrolled; 30 completed the intended treatment course (median/mean 186/241 days). 
Nine of twelve tumours checked, demonstrated c-kit mutations. Grade distributions per treatment 
group and median/mean PFS (days) were: MS 33gr2/17gr3/15SQ/2OL, median/mean PFS 112/304; 
MP 1gr1/25gr2/19gr3/8SQ/4OL, median/mean PFS 217/373; MPC 8gr2/5gr3/3SQ/2OL, 
median/mean PFS 49/202; Rescue 2gr2/2gr3/1SQ, median/mean PFS 38/71. Difference in PFS was 
significant for MS-MPC (P<0.001) and MP-MPC (P=0.0056), but not for MS-MP (P=0.118). This 
treatment effect was consistent at both centres, despite PFS differed significantly between them 
(P<0.001). PFS was significantly influenced by remission (P<0.001) and metastasis status (P<0.001), 
but not by grade or previous surgery. Severe adverse events included anaemia (n=3), 
hypoalbuminaemia (n=3), hepatopathy (n=3), gastrointestinal toxicity (n=2) and neutropenia (n=1). 
Conclusions 
Treatment protocol, completeness of remission and metastasis status, but not grade, were the most 
significant prognostic factors for PFS. Adding chemotherapy negatively influenced PFS. Impact of c-kit 
mutation could not be analysed as too few cases were evaluated. 
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Introduction 
The goal of this prospective study is to assess the median survival time (MST) of a population of dogs 
with mast cell tumours (MCT), treated with a lomustine-toceranib-prednisolone protocol. 
Materials and Methods 
Dogs with measurable non-resectable, metastatic or recurrent grade II/III MCT, with a minimal 
estimated life expectancy of 8 weeks, were incorporated. Routine MCT staging was performed. Dogs 
were treated with lomustine at 70mg/m2 (60-80) every three weeks and toceranib at 2.7mg/kg EOD. 
Prednisolone (1mg/kg EOD) was administered the day without toceranib. Response to treatment and 
treatment related toxicity were monitored according to RECIST 1.1 and VCOG-CTCAE v1.1, 
respectively. Tumour samples were analysed for c-kit status, Ki67, VEGFR expression levels utilizing 
immunohistochemistry. 
Results 
So far 12 dogs are included in the study and complete data are available for 8 dogs. Four dogs had 
multiple tumours, 4 dogs a single MCT. Response included 3 CR, 2 PR, 2 SD and 1 PD. Two patients (1 
CR, 1 PR) are still alive (MST 432 days), 4 patients died due to different reasons, including PD and 
treatment related side effects (MST 147.8 days). Two patients were removed due to drug 
intolerability. Most common severe adverse events were neutropenia (n=9), vomiting (n=4), pyrexia 
(n=2), pancreatitis (n=1), and increased liver enzymes (n=1). Treatment delays and dose reductions 
were necessary in all 8 patients. 
Conclusions 
Treatment responses were encouraging. However, treatment related toxicities that resulted in 
multiple dose delays and reductions were frequent, indicating summation of common 
gastrointestinal and bone marrow associated side effects. Protocol modifications could improve 
tolerability. 
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Introduction 
Historically, canine cutaneous mast cell tumors (MCTs) have been graded according to the Patnaik 
system. Recently, a new two-tier grading system was proposed. We retrospectively evaluated the 
clinical impact of both grading systems by taking into consideration clinical staging and outcome. 
Materials and Methods 
386 dogs with newly-diagnosed, histologically-confirmed MCTs undergoing complete staging were 
included for the investigation of clinical, histopathologic, therapeutic and survival data. 
Results 
All Patnaik grade 1 (P-G1) and Patnaik grade 3 (P-G3) MCTs were classified as Kiupel low-grade (K-LG) 
and Kiupel high-grade (K-HG) MCTs, respectively. Dogs with P-G1 and K-LG MCTs had a better 
outcome than dogs with P-G3 and K-HG MCTs, respectively. The majority of P-G2 MCTs were 
classified as K-LG tumors, and a small percentage (16.5%) as K-HG MCTs. Forty-four of 295 (14.9%) 
dogs with K-LG tumors had metastatic disease at presentation. When considering the combination P-
G2/K-LG, 41/243 (16.9%) dogs had metastatic disease at presentation. Among dogs with P-G2 MCTs, 
the Kiupel grading system did not predict the development of metastases. A node-positive status was 
associated with a worse prognosis in the whole series as well as in the different subgroups, including 
P-G2/K-LG and P-G2/K-HG MCTs. 
Conclusions 
Patnaik and Kiupel grading systems are important parameters for the risk assessment in canine 
MCTs, and should be assessed in tandem. Histologic grading and nodal metastases equally 
contributed to anticipate the survival probability. The therapeutic management and prognosis of 
canine MCTs should not rely on the sole histologic grading, rather taking into account the clinical 
stage as well. 
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Introduction 
Therapy of canine genitourinary carcinomas has been challenging and limited to the use of Cox-2 
inhibitors, chemotherapy and surgery. However treatment response and outcome remain poor. 
Patient referrals for radiotherapy are still rare and often limited to palliative care for advanced cases. 
This study attempts to describe the profile of cases, and the response and tolerance to various RT 
techniques, and associated survival. 
Materials and Methods 
This multi-institutional study evaluated retrospectively treatment outcomes of 52 dogs with 
macroscopic genitourinary carcinomas (bladder, urethral, prostate) that received megavoltage 
external beam RT (n=27) and HDR brachytherapy (n=25) between 2008 and 2013. Univariate, 
multivariate and survival analysis were performed. 
Results 
The treatments were well tolerated. The overall clinical response rate was 65.4%. OST was 231 days 
(n=52) and ST after radiotherapy was 195 days (n=49). ST was higher for dogs treated with RT doses 
>35Gy (208 vs. 81 days; p=0.028). Cases treated with adjuvant chemotherapy (n=32) had longer OST 
(317 vs. 122 days; p=0.005). Patients with regional metastases at diagnosis (n=9) had lower OST (59 
vs. 239 days; p=0.000). Invading tumours also showed lower survival times (157 vs. 306 days; 
p=0.016). Long-term survival (>1 year) was achieved in 19.6% of cases. 
Conclusions 
These preliminary results confirmed the role of chemotherapy in genitourinary cancer patients. The 
clinical responses and treatment tolerance support the use of radiotherapy and suggest a better 
impact of higher doses protocols. Further recruitment is ongoing, yet later prospective studies are 
needed to define standard RT protocols for early stage and more advanced cases. 
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Introduction 
Systemic therapy for non-resectable or metastatic canine mammary tumours is not well documented 
and there is little evidence of effective treatment options. Toceranib (Palladia®), a receptor tyrosine 
kinase inhibitor, was previously used in a Phase I trial, with a response for over 10 weeks in 4/5 
canine mammary tumours. 
Materials and Methods 
Response to toceranib of measurable, recurrent or metastatic mammary carcinomas in dogs from 
four European countries was prospectively evaluated. Remission according to RECIST 1.1, adverse 
events, concurrent treatments, median treatment duration (TD), progression-free-interval (PFI) and 
quality of life survey were evaluated (QoL). 
Results 
Thirty-eight dogs were enrolled: 1CR, 8PR, 15SD and 14PD were reported. The median dose of 
toceranib was 2.98 mg/kg e.o.d. Side effects were reported in 40% of cases: gastroenteric (69%), 
haematologic (23%) and musculoskeletal (8%). Eight cases, 1 carcinosarcoma, 3 anaplastic 
carcinomas, 2 grade III simple carcinomas, 1 complex carcinoma and 1 carcinoma of unknown grade, 
showed a clinically relevant response with a duration of >10 weeks: 1CR, 4PR and 3SD. Median PFI 
and TD of these 8 dogs were 144 and 159 days, respectively. In the remaining 30 cases, there were 4 
PR and 12 SD, with a mean PFI and TD of 26 and 28 days, respectively. PD was reported in 14 dogs. 
QoL under treatment was judged as good in most cases. 
Conclusions 
In 21% of dogs with advanced disease, a clinically relevant response was achieved, with a PFI of 144 
days in comparison to 32 days for the non-responders. 
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Introduction 
Human inflammatory breast cancer (IBC) and Canine inflammatory mammary cancer (IMC) are the 
most aggressive forms of mammary cancer. The clinical course is rapid and characterized by early 
metastasis and short survival times. Current research aims to establish new therapeutic targets to 
provide better treatment options. Here, we investigated protein and gene expression levels 
associated with the inflammatory microenvironment. 
Materials and Methods 
RNA was extracted from 32 formalin-fixed paraffin-embedded samples of canine mammary tumours 
(IMC=26; tubular carcinoma=6). The same tumour samples were processed and analysed for 
clinicopathological characteristics. cDNA was then obtained by Single Primer Isothermal 
Amplification technology and qPCR performed to measure relative gene expression levels of COX-2, 
Tribbles1, Synuclein Gamma (SNCG), Vimentin, CCL2, VEGF, CCR2 and CSF1R. Immunohistochemical 
(IHC) analysis of CCR2 and CSF1R expression was also performed. Statistical analysis was carried out 
using JMP - Statistical Analysis Software 5.0.1 and Statistical Package for the Social Sciences 17.0. 
Results 
Gene expression differences between IMC and non-IMC types were obtained for COX-2 (P=0.004), 
SNCG (P=0.006), Tribbles1 (P=0.025), VEGF (P=0.017) and CSF1R (P=0.045). Among these biomarkers 
correlations were found, particularly between SNCG and Tribbles1 (R=0.512, P=0.001). For IHC 
analysis, CCR2 expression was associated with presence of tumour emboli and a nuclear subcellular 
localization was observed predominantly in IMC tumours. 
Conclusions 
Upregulation of both SNCG and Tribbles1 in IMC might be the result of cooperation between the 
microenvironment and cancer cells, promoting efficient metastasis formation through epithelial to 
mesenchymal transition. However, further investigation is required to support this hypothesis. 
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Introduction 
RON/stk tyrosine kinase receptor, identified in cat as feline-stk, is activated by MSP and over-
expressed in human breast cancer. Human RON gene is able to generate respectively the full length 
(fl) and the short forms (sf) of the transcripts. sf-RON is generated from an alternative transcriptional 
start from a second promoter within the intron 10 which preserves the kinase activity of the 
receptor. The aim of this research was to identify the presence of the sf-RON in feline mammary 
tumors (FMCs) and evaluate the expression of sf-RON and fl-RON in FMCs in relation to clinical 
follow-up and histological grading. 
Materials and Methods 
Immunohistochemical expression of RON and MSP was evaluated on 50 FMCs. To detect sf-RON, 
RNA was extracted from 47 FMCs and RT-PCR with primers annealing on exon 10 and exon 11 was 
performed on cDNA. 
Results 
Immunohistochemical expression of RON and MSP was observed in the 68% and 58% of FMCs 
respectively while the 52% of the cases co-expressed both proteins. The feline short form of RON was 
detected in 27/47 FMCs and resulted statistically associated with the poorly differentiated 
histological grade. Queens with FMC showing the sf-RON had a shorter disease free period and a 
shorter survival if compared with patients negative for sf-RON. Expression of RON, MSP or both in 
FMC was not correlated with clinical outcome. 
Conclusions 
The presence of the sf-RON in feline specie was firstly identified and only this isoform represents a 
prognostic factor of poor outcome in feline mammary carcinomas. 
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Introduction 
Neutron capture therapy (NCT) is an experimental treatment used for human patients with head and 
neck cancer, particularly, glioblastoma and metastatic melanoma [Yasui L.S. et al., 2008; Barth R.F. et 
al., 2012]. Gadolinium is a potential agent for NCT as a nuclear capture reaction occurs when Gd-157 
is irradiated with low energy thermal neutrons. The release of focal high-dose radiation induces 
chromosome aberrations. In vitro studies show effectiveness of Gd-NCT in inducing cell death 
[Franken N.A. et al., 2006]. The study was undertaken to assess efficacy and adverse effects of Gd-
NCT in 34 dogs with oral malignant melanoma (OMM). 
Materials and Methods 
34 dogs with III stage OMM were treated with Gd-NCT. Contrast agent Gd-DTPA was administered 
intratumoral immediately prior to irradiation. NCT was performed at the IRT MEPhI reactor with 
neutron beam characteristics as described by Mitin V.N. et al. (2009). In dogs with confirmed regional 
lymph node metastasis lymphadenectomy was also performed. Response rates and overall survival 
time were recorded. Adverse effects after treatment were also noted. 
Results 
Gd-NCT induced partial response in 50% (17/34) of dogs and complete response in 47% (16/34). The 
overall survival time calculated using Kaplan-Meier method was 204.2 days. Common adverse effects 
were skin depigmentation (13/34), alopecia (10/34) and radiation-induced stomatitis and dermatitis 
(10/34), in rare cases – radiation necrosis of skin and soft tissues (5/34) and conjunctivitis (2/34). 
Conclusions 
Gd-NCT showed promising results in dogs with oral malignant melanoma and needs further 
investigation. 
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Introduction 
Gemcitabine is a nucleoside analogue with unique metabolic and mechanistic properties. Preliminary 
studies in dogs have shown a mild, schedule-dependent toxic profile with a broad range of 
gemcitabine dosages (350-800 mg/m2). We determined maximally tolerated dose (MTD), dose-
limiting toxicity (DLT), pharmacokinetics, and preliminary antitumor activity of intravenous 
gemcitabine in dogs with advanced solid tumors. 
Materials and Methods 
Dogs with advanced cancer were enrolled in an open-label phase 1 study of 30-min intravenous 
gemcitabine infusion. Gemcitabine was administered starting at 800 mg/m2 using dose escalation of 
50 mg/m2 increments with 3 dogs per dose level. MTD was established based on the number of dogs 
experiencing a DLT after one cycle. Additional dogs were enrolled at MTD to better characterize 
tolerability and pharmacokinetics. Treatment continued until disease progression or unacceptable 
toxicity. 
Results 
Twenty dogs were enrolled and treated at 4 dose levels, ranging from 800 mg/m2 to 950 mg/m2. 
Neutropenia was identified as the dose-limiting toxic event. MTD was 900 mg/m2. DLT was observed 
at 950 mg/m2 in 2 dogs, and consisted of grade 4 febrile neutropenia. There were no non-
hematological DLTs. Eighteen dogs received multiple doses of gemcitabine, and none of them 
experienced severe toxicity from any of their subsequent treatments. At 900 mg/m2 dose level, 5 
complete responses and 5 partial responses were observed. 
Conclusions 
The recommended dose of gemcitabine for future phase 2 studies is weekly 900 mg/m2. In dogs with 
advanced solid tumor this dose level is well tolerated and merits further evaluation. 
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Introduction 
Surgery in stage IIIb anal sac adenocarcinoma (ASAC; any T, N>4.5cm) is often not feasible or 
declined by the owner although clinical symptoms can be life-threatening. Palliative radiation 
therapy (RT) might offer a valuable treatment option. 
Materials and Methods 
Dogs with stage IIIb ASAC treated with a 6-MV linac and computerized 3D treatment planning (3D-
conformal or IMRT) and 8x3.8 Gy (total dose 30.4 Gy) were included. Confining factors such as 
chemotherapy or surgery were evaluated for relevance in progression-free interval (PFI) and overall 
survival (OS). 
Results 
All 14 dogs presented with a palpable mass. 8/14 had defecation problems of which 3 were life-
threatening obstipation, 3/14 dogs were hypercalcemic.  In 29% prior surgery was performed, 
however at presentation all dogs had stage IIIb-disease with a mean gross tumor volume (GTV) of 
166cm3. In addition to RT, 43% received (neo)adjuvant chemotherapy. All dogs showed partial/ 
complete resolution of defecation problems. Median follow-up was 315 days, median clinical PFI 317 
days (95% CI:259-375),  and median OS 319 days (95% CI:227-411). 4 dogs are still alive, 3/10 dogs 
died of causes other than ASAC. Acute radiation toxicity was limited to grade 2 colitis, no late effects 
were seen. PFI was neither influenced by GTV, hypercalcemia, nor chemotherapy; OS was not 
influenced by GTV nor hypercalcemia, but shorter in cases receiving chemotherapy. 
Conclusions 
Hypofractionated RT is well tolerated and a valid treatment option in large ASAC. Although true 
palliative RT is defined as sole pain/symptom relief, the present results suggest prolonged 
locoregional disease stabilization in the majority of dogs. 
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Introduction 
Histiocytic disease is rare in cats. Our aim was to document clinical findings and outcome in feline 
histiocytic disorders, and to identify potential treatment targets. PDGFrβ expression has been 
demonstrated in human histiocytic diseases that responded to tyrosine kinase inhibitors (TKIs), and 
TKIs that target this molecule and CD117 are available in veterinary medicine (masitinib and 
toceranib). 
Materials and Methods 
Samples from cats with confirmed histiocytic disorders were reviewed and characterised by 
immunohistochemistry (CD18, MHC II, leukocyte markers, toluidine blue, C-Kit and PDGFrβ). Clinical 
presentation, treatment and outcome were evaluated. 
Results 
Fifteen cats were enrolled (two were excluded). Five feline progressive histiocytosis (FPH) cases, 6 
histiocytic sarcomas (HS) and 2 haemophagocytic syndromes were identified C-kit was negative in all 
cases. Approximately half showed high PDGFrβ expression and half low. All FPHs highly expressed 
PDGFrβ. Low PDGFrβ appeared correlated with shorter survival. Treatments included surgery, 
corticosteroids, lomustine, TKIs and radiotherapy. Survival times ranged from 7 to 515 days, with 5 
patients still alive 1-3 years after the diagnosis. Due to low numbers, it was difficult to correlate 
treatment modalities with outcome. However, partial responses were recorded in measurable 
disease with masitinib, toceranib and lomustine, and radiotherapy achieved long term control in 
some cases.  
Conclusions 
The prognosis for feline histiocytic disease is guarded, though localised HS may be more manageable. 
PDGFrβ, but not CD117, may represent a therapeutic target. Radiotherapy in combination with 
lomustine can achieve long-term survival in localised HS. 
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Introduction 
The Flat-coated retriever is predisposed to development of poorly differentiated, highly malignant 
sarcomas,classified as histiocytic sarcoma, with an immunophenotype consistent with myeloid 
dendritic antigen presenting cell origin: CD1+, CD4-, CD11c+, CD11d-, MHC II+, ICAM-1+, Thy-1+.The 
cellular origin of canine histiocytic sarcomas remains unknown.This tumour typically arises in the 
deep musculature of the limbs, splenic and disseminated form are also recognised.The purpose of 
the present study was to establish the presence of Tregs in histiocytic sarcoma of FCR,and to assess 
possible differences in their distribution between different locations. 
Materials and Methods 
Forty samples of histiocytic sarcoma were examined.Diagnosis was confirmed by H&E and positive 
immunostatining with MHCII and CD18.Three micron sections were cut and stained with CD3, CD79, 
CD25, CD45, Foxp3.Five fields for each slide were examined and the percentage and strength of 
staining was assessed and scored. 
Results 
Of the 40 samples, 15 originated in spleen, 11 limb and 14 „other location”. All tumours had a 10 - 
20% infiltrate of CD3 positive cells. Foxp3 was expressed in tumours from all three locations although 
the percentage Foxp3 expression was significantly higher in tumours from the limb, whereas 
expression of CD45 was higher in tumours from the spleen. 
Conclusions 
The significant difference in expression of Foxp3 and CD45 in histiocytic sarcomas originating in 
different locations may provide a valuable insight into the difference in tumour microenviroment. 
Further work is needed to better evaluate histiocytic sarcoma’s microenvironment by looking at fresh 
tissue and assessing other factors & cells of the immune system in the tumour microenvironment. 
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Introduction 
Exploring the downside of canine inbreeding strategies, the soft tissue- and the visceral form, we aim 
to determine if there are differences in gene expression within these two common subtypes of 
histiocytic sarcomas, and furthermore whether we can identify common differences in gene 
expression of histiocytic malignancies when comparing with healthy spleen. 
Materials and Methods 
Microarray analysis and pathway analyses were performed on fresh-frozen tissues obtained from 
Flatcoated retrievers with localized, soft tissue histiocytic sarcomas (STHS) and disseminated, visceral 
histiocytic sarcomas (VHS) and on normal canine spleens from various breeds. Expression differences 
of several genes were validated with quantitative real-time PCR (qPCR) analyses. 
Results 
When comparing both the soft tissue and the visceral form with healthy spleen, QPCR analyses 
identified the significantly altered expression of nine genes; PPBP, SpiC, VCAM1, ENPEP, ITGAD 
(down-regulated), and GTSF1, Col3a1, CD90 and LUM (up-regulated). QPCR analyses could also 
confirm the significantly aberrant expression of three genes when comparing STHS and VHS; C6 was 
up-regulated; CLEC12A and CCL5 were down-regulated in the visceral histiocytic sarcoma compared 
to the soft tissue form. 
Conclusions 
At the comparison of histiocytic malignancies as a group with healthy spleen, this study was able to 
identify altered expression of several genes that were not yet implicated in histiocytic sarcoma 
manifestations in the dog. Also, this study found some variations in gene expression between the 
two forms of histiocytic malignancies. 
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Introduction 
Cancer stem cells (CSCs) are key target in developing novel anti-cancer therapeutics, since CSCs are 
responsible for initiating metastasis, and for the resistance to chemotherapy and radiation. Currently, 
there is only limited evidence of the existence of CSCs in pancreatic neuroendocrine tumours (NETs) 
and in its subgroup insulinomas (INS), which are rare tumour types. The focus of this study was to 
develop enrichment methods for selection of CSCs and to find subgroups of cells, within the 
heterogenous population of pancreatic NET cells, displaying specific CSC characteristics. 
Materialss and Methods 
Sphere culture assays and doxorubicin cytotoxicity assays were developed and used to enrich an INS 
(CM) and a pancreatic carcinoid (BON1) cell line for CSCs. Gene expression of stem cell genes and 
surface markers was measured by quantitative real-time polymerase chain reactions (qPCR). A 
cluster analysis was performed to assess expression linkage between the different culture assays.  
Results 
Upregulation of stem cell markers CD34, CD45, CD90 and Oct4 was seen in doxorubicin resistant 
cells. Cultured tumourspheres showed higher mRNA expression of surface markers CD45, CD133 and 
CD227 compared to monolayer cells. Cluster analysis showed closer gene expression linkage 
between enrichment methods compared to cell line identities. 
Conclusion 
This research shows two methods of enrichment for CSC-like cells in pancreatic NETs and 
characterises the gene expression pattern in these CSC-like cells. This study provides an in vitro non-
adherent culture system to grow pancreatic NET tumourspheres.  
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Introduction 
Radiation therapy with curative or palliative intent is regarded standard of care in dogs with 
intranasal neoplasias. The majority of intranasal carcinomas express COX-2. The goal of this 
prospective study was to evaluate the response of canine intranasal tumors to a COX-2 inhibitor 
(Meloxicam) alone and in combination with palliative radiation therapy. 
Materials and Methods 
25 dogs with intranasal tumors (15 carcinomas, 9 sarcomas, 1 aesthesioneuroblastoma) were treated 
with Meloxicam for 2-3 weeks followed by palliative hypofractionated radiation therapy (3 x 8 Gy). 
Response to therapy was determined by CT-based measurement of tumor volume. COX-2 expression 
was determined by immunohistochemistry. 
Results 
84% of all nasal tumors (13/15 carcinomas, 7/9 sarcomas and the aesthesioneuroblastoma) stained 
positive for COX-2 expression. After Meloxicam therapy a partial remission (PR) by an average of 
36.4% (range, 12-75%) was observed in 5 (33%) of the 15 patients with carcinomas, but there was no 
association with the degree of COX-2 expression. Following radiation, 11/25 (44%) of the patients 
showed a >50% remission of their tumors, including all 5 Meloxicam-responders. The median PFI for 
all dogs was 147 days (0-545d), median ST was 214 days (57-1828d). Tumor stage was significantly 
associated with ST (p ≤0.010). Dogs with carcinomas with a PR on combined Meloxicam-radiation 
therapy had a significantly longer median ST compared to dogs with carcinomas that did not respond 
(285d vs 107d; p=0.02). 
Conclusions 
Therapy with Meloxicam can lead to partial tumor remissions in dogs with intranasal carcinomas. 
Responders have significantly improved ST after palliative radiation compared to patients without 
response. 
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Introduction  
In dogs the most common WHO entity seems to be Diffuse Large B cell lymphoma. Studies evaluating 
recent WHO lymphoma entities treatment response, as well as prognostic markers are lacking. 
Materials and Methods  
Thirthy seven cases of canine diffuse large B cell lymphoma (cDLBCL) treated with a 19 week CHOP 
protocol were analysed for haematological abnormalities at presentation. Hematological data was 
obtained with an in-house multi-parameter counter and results confirmed by microscopic evaluation 
of stained blood smears.Survival analysis using Kaplan-Meier test was performed for each different 
observed abnormalities. 
Results  
Sixty seven percent of dogs had anemia at presentation, 24% had trombocytopenia and 30% 
lymphopenia. Neutrophil:Lymphocyte ratio was below the reference value on 30% of dogs. Median 
survival time for the group was 253 days. Patients with anemia and monocytopaenia had a MST of 81 
days, and 51 days, respectively. For Neutrophil:Lymphocyte ratio, patients with result >3.0 had MST 
of 103 days.  
Conclusions 
Aneamia and lymphopenia are the most common findings and are associated with lower MST in dogs 
with DLBCL. This data may indicate a possible prognostic relevance of these parameters for cDLBCL. 
Monocytopenia, a new identified abnormality was strongly associated with shorter MST as well as 
Neutrophil:Lymphocyte ratio higher than 3.0. Despite our statistical relevant data, further, 
prognostic, multicentric studies are required to strongly evaluate wich haematological abnormalities 
can have prognostic value. 
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Introduction 
Canine multicentric lymphoma (CML) is routinely treated with a multidrug chemotherapy protocol. 
Although initially successful, tumor recurrence is common and often refractory to treatment. Failure 
to respond to chemotherapy is thought to result from drug resistance and associated with active 
efflux of cytostatic drugs by ABC-transporter proteins. The goal of the current study was to 
characterize ABC-transporter expression in CML and assess their use as a prognostic factor. 
Materials and Methods 
Lymph node aspirates were collected from 64 dogs with CML treated with a standardized 
doxorubicin-based chemotherapy protocol. ABCB1, -B5, -B8, -C1, -C3, and -G2 mRNA expression 
(qPCR) were measured and related to clinical data and treatment outcome. 
Results 
No significant correlations were found between ABC-transporter expression and sex, age, weight, 
stage or substage. T-cell lymphoma and hypercalcemia were associated with a higher ABCB5- (3.91 
fold, P = 0.08;11.34 fold, P = 0.03) and ABCC5-expression (3.50 fold, P = 0.001; 10.50 fold, P < 0.001), 
and lower ABCC1-expression (0.32 fold, P < 0.001; 0.30 fold, P = 0.01) than B-cell lymphomas and 
normocalcemia. Expression of ABC-transporters was not significantly correlated with length of first 
DFP or OS. Expression of the various ABC-transporters was strongly correlated suggesting three 
distinct groups of ABC-transporters, as was confirmed with an unsupervised hierarchical cluster 
analysis. 
Conclusions 
ABC-transporter mRNA was detected in all CML samples and a significant difference in expression 
was found between T- and B-cell lymphomas, potentially explaining the difference in response to a 
CHOP-base protocol. Unexpectedly, ABC-transporter mRNA expression was not prognostic for DFP or 
OS. 
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Introduction 
Ki67 is associated with tumor grading and prognosis in different subtypes of human non-Hodgkin 
lymphoma. We recently reported that flow cytometric detection of Ki67 is useful in discriminating 
between high and low grade canine lymphomas, but its reliability as prognostic marker is still 
unclear. Aim of the study was to assess the prognostic significance of Ki67 in dogs with high grade B-
cell lymphoma (HGB-LSA). 
Materials and Methods 
45 HGB-LSAs treated with Wisconsin-Madison protocol were included. Diagnosis was based on flow 
cytometric immunophenotyping and cytology (updated Kiel classification). Ki67-positive cells (Ki67%) 
were determined by flow cytometry on lymph node aspirates using FITC-conjugated monoclonal 
antibody (clone MIB-1). Following variables were investigated for association with overall survival 
(OS) and relapse free interval (RFI) using univariate, multivariate and survival (Kaplan-Meyer) 
analyses: Ki67% (≤20%, 20.1-40%, >40%), breed (purebred or crossbred), sex (male or female), age (< 
or ≥ 10yrs), stage  (I-IV or V), substage (a or b), complete remission (CR, yes or no).  
Results 
On multivariate analyses Ki67% (P=0.036) and achievement of CR (P=0.009) were independent 
prognostic factors for OS, while none of the considered variables reached significance for RFI. Dogs 
with Ki67=20.1-40% presented significantly longer OS and RFI (median=593 and 406 days, 
respectively) than dogs with Ki67≤20% (median=177 and 200 days) and Ki67%>40 (median= 258 and 
142 days). 
Conclusions 
Ki67 is an independent predictor of OS in treated HGB-LSAs; intermediate values are associated with 
best prognosis. We suggest flow cytometric determination of Ki67 as a diagnostic and prognostic tool 
to improve clinical usefulness of cytology and immunophenotyping. 
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Introduction 
H2A is one of the component of the histone octamer that forms the nucleosome. The isoform H2AX 
represents 2 to 25% of the total histone H2A expressed by cells and is implicated in the genomic 
response to DNA damage. Phosphorylated H2AX (P-H2AX) accumulates at DNA double strand breaks, 
where it assists to the recruitment of DNA repair and signaling factors. Therefore, induction of P-
H2AX is a reliable marker of DNA damage. We hypothesize that P-H2AX could identify early genomic 
damage in lymphoma cells of dogs undergoing chemotherapy with Doxorubicin, an information that 
is not provided by markers of cellular proliferation, such as Ki-67. 
Materials and Methods 
Dogs presented at the Oncovet center, in which naive multicentric high-grade lymphoma was 
identified, were prospectively recruited. Chemotherapy (CT) with doxorubicin was initiated and serial 
lymph node biopsies and fine needle aspiration (FNA) were performed before chemotherapy and 2 
to 6 hours post-CT. Lymph node tissues were used for measurement of Ki-67 expression, whereas 
FNA samples were used for measurement of P-H2AX (using flow cytometry method). 
Results 
Eight cases were prospectively recruited, of which 6 provide adequate samples for measurement of  
P-H2AX. A marked increase in the expression of P-H2AX was observed 2 and 4 hours post-CT, 
whereas  
Ki-67 expression was not modified following treatment. 
Conclusions 
Assessment of P-H2AX on FNA of lymph node is feasible in dogs with lymphoma, and allows early 
assessment of DNA lesion. This biomarker could be used in prospective clinical studies focusing on 
the early detection of tumoral cell resistance to treatment. 
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Introduction 
High-grade T-cell lymphoma (HGTCL) in dogs is associated with a worse prognosis compared to high-
grade B-cell phenotypes. Independent of the immune-phenotype, most dogs with high-grade 
lymphoma are treated with a (L)-CHOP protocol, while lomustine (CCNU) is reserved as treatment for 
therapy-resistant high-grade lymphomas. The purpose of this retrospective study was to compare 
Progression Free Survival (PFS) of dogs with HGTCL treated with first-line (L)-CHOP or CCNU-(L)-CHOP 
protocols. 
Materials and Methods 
Records of two veterinary oncology referral centers were reviewed. Included were dogs with HGTCL, 
first-line treated with either (L)-CHOP or CCNU-(L)-CHOP-based protocols. Kaplan-Meier method and 
log-rank test were used for survival analysis. Adverse events were documented according VCOG-
CTCAE v1.1. 
Results 
Forty-two dogs were included. Twenty received (L)-CHOP, 17 CCNU-(L)-CHOP and 5 CCNU-
prednisolone. In the (L)-CHOP group 45% achieved CR, 20% PR, 25% SD and 10% PD. In the CCNU-(L)-
CHOP group 82.3% achieved CR, 11.8% PR and 5.9% SD. These differences were, however, not 
significant. PFS for (L)-CHOP and CCNU-(L)-CHOP differed significantly (P=0.005), with a median of 49 
and 243 days, respectively. In the CCNU-prednisolone group CR was 40%, with a median PFS of 239 
days. No significant adverse events were noticed in the (L)-CHOP group. In the CCNU-based group, 
grade 2-3 renal toxicity (n=11), grade 1-3 neutropenia (n=10), grade 1-2 thrombocytopenia (n=9) and 
grade 3 hepatotoxicity (n=2) were reported. 
Conclusions 
The significantly increased PFS after inclusion of CCNU in first-line protocols for dogs with HGTCL 
seems to justify a prospective study with a predetermined CCNU-L-CHOP protocol. Renal toxicity 
might be a limiting factor using CCNU. 
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Introduction 
Canine lymphoma represents one of the most common spontaneously occurring tumors in dogs. 
Cancer stem cells (CSCs) are considered to be responsible for tumor formation, progression, 
recurrence and metastasis and to play a key role in therapeutic failure rates in several neoplasias. 
The aim of the present study was to identify CSCs within the canine B-cell lymphoma cell lines CLBL-1 
and CLBL-1M. For this purpose, the expression patterns of stem cell marker genes in the two B-cell 
lymphoma cell lines as well as in primary lymphoma samples were analyzed. 
Materials and Methods 
Expression of the stem cell marker genes CD34, CD133, CD44, c-KIT, OCT4, KLF4, Nanog, c-MYC, 
SOX2, DDX5, ITAG6 and MELK in CLBL-1, CLBL-1M cell lines and 14 primary lymphoma samples was 
analyzed using conventional RT-PCR and real-time PCR. The cell surface markers CD44, CD133, CD34 
and CD49f were additionally examined in CLBL-1 and CLBL-1M by flow cytometry. 
Results 
CLBL-1 and CLBL-1M cell lines had similar expression patterns as primary B-cell lymphoma samples 
showing expression of CD44, c-MYC, DDX5, ITAG6 and MELK. Flow cytometry analyses showed highly 
frequent expression of CD44 and weak expression of CD49f in both cell lines. However, there was no 
CD34 or CD133 positive subpopulation. 
Conclusions 
Based on the similar expression patterns of selected stem cell markers, CLBL-1 and CLBL-1M can be 
valuable tools for further research analyzing stem cell markers and the biology of potential tumor 
stem cells. 
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Introduction 
The prognostic significance and response to therapy of aberrant phenotypes in canine lymphoma is 
unclear. The goal of this study was to determine the clinical presentation and response to 
chemotherapy of canine aberrant lymphomas. 
Materials and Methods 
Medical records of the Royal Veterinary College were searched retrospectively for confirmed cases of 
canine lymphoma. The following antigen patterns were considered aberrant: diminished/absent 
expression of common leukocytes antigen (i.e CD45), over/under expression of lineage specific 
antigen, positivity to precursor marker (i.e.CD34), double positivity or double negativity to CD4 and 
CD8 in T-cell lymphoma, and biphenotype pattern (CD3+CD21+ or CD3+CD79a+). Signalment, clinical 
presentation, staging, response to therapy, and progression free interval (PFI) were recorded. 
Results 
17 canine aberrant lymphomas were identified, 15 high-grade and 2 low-grade. Five lymphomas 
were of B-cell origin (29%), 10 of T-cell origin (59%) and 2 were null (12%). The most common 
aberration was double negativity to CD4 and CD8 in T-cell lymphoma (29%). The majority of cases 
presented as stage V (47%) and sub-stage b (76%). Ten cases had unusual localizations of the disease 
(i.e. lungs). Overall response rate to chemotherapy was 60% with only 2 patients achieving complete 
response. Responses were generally short-lived (PFI 90 days), 10 patients died or were euthanized 
due to progressive disease, 5 were lost of follow-up, and only the 2 low-grade lymphomas were still 
alive. 
Conclusions 
The majority of aberrant lymphomas of our study presented with negative prognostic factors (stage 
V, sub-stage b). Further studies are necessary to evaluate whether aberrant lymphomas carry a 
worse prognosis 
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Introduction 
Molecular diagnostics allow for sensitive detection of canine lymphoma and sub-type discrimination. 
Treatment decisions are often made based on whether a lymphoma is indolent or aggressive. Using 
molecular diagnostics we have identified dogs with simultaneous T zone and B cell lymphoma. The 
presence and persistence of the indolent T zone lymphoma necessitates more critical assessment of 
treatment response and duration to avoid unnecessary therapy. 
Materials and Methods 
Retrospective analysis of 7 cases of canine lymphoma where flow cytometry and PARR detected 
concurrent T zone and B cell lymphoma. Follow-up data including clinical staging, treatment, cytology 
and sequential molecular diagnostics and outcome were obtained. 
Results 
In 3 dogs T zone disease was detected prior to the coexisting B cell tumor and in 4 dogs the two 
tumors were diagnosed simultaneously. Median age at diagnosis of the B cell lymphoma was 11.2 
years and 4 of the dogs were Golden retrievers. Median survival time after the diagnosis of B cell 
lymphoma was 15 months. Four dogs with follow up PARR testing were in molecular remission for 
the B cell lymphoma while T cell clonality remained detectable. Lack of awareness of the coexistent T 
zone lymphoma would have resulted in the incorrect clinical assessment of treatment response or 
remission duration for the B cell lymphoma in 4 of the 7 dogs. 
Conclusions  
Knowledge of the concurrent presence of T zone and B cell lymphoma in a patient is important to 
avoid misinterpretation of clinical response to treatment and the necessity for additional therapy. 
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Introduction 
The role of genomic alterations (GA) at high resolution in Diffuse Large B-cell Lymphoma (DLBCL) has 
been scarcely investigated in dogs. 
Materials and Methods 
We analysed 12 newly-diagnosed multicentric DLBCLs using an 180,000 Oligonucleotide aCGH on 
lymph nodes (LN) samples. aCGH was also repeated on LNs of 3 relapsing dogs and 4 dogs in 
remission after chemotherapy. All LNs were matched with corresponding skin biopsies. 
Results 
In pre-treatment DLBCLs, the pattern of GA consisted of 90 different genomic imbalances (mean per 
tumour, 17), 46 gains and 44 losses. In the LNs of 4 dogs in remission after chemotherapy, 4 new GA 
were found, whereas 3 new GA were observed in relapsing dogs, compared with the initial sample. 
Two gains in Chr13 were significantly correlated to stage III-IV of disease (p=0.002). Statistical 
analysis identified regions of gains and losses significantly associated to time of remission (FDR 
<0.001). 
Conclusions 
In pre-treatment DLBCLs, individual variability in the number of GA was found, however 14 recurrent 
aberrations (frequency >30%) were identified. Losses involving IGK, IGL and IGH were found in all 
tumors and in 2 dogs in clinical remission. Gains along the length of Chr13 and Chr31 were often 
found (>41%). In these segments, MYC, LDHB, HSF1, KIT and PDGFRA were annotated. One ex novo 
GA, involving TCR, was present in dogs in remission after chemotherapy. A reduced number of 
chromosomal rearrangements was found in relapsed (n=17) DLBCLs when compared with pre-
treatment DLBCLs (n=90). Further studies are needed to identify an association with the clinical 
behaviour of DLBCL. 
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Introduction 
Feline lymphoma is one of the most common hematopoietic tumours in this species. B-cell 
lymphoma gene 2 (BCL-2) encodes an anti-apoptotic protein,and itsexpression was previously found 
in feline lymphoma (mainly T-cell lymphoma). Ki-67 protein is closely associated with cell 
proliferation and it is used for mytosis identification in histological samples. 
Materials and Methods 
Forty five Feline non-Hodgkin lymphomas (FnhL) were classified according to the WHO scheme by 
histopathology and immunohistochemistry (IHC). For IHC we used anti-CD3 antibody (A452; Dako), 
anti-CD79a antibody (clone HM57; Dako), anti-Pax5 antibody (NCL-L-Pax5, Novocastra), anti-BLA.36 
antibody (M0533; Dako), for WHO classification and anti-Bcl-2 antibody (clone 124; Dako) and anti-
Ki-67 antibody (clone MIB-1, Dako). 
Results 
Of all 22 T cell lymphomas 17 (77%) were found to express BCL-2 protein. Of all B cell lymphomas 
only 8/23 (34,3%) stained positively for BCL-2. In general T-cell lymphomas shown higher Ki-67 
indexes (59,1%, more than 10 mytosis per higher power field) than B-cell lymphomas (34,8%, more 
than 10 mytosis per HPF). 
Conclusions 
We show in this study the aplicability of BCL-2 and Ki-67 staining in FnhL paraffin-embbeded samples. 
BCL-2 protein may be of interest for IHC in order to facilitate the distintion between lymphoma and 
Inflammatory Bowel Disease, to identify a potential therapeutic target and to evaluate its prognostic 
relevance in this species. Further prospective studies are required to assess BCl-2 prognostic 
implication on fnHL. 
 
  
ESVONC, Vienna 2014 - 77 - 
Results of PEG-L-asparaginase (Oncaspar®) incorporation in a modified COP-protocol, or added to 
prednisolone, for the treatment of high-grade lymphoma in cats 
 
Ada Krupa1, Erik Teske2, Jetty Maltha1, Paula Hendriks1, Evert van Garderen3, Johan de Vos1 
 
1
Collaborating Dutch and Belgian Veterinary Cancer Centres (SDK), c/o van Diemenstraat 83, 4535 AR, Terneuzen,  
 The Netherlands 
2
Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands 
3
Laboratory for Pathology and Histology, Animal Health Service, Deventer, The Netherlands 
 
ada.krupa@yahoo.com 
 
Introduction  
Polyethylene-glycol-L-asparaginase (PEG-ASP) has reduced immunogenicity and longer half-life 
compared to native L-asparaginase. The objective of this study was to assess Progression-Free-
Survival (PFS) in cats with high-grade lymphoma, treated with first-line PEG-ASP-COP or PEG-ASP-
prednisolone, designed to reduce the number of vincristine/cyclophosphamide administrations. 
Materials and Methods  
Records of a veterinary oncology consortium were reviewed (2000-2013). Included were cats, 
treated minimum one month with ≥ 2 PEG-ASP injections (40 IU/kg i.m. every 2-4 weeks). Continuing 
PEG-ASP, first injection required tumour reduction. Kaplan-Meier method and log-rank test were 
used for survival analysis. Retrospective immunophenotyping of gastric and intestinal lymphomas 
was attempted. 
Results  
Thirty-two cats were excluded, of which 7 (all high-grade) did not respond to first PEG-ASP. Thirty-
eight were enrolled in the study: 32 PEG-ASP-COP and 6 PEG-ASP-prednisolone. CR in PEG-ASP-COP 
was 81.3%: 5/8 gastric (5B/1Tcell/2 not-phenotyped), 3/4 intestinal (3B/1Tcell), 4/5 other-abdominal, 
9/10 nasal, 2/2 multicentric, 3/3 miscellaneous lymphomas. Thirteen cats completed PEG-ASP-COP: 
median number of 9 vincristine/cyclophosphamide, 13 PEG-ASP doses, median treatment time 296 
days. Eleven cats died tumour related, 3 therapy related. Estimated one-/two-year PFS is 67.5/61%. 
CR in PEG-ASP-prednisolone was 100%: 1 intestinal (not phenotyped), 1 other-abdominal, 2 nasal, 2 
multicentric. Three cats completed PEG-ASP-prednisolone: median number of 26 PEG-ASP doses, 
median treatment time 539 days. Estimated one-/two-year PFS is 62%. PFS for gastric and intestinal 
lymphoma differed significantly (P=0.044) with a median of 414 and 105 days, respectively. 
Conclusions 
Treating feline high-grade lymphoma, PEG-ASP can reduce the number of 
vincristine/cyclophosphamide doses, preserving PFS. Gastric lymphoma may have a better prognosis 
compared to other alimentary lymphomas. 
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Introduction 
The presented research shows the result of an autologous dendritic cell-based cancer treatment in 
10 dogs suffering from malignant melanoma in various localizations. The autologous production of 
dendritic cells and the ability to present autologous antigens to the immune system yields very good 
clinical results. 
Materials and Methods 
Through gradient centrifugation and a adherence step, a monocyte culture is extracted from the 
fresh whole blood of the patient. These monocytes are then cultivated with specific cytokines in 
order to derive autologous DCs. Finally, the DCs are primed with autologous tumor lysate. The 
antigen presenting DCs are then harvested, resuspended and injected intradermal in the patient. 
Results 
10 dogs have been treated with dendritic cell-based cancer vaccines. Median survival time is 785 
days after the initial treatment with DC vaccine. Survival rate after 446 days is 66,7% and after 830 
days still 40%, remaining constant until the end of the observation period. Due to the fact that 4 of 
the 10 patients are still alive, the censored result is preliminary and subject to further improvement. 
Conclusions 
Independent of localization (oral mucosa and different skin localizations), the expected longevity of 
the patients increased. Together with surgical excision of the cancer cells, the application of DC-
based vaccines yields promising results in the treatment of malignant melanoma in dogs, also in 
rather difficult localizations such as the oral mucosa. Additionally, since no or very slight side effects 
could be observed, the quality of life of the patients was maintained. 
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Introduction  
Many types of whole body 3D hybrid methods (PET/CT, SPECT/CT) is a daily routine in human centers 
but not yet in veterinary medicine. Several hybrid imaging techniques using different radiolabelled 
ligands have a great potential in early and specific primary tumor detection, metastases localization 
(staging) and follow-up, restaging examinations. 
Materials and Methods  
Altogether 46 dogs were referred for PET/CT or SPECT/CT examination at our Institute, with known 
malignant melanoma diseases. In 22 out of 46 dogs two or more hybrid imaging were performed. 
Dogs were sedated (propofol and diazepam iv, then isoflurane inhalation), injected with different 
radiopharmaceuticals 40-60 MBq/10 bwkgs (99mTc-MIBI, 99mTc-DMSA(5), 99mTc-colloids, 18FDG, 
68Ga-DOTATOC). Whole body native and contrast CTs and nuclear medicine scans were evaluated 
also separatedly but fusion images were reconstructed, evaluated visually and quantitativelly. 
Results  
Hybrid imaging detected all the earlier known metastases, and 6 cases we could detect laesions that 
were not seen in earlier CTs. We found 18FDG and 99mTc-DMSA5 extremelly usefull (with high SUV-
values) in melanoma staging and restaging while 68Ga-DOTATOC proved to provide too low SUV 
values. 99mTc-folate targetting colloid seems to be also a very promising agent however only 8 
melanoma cases were scanned using that radioligand. Sentinel node detection using SPECT/CT 
before surgery also feasible and makes easier to find the non-enlarged nodes too. All of the applied 
whole body methods proved to be harmfull even in late-stage diseased dogs. 
Conclusions 
A variety of whole body hybrid imaging methods might be introduced in the near future in staging 
and restaging our four-legs animal patients. 
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Introduction 
Soft tissue sarcoma (STS) is a common canine subcutaneous tumor. Surgery with or without radiation 
therapy (dependent on surgical margins) is the current standard of care in dogs. Typical protocols for 
treating incompletely excised STS involve curative intent radiation with total dose in excess of 50 Gy. 
The purpose of this study was to evaluate progression free survival (PFS), time to local failure (TLF) 
and overall survival (OS) for canine STS treated with an hypofractionated radiation therapy (RT) 
protocol. 
Materials and Methods 
Histologically confirmed microscopicly incomplete or closely excised STS confined to the primary site 
were treated with once weekly fractions of radiation (6 - 8 Gy/fraction) to a total dose of 24-36 Gy. 
Results 
Forty-eight dogs were included. Histologic grade was available for 44 dogs (13 grade 1, 22 grade 2 
and 9 grade 3). Total radiation dose ranged from 24 to 36 Gy. Eleven dogs (23%) developed local 
recurrence.  
Twelve dogs (25%) developed metastasis. The median PFS probability was calculated to be 698 days 
(with 1, 2 and 3 years PFS of 63%, 44% and 23%), the median TLF was not reached (with 1, 2 and 3 
years TLF of 81%, 73% and 73%) and the median OS was not reached (with 1, 2 and 3 years OS of 
81%, 75% and 61%). Only histologic grade was prognostic for PFS and OS. 
Conclusions 
The hypofractionated RT protocol employed achieved long-term local tumor control in the majority 
of dogs. It is, therefore, reasonable to prescribe in older patients or when financial limitations exist. 
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Introduction 
Meningiomas represents about half of primary intracranial tumours in dogs. There are limited 
comparative studies regarding the various treatment modalities. Aim of this study was to compare 
palliative therapy, surgery and stereotactic radiosurgery in canine meningioma. 
Materials and Methods 
Data were collected retrospectively from 198 dogs referred to one institution over a 15-year period 
with histopatologically confirmed or MRI consistent with meningioma. Dogs were grouped by 
anatomical site (supratentorial - E, infratentorial - T, spinal - S) and by therapeutic option (palliation - 
P, surgery - S, radiosurgery - R). Surgery goal was total tumour resection. LINAC based VMAT 
radiosurgery was performed in 1 - 5 fractions. Serial clinical and MRI examinations were conducted. 
Signalment, clinical signs, neuroanatomic tumour location, relapse specifics, adverse events, best 
response and overall survival (OS) time were evaluated. OS estimates were calculated using Kaplan-
Meier method and the differences between groups compared using logrank analysis. 
Results 
91 dogs (51 E, 33 T, 7 S) had been palliated, 69 dogs (33 E, 31 T, 5 S) had been treated with 
stereotactic radiosurgery, 38 dogs (32 E, 1 T, 5 S) with surgery. OS in PE was 190 days, in PT 38 days, 
in PS 89 days, in RE 781 days, in RT 654 days, in RS 813 days, in SE 567 days, in ST 3 days, in SS 210 
days. Variables predictive of OS are localisation and therapy option. 
Conclusions 
Dogs suffering from meningioma undergoing stereotactic radiosurgery had superior outcome to 
those treated with surgery or palliation. 
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Introduction 
Feline injection-site sarcomas (ISS) treatment is a challenge for veterinary practitioners. Standard 
treatment includes: surgery, radiotherapy and chemotherapy. Doxorubicin is a first choice 
therapeutic agent, however, its effectiveness is debatable. The main aim of the study was to assess 
the effectiveness of colloid gold nanoparticles conjunct with doxorubicin (DoxAu) using novel chick 
embryo chorioallantoic membrane (CAM) model. 
Materials and Methods 
DoxAu was prepared using non-covalently attached doxorubicin (Dox)and glutathione passivated 
(4nm) gold nanoparticles (Au). Feline fibrosarcoma cell lines (FSS1WAW, FFS1, FFS3, FFS5) were 
cultivated in DMEM enriched with glucose under standard condition. Performed in vitro tests: MTT 
assay, test with Annexin V and verapamil CAM assay: on the 6th day of chick embryo incubation a 
sterile silicon ring was put into CAM of each egg. Then 5x106 FFS1 and FFS3 cells were inoculated 
exactly into silicon rings. After 10 days tumors growth was measured. Tumor bearing chick embryos 
were divided into 4 groups and Dox, DoxAu, Au and saline were injected intratumoral (in DoxAu IC50 
doses obtained in MTT assay). After 72 hours tumors were measured one more time. Statistical 
analyses were performed using Graph Pad Prism 5.0. 
Results 
DoxAu was more cytotoxic than free Dox for fibrosarcoma cell lines with high glycoprotein P activity 
(FFS1WAW, FFS1, FFS3). DoxAu significantly inhibits tumors growth after single intratumoral 
injection. 
Conclusions 
DoxAu is a potent new therapeutic agent for ISS treatment. CAM model is a good model to assess the 
effectiveness of anticancer drugs.  
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Introduction 
Wide surgical resection or a marginal/incomplete resection followed by full-course radiation therapy 
(RT) is the current standard of care for canine STS. Shorter, coarse fractionated RT protocols are 
often used for inoperable cases, elderly, or co-morbid patients, but also due to financial or logistical 
restraints of treatment machine availability. The herein presented results of a retrospective, bi-
institutional study describe efficacy and toxicity of a 5x6Gy protocol on macroscopic and microscopic 
canine STS in terms of tumor progression (PFI) and overall survival (OS), identifying prognostic factors 
on outcome. 
Materials and Methods 
Dogs with microscopic or macroscopic STS irradiated with 5x6Gy were included. RT (electron field or 
3D-conformal 6MV photons) was administered with palliative intent. PFI and OS were compared with 
respect to different tumor and patient characteristics by the Kaplan-Meier-method and multiple Cox-
regression analysis. 
Results 
97 dogs were included: 18 had microscopic disease and 79 had macroscopic disease. All dogs 
received the same RT protocol; part of the macroscopic group received post-radiation metronomic 
chemotherapy. Median PFI for microscopic disease was not reached and longer than for macroscopic 
disease with 378 days (95%CI:322-434) (p=0.04). There was a trend for longer OS (all deaths) for 
microscopic vs macroscopic disease with 645 (95%CI:168-1122) and 380 days (95%CI:285-507), 
respectively (p=0.07). Toxicity was low in both groups. Neither for PFI nor for OS significance was 
found in outcome of the group treated with additional metronomic chemotherapy (n=32) or without 
(n=47). 
Conclusions 
The 5x6Gy RT protocol provided long PFI in the microscopic disease setting, and reasonably 
prolonged stabilization in the macroscopic setting. 
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Introduction 
The architectural transcription factor HMGA2 is abundantly expressed during embryonic 
development but mostly undetectable in differentiated tissues. Several malignant neoplasms 
including prostate cancer show high re-expression of HMGA2 correlating with malignancy and poor 
prognosis. HMGA2 is negatively regulated by let-7 miRNAs and the HMGA2-let-7 balance plays a 
major role in tumour aetiology. To analyse the role of HMGA2 in prostate cancer, a stable, highly 
reproducible in vitro model system is precondition. Therefore, we established a canine EGFP-HMGA2 
prostate cancer cell line stably overexpressing HMGA2 linked to EGFP (Enhanced Green Fluorescent 
Protein). To exclude EGFP-induced effects, an EGFP-expressing reference cell line was created. 
Materials and Methods 
Both recombinant cell lines were characterised by fluorescence microscopy, flow cytometry and 
immunocytochemistry. The proliferative effect of ectopically overexpressed HMGA2 was determined 
via proliferation assays and the chromosome consistency of the derived cell lines was analysed 
comparatively versus native cells. The impact of overexpressed HMGA2 on let-7a was analysed via 
real-time PCR. 
Results 
Fluorescence microscopy and immunocytochemistry detected successful EGFP-HMGA2 fusion 
protein expression. The HMGA2 overexpression in EGFP-HMGA2 cells was confirmed by real-time 
PCR. Significantly higher let-7a expression levels were detected in both fluorescent cell lines. The 
HMGA2-EGFP cell line showed increased proliferation compared to EGFP- and native cells. 
Cytogenetic analyses of both fluorescent cell lines resulted in a comparable hyperdiploid karyotype 
as described for the native cell line. 
Conclusions 
The new fluorescent EGFP-HMGA2 cell line is a stable tool enabling further in vitro and in vivo 
analyses of HMGA2-mediated effects potentially being involved in the pathogenesis of prostate 
cancer. 
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Introduction 
We have already demonstrated that vaccination with empty BPV1 capsids termed virus-like particles 
(VLP) protects horses from experimental infection with BPV1 virion and associated tumour 
formation. Long term monitoring of antibody titres in experimental horses and data from other 
species suggest that this protection is long lasting. 
Materials and Methods 
Seven horses, vaccinated in 2007/2008 with different doses of BPV1 L1 VLP and 3 unvaccinated 
control horses were challenged by intra-dermal inoculation with cow wart derived BPV1 virion 
(5x107 BPV-1 virions per wheal, 10 wheals per horse). Inoculation sites were monitored for 10 weeks. 
Blood for serum antibody titre determination by pseudovirion neutralisation assay was taken on the 
day of challenge and after 6 months. 
Results 
Six of 7 vaccinated horses had measurable serum antibody titres (1:50 – 1:400). These titres were 
boosted by inoculation (about one step of dilution). Two of 3 unvaccinated controls remained sero-
negative. One control showed sero-conversion. All controls developed tumours at all 10 inoculation 
sites. Tumours appeared approximately 2 weeks after inoculation and reached maximum sizes of up 
to 8 mm. Regression was complete by 8 weeks after their first appearance in all horses. All 
vaccinated horses remained completely free from tumours. 
Conclusions 
BPV-1 L1 VLP vaccination proves to be fully effective in protecting horses from experimental infection 
and tumour formation 5 years post immunisation. The protection was complete even in horses with 
low or unmeasurable antibody titers. This is another step towards establishing a vaccination against 
equine sarcoids. 
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Introduction 
Epidermal growth factor receptors 1 and 2 (EGFR, ErbB2), and cytosolic Src (c Src) are tyrosine 
kinases that stimulate cell survival, proliferation and migration and if dysregulated can act as 
oncogenes. Several tyrosine kinase inhibitors (TKIs) have recently gained approval, but long term 
treatment with TKIs against a single target often lead to acquired resistance. The aim of this study 
was to investigate the effect of targeting multiple signalling pathways simultaneously in naïve and 
TKI-resistant cell lines. 
Materials and Methods 
The ErbB2 and c-Src genes were sequenced and small interfering RNAs (siRNAs) targeting them were 
developed. Effective siRNAs as well as ErbB2, Egfr and c-Src TKIs (AG828, gefitinib, GW583340 and 
saracatinib) were evaluated in canine and feline carcinoma cell lines. The effects of combined RNAi 
targeting of Egfr, ErbB2 and c-Src were assessed. 
Results 
Inhibition of c-Src and Egfr inhibited cell proliferation, migration and colony formation in feline and 
canine carcinoma cell lines while ErbB2 targeting exhibited no effect. Chronic drug exposure with 
gefitinib and saracatinib lead to resistance which was not associated with ATP binding site mutations. 
RNA interference (RNAi) strategies targeting Egfr plus ErbB2 and c Src plus either Egfr or ErbB2 
showed a synergistic inhibition of cell proliferation. When targeting multiple areas of an oncogene or 
multiple oncogenes simultaneously significantly lower concentrations of siRNAs were required. Cells 
rendered resistant by chronic drug exposure were still sensitive to RNAi. 
Conclusions 
Targeting multiple pathways simultaneously improves growth inhibition, reduces the siRNA 
concentrations required and are still effective in cells rendered resistant to TKIs. 
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Introduction 
Surgery is the standard treatment of adrenal tumours, but it is full of potential difficulties, 
particularly in cases of intracaval extension. Aim of this study was to evaluate the technical feasibility 
and therapeutic efficacy of adrenal tumours ablation using hypofractionated volumetric modulated 
arc stereotactic radiotherapy (VMAT) in dogs with vascular invasion. 
Materials and Methods 
10 dogs suffering from adrenal tumours with vascular invasion were treated using a LINAC with 
micromultileaf collimator. The VMAT plans were computed using a MonteCarlo statistic algorithm 
and the Monaco 3.0 treatment planning system. Dose constraints have been derived from AAPM TG 
101.    The plan has been evaluated for quality assessment with DosimetryCheck. The prescription 
dose was           33-39 Gy in 3 fractions. The follow up have provided biochemical exams and CT/MRI. 
Results 
According to RECIST criteria, 7 partial responses and 3 stable diseases were obtained, but all patients 
showed a better performance status. Ascites disappeared immediately after the treatment 
completion. At 1 year all patients are alive. In 3/4 dogs with an elevated cortisol level, a value 
normalisation was obtained. According to VRTOG criteria, a grade I pancreatitis and a focal renal 
cortical atrophy were observed. 
Conclusions 
Results of this study are better than the median survival time reported in literature. Stereotactic 
hypofractionated VMAT may be an option in cancer treatment and control of endocrine clinical signs, 
with a low morbidity and mortality rates. Further studies of dose escalation are suitable. 
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Introduction 
Radiotherapy is a treatment option for rabbit thymoma but toxicity is frequent. The aim of this study 
was to define an optimised plan set up to reduce the incidence of complications. The hypothesis was 
that image-guided dynamic IMRT would allow to deliver higher doses to the target with better 
sparing of organs at risk in comparison to 3D conformal radiotherapy. 
Materials and Methods 
Five rabbits suffering from thymoma were treated with LINAC-based hypofractionated dynamic 
IMRT. Dose prescription was 40 Gy in 6 fractions. Throughout treatment, 3 subsequent CT/MRI scans 
were performed; positioning was verified with cone beam CT. Treatment plans were computed with 
MonteCarlo statistic algorithm and Monaco 3.0 planning system, verified with DosimetryCheck 
system. Parameters evaluated were: number and width of arches, control points, modulation degree, 
margin to target and organs at risk. The goals were: obtained V95% >95%, target EUD >95%, V107% 
Results 
Prescription goal were obtained in all five cases with 1 arc of 360°, 137 control points, 2.5 modulation 
degree, 2 mm margin to target and 3 mm margin to organs at risk. In all patients tumour disappeared 
and at 1 year no complications were observed. 
Conclusions 
Image-guided dynamic IMRT with suitable parameters is feasible in rabbits. No morbidity or mortality 
events were reported in animals treated. Treatment schedule is effective in disease control and 
usable in clinical setting. 
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Introduction 
Neutron capture therapy (NCT) is an experimental treatment with low energy thermal neutrons used 
for human patients with head and neck cancer. Gadolinium neutron capture therapy (GdNCT) was 
compared to hypofractionated radiation therapy in dogs with oral malignant melanoma (OMM) for 
local tumor control and survival times. 
Materials and Methods 
Dogs with III stage OMM were divided into two groups. Hypofractionated radiation therapy was 
performed in 33 dogs (group 1) in a total dose of 50-60 Gy once a week in 7.5 Gy fractions. Group 2 
of 34 dogs was treated with GdNCT. Neutron capture therapy was reformed at the IRT MEPhI reactor 
with tharmal neutron flux 1.1×10(9) n/cm2/s. Gadolinium-containing drug Gd-DTPA was administered 
intratumoral immediately prior to irradiation. In dogs with confirmed regional lymph node metastasis 
lymphadenectomy was also performed. Response rates (PR – partial remission, CR – complete 
remission) and overall survival time were recorded in each group. 
Results 
In the external beam radiation therapy group 45.5% dogs had PR and 30.3% CR. In the GdNCT group 
PR was detected in 50.0% of dogs and CR in 47.1%. Although there were no statistical significant 
differences in local tumor responses in the two groups, the overall survival differed significant – 
132.7 days in the radiation therapy group comparing to 204.2 days in the GdNCT group (p=0.049). 
Conclusions 
GdNCT is effective in local disease control of canine oral melanoma III stage and in our study 
significant enhanced overall survival times comparing to external beam radiation. 
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Introduction 
Histopathologic grade is currently used to determine the metastatic potential of canine soft tissue 
sarcomas (STS). Grading schemes for STS are subjective and variable. At best, high-grade STS have a 
30-40% metastatic rate, resulting in many dogs potentially receiving chemotherapy who will not 
benefit and may be harmed. Our hypothesis is that utilization of a gene expression signature (GES) 
would be able to predict future development of metastasis with 70% accuracy. 
Materials and Methods 
Canine Genome 2.0 microarrays (Affymetrix) were run on 12 metastatic STS and 24 non-metastatic 
STS (with at least 1 year follow-up). There were 804 probes identified as differentially expressed 
between these two groups at the 2-fold level. After deletion of probes without known genes 
associated with them, and averaging across probesets for individual genes, 322 genes remained. 
Random Forest analysis was used to determine the relative importance of each gene in separating 
the two data sets, as well as the classification error produced by each set of genes included. The final 
GES was validated with qPCR in a second set of 31 STS evenly divided between metastatic and non-
metastatic tumors. 
Results 
Between 4 and 16 of the most important genes gave the highest correct classification of the STS. 
qPCR of these 16 genes has been performed in 31 additional STS, and the predictive value of this GES 
is currently being calculated, along with the minimal number of genes necessary to accurately classify 
a STS as metastatic or non-metastatic. 
Conclusions 
The final step will be prospective evaluation of the GES. 
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Introduction 
The NSAID mavacoxib (Trocoxil™) is a selective COX-2 inhibitor used for the management of 
inflammatory disease in dogs. It has a long plasma half-life, requiring less frequent dosing and 
supporting increased owner compliance in treating their dogs. COX-2 overexpression is associated 
with tumorigenesis in dogs. In this study we compared the in vitro activity of a short-acting non-
selective COX inhibitor (carprofen) with mavacoxib, on cancer cell and cancer stem cell survival. 
Materials and Methods 
A panel of canine cell lines was tested including KTOSA5 (osteosarcoma), CSKOS (osteosarcoma), D17 
(osteosarcoma), J3T (glioma), C2-S (hemangiosarcoma), SB (hemangiosarcoma), 3132 (lymphoma), 
and CPEK (normal epidermal keratinocyte). Putative cancer stem cells were isolated from KTOSA5 
cells by cell sorting for CD34. To examine sensitivity to these NSAIDs, we assayed for cell viability and 
colony forming ability. The effect of NSAIDs on apoptosis was determined by annexin V-FITC staining. 
Results 
Using a panel of canine cancer cell lines we demonstrate that both carprofen and mavacoxib has a 
direct cell killing effect on cancer cells, and increases apoptosis in cancer cells in a manner that may 
be independent of caspase activity. Furthermore, mavacoxib, but not carprofen, is cytotoxic to 
cancer stem cells derived from osteosarcoma cell lines. 
Conclusions 
Both NSAIDs can inhibit cancer cell proliferation and induce apoptosis in vitro. Importantly, cancer 
stem cells derived from an osteosarcoma cell line are sensitive to the cytotoxic effect of mavacoxib. 
Our results suggest that mavacoxib has anti-tumour effects and that this in vitro anti-cancer activity 
warrants further study. 
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Introduction 
Low dose continuous (metronomic) chemotherapy (MC) is a now well-recognized therapeutic option 
in dogs with various tumors, acting by inhibition of angiogenesis and immunologic modulation. It has 
recently been demonstrated that a dosage of 15 mg/m2 of cyclophosphamide is required to achieve 
inhibition of angiogenesis. However, long term safety of continuous treatment with this continuous 
dosage of cyclophosphamide remains undetermined. 
Materials and Methods 
Dogs presented at the Oncovet center, in which MC was proposed as part of the treatment of well-
identified and staged tumors were retrospectively reviewed. Follow up was assessed, with 
registration of side effects, associated treatment and outcome. 
Results 
A total of 75 cases, receiving an initially-planed daily dosage ranging from 15 to 25 mg/m2 were 
identified. This includes 30 dogs with various carcinoma, 10 dogs with hemangiosarcoma, 10 dogs 
with oral melanoma, 9 dogs with osteosarcoma and 16 dogs with soft tissue sarcoma. Treatment 
with MC was used as part of a multimodal therapy was usually well tolerated. Sterile hemorrhagic 
cystitis (SHC) was the main side effect and was observed in 19% of dogs. Two-thirds of dogs with SHC 
were female. 
Conclusions 
The use of a continuous treatment with a 15-to-25 mg/m2 dosage of cyclophosphamide is associated 
with a relatively high incidence of SHC, particularly in female dogs. Frequent qualitative monitoring of 
urine is recommended in dogs undergoing MC with cyclophosphamide. 
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Introduction 
Tumour cytogenetics is focused on detection of specific tumour-associated chromosome aberrations. 
To do so, a sufficient number of qualitatively good metaphases are prerequisites. Chromosome 
preparation from canine cells is not as simple as in human beings, as available human standard 
protocols cannot be transferred directly on canine cells. Thus, the aim herein was to establish reliable 
standard protocols for preparation of canine cells for routine chromosome analysis. 
Materials and Methods 
Blood samples from healthy dogs (n=10) and two different cultures of mammary tumour cells (n=10 
each, designated as T120 and T121) were analysed. The blood cells were cultured in different media 
(Chromosome Medium B®, Chromosome Medium P® and LymphoGrow®) and the tumour cells in 
Medium 199® at 37°C with 5% CO2/air. To arrest the cells in metaphase, 62.5µL of 0.05M 
colcemid/mL were used for blood cells during 30 min and 14µL/mL for tumour cells during 2h. 
Hereafter, the cells were swollen using hypotonic solutions (tumour cells – 1:6 medium:ddH2O; 
blood - 0.05M KCL) and fixed with methanol:glacial acetic acid (3:1). The fixed cell suspensions were 
dropped onto ice-cold slides and dried prior to G-banding. 
Results 
For blood sample preparation, specific conical tubes (TPP AG) and Chromosome Medium P® showed 
the best outcome to gain numerous mitotic cells. For tumour cell cultures, variation in the handling 
steps resulted in qualitatively good metaphases, revealing a complete canine chromosome set for 
T120A while T121 showed varying chromosomes numbers (67-77). 
Conclusions 
Modified human protocols allow generation of metaphases in sufficient number and quality, 
enabling us to perform routine analyses. 
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Introduction 
40 dogs with surgically treated gingival squamous cell carcinomas (SCC) were analysed 
retrospectively regarding breed, age, tumor localisation, postsurgical complications, and survival 
times (ST). Prognostic factors were evaluated. 
Materials and Methods 
Patients were staged using CT scans of the head and lungs and palpation/FNA of tributary lymph 
nodes. All dogs were treated with jaw resections. Dogs with metastatic disease received adjuvant 
Carboplatin chemotherapy. 
Results 
Medium to large breeds and male dogs were overrepresented. Median ST of all patients was 44.8 
months. There was no significant difference in median ST for maxillary (n=15) and mandibular tumors 
(n=25) (p=0.985). On multivariate analysis only tumor stage was significantly associated with ST 
(p=0.0047). 38/40 (95%) of the patients were N0 upon presentation and reached a median ST of 44 
months. Two patients with N1 survived 18 and 70 months following jaw resection and Carboplatin 
chemotherapy. Of the 5 patients with unclean resection margins (ST 6-146 months) only one dog 
experienced tumor recurrence after 5 months. In 2 dogs postsurgical suture dehiscence occurred. 
Functional outcome was good to excellent in all dogs. 
Conclusions 
Prognosis in canine gingival SCC depends on tumor stage. Complete excision carries a good prognosis 
and in the majority of cases a cure can be expected. Patients with metastasis to local lymph nodes 
can have acceptable STs. The allegedly more malignant behaviour of caudally located gingival SCCs 
could not be confirmed. Jaw resections bear a low rate of complications. 
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Introduction  
Canine mast cell tumors (MCT) of hight grade, non-resectable, with low margins or recurrent after 
surgery require adjuvant therapies. Aim of this study was to evaluated the toxicity and the efficacy of 
radiotherapy (RT) with concomitant and subsequent toceranib, chlorambucil and prednisone. 
Materials and Methods  
Fourteen dogs were treated with curative RT for MCT (three G2SI of lips, one G3SIII of hard palate, 
one G2SIII of digit), with adjuvant RT for MCT recurrent after surgery (two G3SIII of shoulder muscles) 
or resected with low margins (three G2 of interscapular muscles, two G2 of stifle skin, two G2 of 
penis skin). The dose to the tumor bed and local limph nodes was 4 x 800cGy fractions at 7-day 
intervals. During the treatment, toceranib (2.5 mg/kg/48h), chlorambucil (0.1 mg/kg/24h) and 
prednisone (0,5 mg/kg/24h) was administered, continuing toceranib for 6 months, chlorambucil and 
prednisone for 2 months. Toxicity, response, and survival were evaluated along 2,5 years. 
Results  
All the dogs achieved a complete remission. All three dogs with MCT G3 experienced local recurrence 
and metastasis, with progression free interval (PFI) of 8 months and median survival time (MST) of 13 
months. Median PFI and MST was not reached in dogs with MCT G2. Six of 14 dogs have requested 
temporary suspension of chemotherapy. Five and three dogs experienced, respectively, grade II 
acute and grade I late radiation morbidity. 
Conclusions 
The protocol is useful in the treatment of canine MCT with slight toxicity, however an extension of 
the study is advisable. 
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Introduction  
Differential expression of microRNAs (miRs) has been associated with tumour suppressive and 
oncogenic patterns in Canine Mammary Tumours (CMTs). However, their clinical value as cancer 
biomarkers has not been completely proved. The analysis of the expression of 10 miRs (miR-16, miR-
21, miR-24, miR-29b, miR 124, miR-155, miR-199b, miR-200c, miR-203, let-7a) and mRNAS in CMTs 
may contribute for the understanding of the molecular basis of CMT tumorogenesis and could 
prompt the discovery of CMT valuable biomarkers. 
Materials and Methods  
Total RNA was extracted from 4 biopsies of paired normal/tumour tissue samples preserved in 
RNAlater. High quality total RNA (RIN values between 7.6-9.4) was used for cDNA synthesis. miRs 
were quantified using LNA Real-Time PCR (Exiqon, Denmark) assay and mRNAs were quantified using 
RT-PCR with Evagreen (Solis BioDyne, Estonia). 
Results  
Our observations revealed an increased expression of DICER1 in non-metastatic CMT samples and 
underexpression in the metastatic CMT. From the 10 miR’s tested we also observed decreased 
expression of miR-16, miR-199b and increased expression of miR-21, characteristic of CMTs without 
metastasis. The metastatic cancer analysed had a distinctive increase in the expression of miR-155.  
 
Conclusions 
Our results seem to support the importance of DICER1 and miR expression in the metastatic 
transition in CMTs. Correspondingly, in human breast cancer, loss of DICER1 expression is correlated 
with cancer progression and recurrence. Furthermore, with the acquisition of metastatic ability, the 
miR expression profile changes can be molecular markers of malignancy in CMTs. Due to our low 
number of samples, we continue to collect more CMTs to complement our result.
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Introduction  
In dogs, malignant melanoma (MM) is notorious for its propensity to metastasize and for its poor 
response to current therapeutic regimens. Better tolerated, less toxic, and more efficacious 
treatments are needed. 
Materials and Methods  
Dogs with newly diagnosed or recurrent, histologically confirmed MM of any clinical stage were 
prospectively enrolled to investigate objective response, time to progression (TTP), and overall 
survival as well as the safety profile of radiation therapy (RT) in comparison with RT and 
temozolomide. The RT protocol consisted of 5 fractions of 6 Gy to a total dose of 30 Gy over 2,5 
weeks. Dogs whose owners wished to pursue chemotherapy received adjuvant oral temozolomide 
(60 mg/m2/die for 5 days). Treatment cycles were repeated every 28 days for 4 cycles. 
Results  
Fifteen dogs were treated with RT (Group 1) and 12 dogs were irradiated and subsequently treated 
with temozolomide (Group 2). Response rate was 73.3% (3 complete remissions [CR], 8 partial 
remissions [PR]) in Group 1, and 75% (2 CR, 7 PR) in Group 2. Median TTP was not significantly 
different among groups. When considering survival time, dogs in Group 2 lived significantly longer 
than dogs in Group 1 (203 days versus 165 days; p = 0.044). Toxicity was similar between groups. 
Conclusions 
Conventionally fractionated RT followed by 4 cycles of temozolomide has a good safety profile and 
increases survival time in dogs with MM. These results warrant future randomized trials to further 
explore the role of adjuvant temozolomide, and support the general concept of combining radiation 
therapy with radioenhancing chemotherapeutic agents. 
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Introduction  
This study reports efficacy of toceranib in advanced mast cell tumours (MCT). 
Materials and Methods  
This open label multicenter study recruited dogs with recurrent, non-resectable grade II or III MCTs 
with minimum estimated life expectancy of at least 12 weeks, appropriate clinical staging, and no 
significant co-morbidities. RECIST tumour response, adverse effects and drug dosages were recorded. 
Results  
93 dogs (51 female, 42 male) were included. Mean age and body weight were 8.9 years (2.6-15.8) 
and 25.8 kg, respectively. Breeds included Labradors (15%), crossbreeds (13%) and Boxers (10%). 
Previous treatments included surgery (80%), chemotherapy (46%) chemotherapy and radiotherapy 
(3%). Dogs had cutaneous (51%) or subcutaneous (60%) tumours (grade II, 69.6%; grade III, 30.4%) 
located on the head/neck (30.1%), legs (37.6%) and trunk (20.4%). 70% of dogs had metastasis 
(lymph node 58%; distant 12% (splenic 6%)). Objective response was obtained in 48.4%, and 
biological response in 82.8%. 
Mean dose was 3.17 mg/kg (2.5-3.75), every other day. Dose alterations were made in 52 dogs, and 
drug “holidays” in 45 dogs. 9 non-serious and 18 serious adverse events were reported. 13 dogs were 
euthanized for reasons possibly related to drug related side effects and/or disease progression. 
Conclusions 
Response rates were encouraging given the high percentage of dogs with metastatic disease. While 
the recommended initial dose level is 3.25 mg/kg it is now common practice amongst oncologists to 
use lower start doses and lower dose ranges of toceranib without having a negative effect on efficacy 
(Bernabe et al, 2013; London et al 2012). 
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Introduction  
ERBB2 is a key proto-oncogene involved in human breast cancer onset, aggressiveness, recurrence, 
mortality and tumour chemoresistance. Our purpose was to evaluate the cat ERBB2 gene expression 
profile in neoplastic and non-neoplastic mammary lesion samples in order to contribute to the study 
of the clinical relevance of the ERBB2 gene in cat mammary tumours. 
Materials and Methods  
ERBB2 DNA copy number (n=10) and mRNA (n=23) status was assessed by qRT-PCR. Protein 
expression was determined by immunohistochemistry (IHC) using two antibodies (n=33) tested by 
western blotting. Results were correlated with the clinicopathological traits of cat mammary lesions 
(CMLs). 
Results  
CMLs evidenced a lower percentage of erbB-2 positive tissues than normal samples (CB11/internal 
domain: 51,51% vs 91,7%; CBE356/external domain: 33,33% vs 66,7%). The percentage of positive 
CMLs was lower for CBE356/external than for CB11/internal labelling. These two anti-human erbB-2 
antibodies were validated for cat species by western blotting onto cat mammary protein extracts. No 
ERBB2 gene amplification was observed. 
Conclusions 
Consistently, the IHC patterns of the erbB-2 protein revealed a disparity in the membrane labelling 
between the two antibodies. We only found a positive correlation between the ERBB2 RNA levels 
and the protein expression labelling of the intracellular region. These results suggest that the ERBB2 
gene is post-transcriptionally regulated and that proteins with truncations are present in cat 
mammary neoplastic lesions. Additionally, in our subset of cat mammary tumours, we found an 
association between low ERBB2 RNA and erbB-2 protein expression levels, without gene 
amplification, and poor prognosis. The first two authors contributed equally to this work.
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Introduction  
COX-2 expression has been shown to affect human mammary tumorigenesis via a number of distinct 
mechanisms: promoting tumour maintenance and development, inducing angiogenesis and cell 
proliferation, encouraging metastatic spread and tumour associated inflammation. In order to better 
understand this subject in canine mammary tumours (CMT) the role of COX-2 was investigated by 
searching the potential relationship with angiogenesis, proliferation and inflammatory infiltrate in a 
large series of cases. 
Materials and Methods  
One hundred and eleven CMT (90 malignant and 21 benign) were submitted to 
immunohistochemical staining to detect the immunoexpression of the following marker: COX-2, Ki-
67, CD31, VEGF, CD3 and MAC387. 
Results  
Considering the group of malignant tumours (n=90), high COX-2 immunoexpression revealed a 
statistically significant association with CD31 (P = 0.021); VEGF (P (r = 0.457; P (r = 0.254; P = 0.026); 
CD3+ T-lymphocytes (r = 0.287; P = 0.006) and MAC387 (r = 0.285; P = 0.021). In benign tumours 
(n=21), COX-2 showed no association and/or correlation with the molecular markers considered in 
the study. 
Conclusions 
Present study demonstrated a link between high COX-2 immunoexpression and increased 
angiogenesis, proliferation and tumoural T-lymphocyte and Macrophage infiltration, parameters 
already described as being related with the promotion of tumoural aggressiveness in CMT. These 
findings reinforce the usefulness of using selective COX-2 inhibitors as a valuable therapeutic tool in 
malignant CMT treatment. 
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Introduction  
In the pathogenesis of canine Inflammatory Bowel Disease (IBD) an aberrant chronic antigenic 
stimulation plays a crucial role in the clonal expansion of certain lymphocyte subsets. This study is 
aimed at investigating the immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement in dogs 
affected by IBD to identify clonal expanded lymphocytes. 
Materials and Methods  
From 36 dogs suffering from IBD and six healthy controls, intestinal biopsies of the duodenum and 
colon were taken and examined by histopathology and immuno-histochemistry. In total, 77 snap-
frozen bioptic samples were retrieved and the ge-nomic DNA (gDNA) was purified following standard 
protocols. To assess clonality, gDNA samples were subjected to triplicate PCR using primers targeting 
the variable regions of B- and T-cell receptors (PARR). Size-separation of the Ig and TCR gene 
rearrangements was performed by high-resolution capillary electrophoresis. 
Results  
All cases showed an Ig polyclonal pattern indicating a non-tumorigenic status. Four patients out of 36 
(11.1%) exhibited reduced diversity of the TCR repertoire by dis-playing oligoclonal or monoclonal 
peaks in the electropherogram. T-cell clonality of these patients was verified by sequencing the 
rearranged TCR segments. 
Conclusions 
To date, PARR is the only test, able to confirm clonality in a population of canine lymphoid cells. Four 
of the IBD patients were identified having an intestinal clonal T-cell population. This leads to the 
recommendation of using PARR as an adjunct diagnostic tool in early detection of a borderline state 
from severe chronic inflammation to clonal expansion of certain lymphocyte subsets in the 
pathogenesis of canine IBD. 
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Introduction  
Cyclo-oxigenase-2 (COX-2) and multidrog resistance protein 1 (MDR1 or Pgp) are considered to have 
prognostic value in canine neoplasms, like mammary gland tumours. Although, debating research 
findings has been issued about the practical usage of these markers. 
Materials and Methods  
Mammary gland neoplasms (n=33) were analysed. After routine histopathological evaluation, we 
performed immunohistochemistry to detect COX-2 (monoclonal rat IgG1 368-604), and MDR1 
(monoclonal mouse Ig G, C494, Signet Laboratories). Tumour bearing dogs had been treated either 
by chemotherapy, and/or NSAIDs. Data of the efficacy of therapy was noted. Four groups were set 
up. 1. low co-expression (<40% MDR1 and COX-2, n=8); 2. high co-expression (>40% MDR1 and COX-
2, n=7); 3. high MDR1 expression (MDR1>40%, COX-2<40%, n=9); 4. high COX-2 expression 
(MDR1<40%, COX-2>40%, n=9). 
Results  
Median overall survival times (days) were different in groups. 1. 152 ±478); 2. 90.5 (±145); 3. 427 
(±561) 4. 19 (±163), respectively. Significant differences were found between high co-expression and 
high MDR1 expression (p=0.0278); between high MDR1, and high COX-2 expression (p=0.043). COX-2 
expression was inversely correlating with the overall survival (r: -0.509, p=0.00245), whereas MDR1 
not (r: 0.0902, p=0.611). MDR1 expression was not correlating with the survival in dogs which 
received chemotherapy (r: -0.282, p=0.611) 
Conclusions 
High COX-2 alone or with high MDR1 expression gave the lowest survival of the patients. MDR1 levels 
were unexpectedly unrelated with the survival times, whereas COX-2 levels were of prognostic 
interest in canine mammary gland tumours. The limitaton of this study is the resonably low number 
of cases. 
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Introduction  
A group of transmembrane proteins called claudins link adjacent cells, seal intercellular space and 
maintain homeostasis in epithelial tissue. Immunohistochemical studies on canine tumors show 
deregulation of claudin-1, -3, -4 and -7 expression. A molecular screening system for the claudin-
genes -1, -3, -4 and -7 was established. Characterisation of claudin-gene-expression in canine cell 
lines and mammary neoplasias was performed by conventional and qPCR. 
Materials and Methods  
Canine cell lines: Mammary: MTH53A. non-neoplastic; ZMTH3, MTH52C: mammary tumors. Prostate: 
CT1258: prostate carcinoma; DT08/46: prostatic cyst. Canine mammary tissues: 10 healthy tissue 
samples, 49 benign neoplasia samples, 60 malignant neoplasia samples. Primers were designed for 
PCR and qPCR. Fragment and sequence verification was done by cloning and sequencing. RNA-
isolation was performed with the RNeasy® Mini Kit including a digestion of genomic DNA. cDNA-
Synthesis was performed using the M-MLV Reverse Transkriptase. qPCRs analyses were performed 
using SYBR Green and REST2009. 
Results  
Conventional PCR and qPCR expression analyses: Cell lines: DT08/46: claudin-1, -3, -4 and -7 positive. 
MTH53A: claudin-7 positiv. ZMTH3: claudin-1 positive. CT1258, MTH52C: low to negative. The 
majority of mammary tissues show claudin expression in conventional PCR. 
Conclusions 
Using the established molecular assays the claudin-1, -3, -4 and -7 -expression of canine cell lines and 
mammary tissues was characterized. Thus we can refine immunohistochemical data and evaluate the 
diagnostic and therapeutic potential of the claudin genes in veterinary oncology. 
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Introduction  
Canine nasosinal tumors are a miscellaneous group of neoplasms with primarily malignant behavior. 
Megavoltage radiotherapy is considered treatment of choice for this tumor entity. At the University 
of Veterinary Medicine Vienna a linear accelerator was installed in 2006. The aim of this 
retrospective study was to analyse the first patient cohort treated at this institution. 
Materials and Methods  
Dogs which were radiated for a nasosinal tumor between 2006 and 2012 were included into the 
study. Medical records were reviewed and patient characteristics, treatment protocols, adjuvant 
therapies and outcome were analysed. Follow-up information was obtained from medical records 
and by phone conversations with veterinarians or pet owners. 
Results 
 Thirty-four dogs fulfilled the inclusion criteria. Mean age was 9.1 years and mean body weight was  
25.2 kg. Male dogs were overrepresented (65%) and Golden Retrievers were the most common 
breed. Twenty dogs were radiated curatively (mean dose 48.4 Gy) and 14 dogs palliatively (mean 
dose 22.6 Gy) and median survival time was 599 and 186 days, respectively. Dogs of earlier-stage 
disease had a significantly better outcome than dogs with more advanced disease. Adjuvant 
chemotherapy was used in 13 dogs. Rhinotomy was performed in four dogs after and in two before 
radiotherapy. Three patients had surgery earlier and were radiated with recurrent disease. 
Conclusions 
Outcome in this study compares favourably to the literature and confirms that radiotherapy should 
be recommended as standard of care for nasosinal tumors. The role of adjuvant treatment options 
could be further investigated in a prospective multicenter study. 
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Introduction  
Thermography is a method used for breast cancer detection in humans, based on "hot spots". 
Understanding of thermographic behavior of MCT can lead us to a possible prognostic/diagnostic 
tool. We evaluated 15 MCT using thermographic images, histologic patterns and IHQ markers, 
looking for a thermographic pattern for this tumor. 
Materials and Methods  
Images were taken following thermographic image protocol. We measured mean themperature of 
central tumor point  (SpT), of healthy skin - away from the surgical margin (SpNT), tumoral area mean 
themperature (AT) and non-tumoral area (ANT). Tumors were histologic graded, AgNOR´s, PCNA, KIT 
and VEGF-A protein marking were studied. 
Results  
All tumors were MCT grade II, low grade. Mean SpT were 33.18oC (28.7-36.5). Mean SpNT were 
33.39oC (28.5-36.3). Mean AT were 33.27oC (29.3-36.1) and mean ANT were 33.95oC (31.0-36.0). In 
47% of the tumors the difference between the tumoral area and healthy skin was negative (tumor as 
a cooler point) and in 53% of the cases, the difference was positive (tumors presenting as hot point). 
We found no correlation between thermographyc variation with histologic patterns or IHQ markers, 
but we did found a statitical difference between the temperature in tumor area and healthy skin area 
(p<0.001). 
Conclusions 
Our data suggest that, besides what human literature suggest, MCT are not always detected as a hot 
spot on thermogaphy. Based on our studies, we believe that thermography, can be a useful tool for 
diagnostic of MCT in the future, but further studies of thermographic behavior of MCT are necessary. 
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Introduction  
It has been described the association of gammaherpesvirus (Epstein-Barr virus) chronic infection in 
human lymphomagenesis. It has also been reported the presence of antibodies and viral Material in 
dogs affected by lymphoma. The exact role of herpesvirus in canine lymphomagenesis is still poorly 
understood,existing a very few data correlating cHV infection and lymphoma in dogs. The aim of this 
study was to evaluate serological status for canine Herpesvirus in dogs with spontaneous diffuse 
large B cell lymphoma. 
Materials and Methods  
Twenty eight dogs with diffuse large B cell lymphomas (cDLBCL)treated with a 19 week CHOP 
protocol were tested for cHV antibodys by a referral lab using ELISA technique. Survival analysis was 
then performed and correlated with cHV infection. 
Results  
Sixteen out of 28 (57%) of dogs revealed positive titers for cHV antibodies. Median survival time 
(MST) was higher in dogs suffering from DLBCL and showing negative titers for cHV (MST= 288 days) 
compared to those with positive titers (MST= 144 days). 
Conclusions 
These results may suggest serological status for cHV as a possible prognostic indicator and a tease to 
search for the possible role of cHV in lymphomagenesis. 
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Introduction  
Canine osteosarcoma (OS) is an aggressive tumor accounting for approximately 90% of all primary 
bone tumors in these species. Although limb amputation with chemotherapy is the gold standard of 
care, treatment including radiation therapy supplemented with chemotherapy can be used for limb 
sparing. In this study we compared radiation therapy/chemotherapy protocol with treatment 
without radiation therapy. 
Materials and Methods  
Sixteen dogs with histologically confirmed OS underwent radiation therapy (group 1) with 60 Gy of 
cobalt 60 radiation in 3.5-5 Gy fractionation 2-3 doses a week. All dogs received concurrent 
chemotherapy with either cisplatin in dose of 70 mg/m2 (n=5), or doxorubicin in dose of 30 mg/m2 
(n=3) or combination of cisplatin (60 mg/m2) and doxorubicin in dose of 25 mg/m2 (n=8).  
Results  
Control group 2 (n=12) underwent limb amputation with adjuvant chemotherapy (n=3) or limb-
sparing surgery (n=9) with adjuvant chemotherapy without radiation therapy. Medial survival in 
group 1 was 4.6 mo, 1/16 dogs was alive after 1 year. In 25% of dogs was observed radiation 
dermatitis. Median survival in group 2 was 5.8 mo and did not differed significantly from that 
observed for group 1.1 year survived 1 patient. 
Conclusions 
Radiation therapy with chemotherapy may be considered an alternative to amputation or limb-
sparing surgical procedures in selected dogs with appendicular osteosarcoma. 
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Introduction  
Electrochemotherapy (ECT) as it is used in the veterinary field treats tumours whose recurrence risk 
is primarily local. The high success of the treatment in several common tumours leads to long-term 
survival of patients thus treated. The fact that these patients have received a cytotoxic drug could 
increase their risk of further malignant tumours. The purpose of this retrospective study is to assess 
the carcinogenic risk of electrochemotherapy using bleomycin. 
Materials and Methods  
This study examines retrospectively the follow-up data on 164 cases treated with 
electrochemotherapy for second malignancy frequency. For a control population, the records of 269 
patients treated for tumours by surgery alone in first opinion practice. Data supplied from Istituto 
Zooprofilattico Sperimentale delle Venezie follows 8195 tumour cases in 7048 dogs; 886 dogs 
(10.8%) developed more than 1 tumor (Vascellari, M: personal communication). 
Results  
The data shows that 17/164 ECT treated (10.3%) and 60/269 surgically (22.3%) patients developed 
second malignancies. Where cases with >2 years follow-up are considered, 10/57 (17.5%) ECT and 
38/110 (34.5%) surgical cases developed second tumours. None of the ECT treated cats developed a 
second neoplasm.  
Conclusions 
It is concluded that ECT does not increase the risk of second tumours. The nature of the control 
groups may not be representative, however. A similar study of patients receiving metronomic 
therapy would be justified. 
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Introduction  
Electrochemotherapy is a new modality of local control of tumors. The intra-operative approach is an 
alternative to infiltrated surgical margins. The Electrochemotherapy has high selectivity neoplastic 
cells, allowing to treat a wide margin, without needless destruction of healthy tissue and reducing 
recurrence. We report 34 cases of canine mast cell tumor (MCT) treated with Electrochemotherapy 
intra-operative, with the aiming of achieving better local control of the disease. 
Materials and Methods  
Thirty-four patients with diagnosis and histopathological grading (Patnaik et al, 1984) of cutaneous 
MCT were treated between 2009 and 2011 and followed for 1882 days. The protocol included 
surgery for the tumor excision and Electrochemotherapy for treating margins, in the same 
procedure. All animals were staged. Tumors with II and III degree were treated with adjuvant 
chemotherapy. 
Results  
Of the 34 cases of MCT 76.5% (n = 26) showed no local recurrence and median survival was 765.5 
days (46-1868). Observed mortality rate of 47%, with 35% attributed to MCT. Of the 34 cases, 25 had 
clinical stage IIIa and all recurrences (n = 8) occurred in this group, all of which were histological 
grade II (n = 6) or III (n = 2). The recurrence rate was 40% in each graduation, however, the group 
grade II three times larger than the third. The follow up time was defined until the writing of this 
paper. 
Conclusions 
The association of these two techniques in the treatment of cutaneous MCT may present greater 
chances of disease free time, lower recurrence rates and better clinical outcomes. 
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Introduction  
In dogs the most common WHO entity seems to be Diffuse Large B cell lymphoma. Studies evaluating 
recent WHO lymphoma entities treatment response, as well as prognostic markers are lacking. 
Materials and Methods  
Twenty three cases of canine diffuse large B cell lymphoma treated with a 19 week CHOP protocol 
were analysed for response to treatment, time to progression and overall survival. Gender, age, 
weight, WHO stage, anatomic presentation and breed were assessed and correlated with prognosis. 
Results  
Median age of dogs was 8.87 years. Multicentric lymphoma was the most common form (87.0%).The 
majority of the dogs were in clinical Stage IV (73.9%). Most of the dogs (60.9%;) were on substage 
“b”. Overall median survival time was 154 days based on the Kaplan-Meier survival analysis. 
Conclusions 
Our study demonstrated that distribution between genders is similar and Rottweiler breed was 
overrepresented. Large dogs (body weight >30 Kg) and small dogs (body weight less than 30 Kg) are 
equally represented and differences in survival  between these 2 groups could be identified by the 
Long-Rank test, with small dogs apparently living less after diagnosis and treatment. No objective 
justification for this association could be identified. The majority of patients presents in an advanced 
WHO stage, mainly stages III, IV and V, respectively, with only substage b making a significant 
difference in worsening prognosis and consequently survival. Probably due to this reason our group 
of cDLBCL had a short median survival time than those reported in literature for general cL.  
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Introduction  
Transitional cell carcinoma is a frequent type of canine urinary bladder cancer. Medical treatment 
with chemotherapy, COX inhibitor has been the mainstay of treatment for dogs with TCC. Surgery is 
rarely suggest, because it’s located trigone region and has a high incidence of metastases. 
Materials and Methods  
From 2009-2013, 27dogs with clinical signs compatible with urinary bladder cancer were identified. 
Results  
The most frequent breeds were 7 Poodle, 6 Mixed Breed, and the remainder included 3 Cocker and 3 
PitBull, 2 of each Bernese and LhasaA, 1 of each Dachshund, Fox, Pinscher and ScottishT. 16 (59%) 
were female and 11 (41%) male. The mean age was 10.5years (median: 12, range: 2-15) and the 
mean weight was 12kg (median: 8, range: 3.3-48). The clinical signs consisted of hematuria (68%), 
dysuria (46%) and  pollakiuria (21%). The mean duration of clinical signs before diagnosis was 3 
months (median: 2, range: 1 week to 8 months). The mean size of the tumor measured by ultrasound 
were 2.9 cm (± 1.7) and the most common location were trigone (n=14=52%), cranial (n=6=22%), 
lateral (n=3=11%), whole wall (n=2=7%), dorsal (n=1=4%) and ventral bladder wall (n=1=4%).  
Diagnosis was obtained by esfoliative cytology (catheterization) in 19 dogs, revealing TCC in 15 (79%) 
dogs and benign epithelial desquamation in 4 (21%). Dogs submitted to surgery had the 
histopathologic confirmation of TCC. 
Conclusions 
The average survival time was correlated with the treatment: 106 (±78)days the group which had 
been treated only with piroxicam; 217 (±201) days piroxicam with carboplatin; 225 (±105) days 
surgery associated with piroxicam and 240 (±252) days surgery associated with piroxicam and 
carboplatin. 
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Introduction  
B-cell lymphomas (BCL) are heterogeneous in terms of epidemiology, immunophenotype and 
outcome in dogs. We have recently shown that immunohistochemistry (IHC) for CD10, BCL-6, MUM-
1, BCL-2 and  
c-MYC, using Hans’ algorithm derived from human medicine, was of prognostic value in canine 
diffuse large B-cell lymphomas (DLBCL) (Nguyen et al. 2013). In this study, we evaluate the prognostic 
value of another IHC marker, Ki-67, in canine BCL. 
Materials and Methods  
253 BCLs diagnosed using histopathological criteria (Valli et al. 2011) and IHC (CD3-, CD20+ and 
CD79acy+) at Oniris, treated by surgery (8%), corticosteroids (53%) or CHOP-like chemotherapy (28%) 
or untreated (11%) and with an available 2-year follow-up period, were evaluated for Ki-67 by 
automated IHC.  
Results  
The BCL were DLBCL (51%), marginal zone lymphomas (30%), follicular lymphomas (4%), other high 
grade (9%) or low grade BCL (6%). The histological grade was of prognostic value (median specific 
survival of 51d for low grades, of 143d for high grades) (p=0.014). The optimal Ki-67 threshold for BCL 
was established at 40%, with correlation to survival (p<0.001, ANOVA test) and separating low and 
high grade BCL with 88% sensitivity and 100% specificity (positive and negative predictive values of 
respectively 100 and 93%).  
Conclusions 
We recommend the threshold of 40% for Ki-67 in canine BCL to better identify dogs having a longer 
survival potential. This threshold is similar to the one defined for human lymphomas (Naz et al. 
2011). 
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Introduction  
Vascular endothelial growth factor (VEGF) is expressed both in vitro and in vivo in human and canine 
lymphoma. Antiangiogenic treatment regimens have shown significant clinical activity in recurrent 
NHL in human medicine. The objective of this study was to prospectively evaluate an antiangiogenic 
treatment protocol in the setting of relapsed canine multicentric lymphoma. 
Materials and Methods  
Inclusion required a cytologic or histologic diagnosis of relapsed multicentric lymphoma. Any prior 
therapy was allowed. The protocol consisted in: Cyclophosphamide at 15 mg/m2/24h PO, toceranib 
phosphate at 2.5 mg/kg Monday, Wednesday and Friday, and prednisone at a tapering dose starting 
at 2mg/kg/24h, to then in one month time continue with 0.5mg/kg/24h PO. Responses were 
evaluated according to the Veterinary cooperative oncology group’s (VCOG) response evaluation 
criteria for peripheral nodal lymphoma in dogs (v1.0). Outcome was measured as time to 
progression. Adverse events were graded according to the Veterinary cooperative oncology group’s 
common terminology criteria for adverse events (VCOG-CTCAE).  
Results  
Ten dogs were enrolled. Inmunohistochemistry was available in 5 cases (4 B-cell, one T-cell 
lymphoma). Four dogs (40%) achieved stable disease, with a median time to progression of 46 days. 
No partial or complete responses were observed. Four dogs experienced gastrointestinal upsets 
(grade II n= 2, grade III n=2), two developed neutropenia (grade I n=1, grade II n=1). Toceranib was 
discontinued in one case during 5 days. 
Conclusions 
This protocol was well-tolerated, but lacked overt benefit in advanced canine lymphoma. The 
protocol may have greater activity in specific sub-classifications of canine lymphoma, or earlier in the 
disease process. 
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Introduction  
Vascular endothelial growth factor (VEGF) is overexpressed in feline mammary tumors and it is 
associated with worse prognosis. Toceranib phosphate (Palladia®), a tyrosine kinase inhibitor (VEGFR, 
PDGFR, KIT) has been used safely in tumor bearing cats. This prospective study evaluated the efficacy 
and safety of toceranib phosphate in cats with measurable mammary tumors. 
Materials and Methods  
Inclusion criteria included a histopathological diagnosis of primary or metastatic mammary 
carcinoma. The initial assessment included physical exam, tumor measurements, CBC, biochemistry 
and UA, thoracic radiographs and abdominal ultrasound. Toceranib phosphate dose was 2.5-3.25 
mg/kg/48h. A CBC and physical exam were performed at two weeks time, response evaluation 
following RECIST criteria was performed one month after initiating the protocol and monthly 
thereafter. Adverse events were recorded and evaluated following VCOG-CTCAE. 
Results  
Sixteen animals have been included until abstract submission. Five patients presented with surgical 
recurrence, 3 had distant metastatic disease, and 8 were “de novo” tumors. One cat had a complete 
response, 6 had partial responses, 4 stable disease and 5 animals had progressive disease. Two 
patients developed grade I neutropenia, one grade II vomiting, one grade III anorexia and a one 
grade II azotemia. Total response rate was 50%, median time to progression of 98 days and clinical 
benefit of 68%.  
 
Conclusions 
Treatment was well tolerated with minor side effects. These data provides evidence that toceranib 
exhibits activity in feline mammary tumors in the macroscopic setting, suggesting a potential role in 
the adjuvant microscopic setting after surgery. Future prospective studies are needed to study this 
possibility further. 
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Introduction  
Cutaneous neoplastic lesions are very common in horses, accounting for 50% of all tumours that 
affect these animals. Retrospective studies have described sarcoids, squamous cell carcinomas (SCC) 
and melanocytic tumours as the most common lesions. The purpose of this study was to analyze, 
through immunohistochemistry, COX-2 expression in various equine cutaneous tumours, in order to 
determine whether COX-2 is a potential therapeutic target. 
Materials and Methods  
Thirty-five tumour samples were subjected to histopathological diagnosis, according to the criteria 
described by WHO. The material selected included 24 melanomas, 5 sarcoids, 4 SCC, 1 papilloma and  
1 fibroma. Pigmented lesions were bleached, for melanin removal, previously to 
immunohistochemical procedures. Immunohistochemical study was performed using the clone SP21 
(ThermoScientific®), diluted in 1:50. COX-2 expression was assessed according to its labelling 
extension and intensity. 
Results  
COX-2 was expressed in 86% (n=30) of the samples studied, scored positive in 20 of 24 (83%) 
melanomas, 3 of 4 (75%) SCC, in 4 of 5 (80%) sarcoids and in both papilloma and fibroma. In positive 
tumours, neoplastic cells always demonstrated a cytoplasmatic labelling pattern, some with an 
increased intensity in perinuclear region. 60% (n=21) of the COX-2 positive tumours had a diffuse 
immunoexpression, with extension superior to 50% of the cells. Regarding the labelling intensity, 
melanoma and sarcoid samples got equally distributed through the three different intensity grades. 
100% of the COX-2 positive CCE presented a strong labelling intensity. 
Conclusions 
In summary, most equine cutaneous neoplasms appear to express COX-2, therefore eligible for 
treatment and prevention by the use of COX-2 inhibitors. 
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Introduction  
Cancer stem cells (CSCs), identified in many human cancers including osteosarcoma (OSA) are drug 
resistant and, likely, play a major role in tumor recurrence and metastasization, thus representing 
candidate drug targets. The aim of this study was to isolate and characterize CSCs from canine OSA 
cell lines, evaluating their responsiveness to metformin, an anti-diabetic drug, that possesses 
antitumor properties and affects CSC survival in different human tumors. 
Materials and Methods  
CSCs isolated from 2 canine primary cultures (one osteoblastic productive and one chondroblastic 
OSA), were enriched in stem-permissive medium and characterized for proliferative potential and 
sensitivity to metformin by MTT assay, self-renewal by spheroid forming-assay, differentiation ability 
and stem marker expression by immunofluorescence. Tumorigenicity was tested by s.c. injection of 
cells into NOD/SCID mice. 
Results  
We identified and enriched CSCs maintaining OSA cells in a medium containing EGF/bFGF. The free-
floating sarcospheres expressed stem cell markers CD133, Oct4 and CXCR4, were able to self-renew 
and, can be expanded for several passages and gave rise to differentiated adherent monolayers in 
serum-containing medium. Injection of CSCs into mice resulted in the formation of tumors that 
recapitulated the features of canine OSA. Finally, metformin induced a significant antiproliferative 
effect on CSCs. 
Conclusions 
Our results indicate that canine OSA contains a subpopulation of CSCs sensitive to metformin and 
may represent a novel experimental model for pre-clinical in vitro drug efficacy screening, further 
confirming the potential for the dog as a model of human tumors. 
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Introduction  
Classical cadherins, E-cadherin (epithelial) and P-cadherin (placental), are the best characterised 
members of the cadherin superfamily. Changes in their expressions have been related to breast 
carcinogenesis, however their role in feline mammary tumours is still poorly understood. The 
purposes of this study were to examine the expression of P-cadherin in feline spontaneous mammary 
lesions and to determine its relationship with the expression of E-cadherin and clinicopathological 
characteristics with known prognostic value. 
Materials and Methods  
The expressions of P-cadherin and E-cadherin were studied by immunohistochemistry in a series of 
feline normal mammary glands, hyperplastic/dysplastic lesions, benign and malignant tumours, and 
related with variables with known prognostic value, such as histological grade, mode of growth, 
tumour largest diameter, presence of necrosis, skin ulceration, lymph node metastases, and 
neoplastic intravascular emboli. 
Results  
In normal tissues and in the majority of hyperplastic/dysplastic lesions and benign tumours, P-
cadherin was restricted to myoepithelial cells, while 80% of the malignant tumours expressed P-
cadherin in the luminal epithelial cells. Furthermore, this pattern was significantly related to high 
histological grade, infiltrative growth, tumour necrosis and presence of neoplastic emboli. The 
combined P- and E-cadherin expression profiles of high grade and infiltrative tumours were very 
similar, the large majority expressing P-cadherin with an almost equitable distribution of preserved 
and reduced E-cadherin expression among them. 
Conclusions 
The present study demonstrated a relation between the aberrant expression of P-cadherin and a 
malignant phenotype, higher histological grade and invasive behaviour, suggesting it as an indicator 
of poor prognosis in feline mammary tumours. 
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Introduction  
Osteosarcoma (OSA) is the most common canine primary bone tumour. Understanding the 
expression and role of tyrosine kinase receptors (TKRs) in OSA is important in order to find innovative 
therapeutic strategies. The aim of this study was to evaluate TKRs expression and assess the effect of 
toceranib phosphate in seven canine OSA cell lines. 
Materials and Methods  
VEGFR2, C-Kit and PDGFRα/β expression (main targets of toceranib phosphate) was assessed by 
quantitative PCR in seven primary canine OSA cell lines and normal osteoblasts. Cell cycle, cell 
proliferation, survival, motility, invasion and soft-agar assays were carried out in absence or presence 
of toceranib phosphate. Cell lines tumorigenicity was tested in vivo. 
Results  
PDGFRα and PDGFRβ were highly expressed in all cell lines. VEGFR2 and C-Kit were overexpressed in 
3 cell lines (Penny, Wall and Lord), in which toceranib phosphate did not affect Ki67 cell proliferation, 
cell cycle and survival. All cell lines showed migratory ability in both transwell and wound healing 
assays that was inhibited (26%-93%) by toceranib phosphate. Only Penny and Wall cell lines were 
able to form soft-agar colonies that toceranib phosphate decreased by 38% and 86%, respectively. 
Penny, Wall and Lord developed tumors in mice. PDGFRα/β and VEGFR2 expression was 
demonstrated by immunohistochemistry 
Conclusions 
All OSA cell lines expressed PDGFRα/β, while VEGFR2 and C-Kit were expressed in 3/7. Toceranib 
phosphate caused inhibitory effect in the migration and anchorage-independent cell growth in all cell 
lines. Three OSA cell lines developed tumours that maintained the original immunohistochemical 
characteristics.
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Introduction  
The rate of tumor growth is determined by tumor cell proliferation and death. An imbalance 
between tumor cell proliferation and death is critical for tumor development, progression and 
regression. The goal of the present study is try to elucidate the relationship between tumoral 
proliferation and apoptose in canine mammary tumours (CMT). 
Materials and Methods  
Samples of 50 CMT (18 benign and 32 malignant) were studied, by immunohistochemical detection 
of active Caspase-3 and Ki-67 antigens in order to determine its association with several clinic and 
pathological parameters. 
Results  
Caspase-3 immunoexpression was statistically significantly higher in benign tumors comparatively to 
malign counterparts (p ≤ 0.001). In the malign tumors’ group, there was no significant association 
between active Caspase-3 and the clinic-pathological variables considered. The Ki-67 
immunoexpression was statiscally significantly higher on malignant tumors comparatively to benign 
ones (P ≤ 0.001). In the malignant tumors’ group, the Ki-67 PI show a statistically significant 
association with the tumor size  
(p = 0.025), histological type (p = 0.010), mitotic index (p ≤0.001), nuclear degree (p = 0.025), 
histological grade of malignancy (p =0.002) and presence of metastases at regional lymph nodes (p = 
0.025). Furthermore, in this study was observed a negative correlation between the Ki-67 PI and the 
expression of the active Caspase-3 (r = -0.034; p = 0.049). 
Conclusions 
Our results highlighted the role of Ki-67 in mammary carcinogenesis and tumor progression. With 
regard the active Caspase-3 our results suggest that apoptotic pathways are inhibited in tumor 
progression. 
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Introduction  
Tumor cells bypass replicative senescence by activating telomere maintenance mechanisms (TMM). 
Activation of telomerase is the most commonly used TMM. Thus, inhibition of telomerase is an 
attractive anticancer strategy. The objective of this study was to screen different telomerase 
inhibitors for their potential to impair canine soft tissue sarcoma cell line viability. 
Materials and Methods  
Three telomerase positive canine fibrosarcoma cell lines (PSTS, CoFSA, MBSa) and three human 
control cell lines of varying origin (sarcoma, carcinoma and glioblastoma) were used for this study. 
Telomerase activity (TA) was modulated by infection with recombinant adenovirus (AV) expressing 
either human wild-type (activation) or dominant-negative (inhibition) catalytic subunit of telomerase. 
Further TA was inhibited with MST-312, BIBR1532 or TMPyP4, a quadruplex ligand. TA was 
determined by qPCR-TRAP, tumor cell viability by MTT and tumor cell senescence by acidic β-
galactosidase assay.  
Results  
Expression of wild-type telomerase caused further activation of TA, whereas expression of dominant-
negative telomerase attenuated TA in 2/3 canine sarcoma cell lines, but induced cell senescence in 
all. MST-312 and BIBR1532 both impaired TA, but MST-312 was more potent inhibiting tumor cell 
viability (IC50 0.78-5.1µM). BIBR1532 required higher drug concentrations (IC50s 43.2 and 53.1µM) 
and could only inhibit 2/3 cell lines. TMPyP4 seemed least effective at repressing tumor viability with 
IC50 of 60µM. 
Conclusions 
In conclusion, TA can be impaired in canine sarcoma cell lines with different inhibitors, but MST-312 
caused the most potent decrease in tumor cell viability. This drug appears promising to further 
investigate its potential for targeted anticancer therapy in aggressive sarcomas. 
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Introduction  
The colorimetric and/or isotopic “sentinel” lymph node (LN) procedure has replaced axillary LN 
dissection for staging of clinically N0 human patients with breast cancer. Despite the prognostic value 
of LN metastatic status, the usefulness of vital dyes injection for lymphatic mapping has not been 
extensively evaluated in veterinary oncology. Because of the variations observed in the mammary 
lymphatic network and the difficulty of axillary LNs surgical removal, it is hypothesized that better 
visualisation of local lymphatic drainage would be helpful for mammary tumour (MT) surgery. 
Materials and Methods  
Fifteen minutes before the mastectomy, 2ml of BLEU PATENTE V 2,5% was injected subcutaneously 
at the direct periphery of the MT on 10 anaesthetized female dogs, with owner’s consent. A small 
incision was performed in the axillary region for resection of the axillary LN(s). The surgery ended 
with the removal of the inguinal LN. The blue coloration was evaluated during mastectomy and on 
removed tissues. 
Results  
MT (60% malignant) were located on M2 (25%), M3 (33%), M4 (25%) and M5 (17%). Clinical evidence 
of toxicity was absent but transitory unwanted staining of non-lymphatic tissues and of excreta 
(mostly urine) was frequent. The blue dye failed to stain locally in one female dog. Successful staining 
was more frequent for the inguinal LN than for the axillary LN, which was not systematically detected 
by the surgeon (60%). Tolerance of the procedure was excellent but induced a blue coloration of the 
surgical operating field, routinely tolerated in human surgery. 
Conclusions 
This promising technique needs further optimisation on a larger series. 
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Introduction  
Photodynamic therapy (PDT) is an alternative modality to treat certain types of tumors, and is based 
on production of free radicals (FR). Patients are administered a harmless light-sensitive drug, and 
after its accumulation in the tumor, the affected area is illuminated with visible light, so cytotoxic 
ROS are produced in a strictly located area, leading to tumor destruction. 
Materials and Methods  
A precursor of a light-sensitive drug, 5-aminolevulinic acid (5-ALA) has been administered to cats 
with tumors. 5-ALA is converted to Protoporphyrin IX in cells during haem production, and has 
excellent photodynamic properties, especially when overproduced. PDT takes advantage of ROS 
production, so mRNA levels of: (i) HIF1-α and HO-1 factors, as well as COX2 enzyme (related to 
oxygen consumption), (ii) and porphyrin-related transporters (ABCG2, ABCB6 and PEPT1) have been 
examined during PDT. In vivo production of Protoporphyrin IX and FR were also measured in tumor 
tissues using fluorescent and EPR spectroscopies, respectively. PDT efficacy was assessed based on 
RFP (recurrence-free period). 
Results  
Efficiency of PDT correlated with COX-2 (R = -0.74), HO-1 (R = -0.70) and PEPT1 (R = 0.69) expression 
of tumor tissues. Grade of tumor progression was also important, and had direct correlation with FR 
production (p = 0.014). 
Conclusions 
PDT efficacy is not related as much to tumor type, as to its grade and oxygen-related factor 
expressions. Among 5-ALA-PDT-related transporters, the most important is the one, that provides 
tumor cells with the protoporphyrin precursor. Other transporters taking part in the process of 
photosensitizer metabolism do not seem to be determinant. 
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Introduction  
Canine melanoma (OM) is a very invasive tumour that represents the most common malignancy in 
the oral cavity. The objective of this retrospective study was to evaluate the clinical benefit, the 
median survival time (MST) and the adverse effects (AE) in dogs with OM, treated with 
antiangiogenic drugs as unique therapy or adjuvant to conservative surgery. 
Materials and Methods  
Seventeen dogs with OM were treated with toceranib (Palladia®) and COX2 inhibitor +/-metronomic 
therapy. Seven received this combination as unique therapy and ten as adjuvant after conservative 
surgery. Clinical benefit (defined as complete or partial response and stable disease) was evaluated 
on days 30, 60, 120, 180, 240, 300, 360. Adverse events were registered following the VCOG-CTCAE 
criteria. 
Results  
Clinical benefit was observed in 4/7 (57%) dogs treated with toceranib and COX2 inhibitor as 
palliative treatment; however it was a short response. Dogs treated with toceranib and COX2 
inhibitor +/- metronomic therapy as adjuvant to conservative surgery (n=10) have a MST of 530 
(±145) days and 2/10 dogs (20%) are still alive 1 year after the diagnosis. Otherwise, MST in the arm 
of dogs treated with the palliative modality was 85 (±19) days. AE were reported in only 2/17 
(11.8%). 
Conclusions 
Most of the dogs tolerated very well this therapy which seems promising when used as adjuvant to 
conservative surgery. The effectiveness looks comparable to that previously reported with the 
classical radiation/chemotherapy approach. Further prospective trials are needed to determine more 
accurately the impact of this therapy in canine oral melanoma. 
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Introduction  
Few publications have evaluated the prognostic value of hematologic abnormalities at time of 
diagnosis of canine lymphoma. Monocytosis, lymphopenia and neutrophil/lymphocyte ratio >3.5 and 
anemia were identified as negative prognostic factors. Objective of this study was to determine the 
nature and frequency of hematologic abnormalities in newly diagnosed canine lymphoma. In a 
retrospective study the initial CBCs of 226 dogs with confirmed lymphoma were evaluated. 
Materials and Methods  
CBC was performed by an ADVIA™ system, manual differentials were performed, when a numerical 
abnormality exceeded 25% of the respective cut-off and/or scattergram abnormalities were present. 
Results  
69% of the patients showed monocytosis (>0.5x103/µl), 56.6% an N:L ratio >3.5, 44.7% a leukocytosis 
(>15x103/µl), 39.4% neutrophilia (>11.25x103/µl), 37.2% combined leukocytosis and neutrophilia. 
22.6% were anemic (Hct<37%, RBC<5.5x106/µl, Hgb<12g/dL). Lymphocytosis (>4.5x103/µl) occurred 
in 15.9%, leukocyosis combined with lymphocytosis in 15%. Leukopenia (<6x103/µl) was seen in 
10.2%. The frequency of neutropenia (<3.3x103/µl) was 8.4%, 7.1% for thrombocytosis (>500x103/µl) 
and lymphopenia (<0.78x103/µl) in 4.9%. PLT counts were available in 168 patients and 25.5% 
showed thrombocytopenia (<150x103/µl). In 116 patients differentiation into B and T-cell lymphoma 
was performed. T-cell lymphoma patients had a higher frequency of leukopenia (16.7%) and 
neutropenia (19%) whereas B-cell lymphoma patients showed leukocytosis (43.8%). Anemia was 
more often recorded in B-cell lymphomas (Hgb<12g/dL in 32.6%). 
Conclusions 
In this cohort monocytosis and a high N:L ratio were present in more than 50% of cases. Their 
significance in terms of prognosis in canine lymphoma has to be investigated as well as the 
differences encountered between B- and T-cell lymphoma. 
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Introduction  
The c-Kit is a tyrosine kinase receptor, which aberrant activation is implicated in a variety of tumors. 
Although c-Kit activity is critical to melanocyte development and migration, its expression tends to be 
lost in most melanomas, mainly in the invasive and metastatic types. This study aimed to analyze the  
c-Kit protein expression in melanotic and amelanotic melanomas from oral cavity of dogs. 
Materials and Methods  
A total of 34 melanomas were collected, being 19 melanotic and 15 amelanotic specimens. All 
samples were immunostained for Melan-A, HMB45, and c-kit (Dako, rabbit antibody). Number of 
positive cells were randomly counted. 
Results  
Amelanotic melanomas grew faster and presented a higher incidence of metastasis. The epithelioid 
melanoma was the most common morphologic type among the melanotic melanomas, but among 
amelanotic melanomas, the same number of epithelioid and spindle types were obtained. The results 
have shown a greater number of c-Kit positive cells in amelanotic tumors and a predominant 
cytoplasmic location of c-Kit in melanotic tumors. The intensity of c-Kit immunolabeling was mostly 
moderate in melanotic melanomas and mostly strong in amelanotic melanomas. 
Conclusions 
These results indicate a potential role for c-Kit in the canine oral melanomas with clear differences in 
expression and location patterns between the two histological types of the tumor – melanotic and 
amelanotic. This study highlights the importance of a detailed study of c-Kit mutations in canine oral 
melanoma to better understand the molecular mechanisms implicated in the development of this 
disease, permitting a more functional classification of the patients into potential therapeutic classes. 
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Introduction  
The use of various evaluation scales helps prevent complications associated with the tumor or tumor 
therapy and / or to implement targeted therapeutic adjustments to improve the quality of life of the 
cancer patient. The objective of this study was to evaluate the implementation and subsequent use 
of information obtained about quality of life in cancer patients initiating chemotherapy, based on the 
adapted scale Villalobos, AE, Quality of Life Scale helps make the final call. 
Materials and Methods  
The scale was provided to the owners of the patients and they were asked to rate from 1 (worst) to 
10 (excellent) 7 itens on quality of life of his animal, such as: Hurt, Hunger, Hydration, Hygiene, 
Happiness, Mobility, and "More Good Days than Bad. " The values obtained in each plot were 
summed and when more than 35 were considered positive. The sample included 20 patients (canine 
and feline) of both sexes evaluated during the first week after initiation of chemotherapy. 
Results  
All itens showed, in average, positive results (above 5), being “Hygiene” the highest with 8,6. The 
average value for quality of life of the patients was 54, therefore positive (above 35). 
Conclusions 
All itens showed positive results, meaning that all strategies implemented like analgesia protocols 
and more palatable diets helped. 
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Introduction 
Mammary tumours (MT) are the most common type of tumour in female dogs, but little information 
about their incidence in dog population is available. Breast cancer is also one of the most common 
cancers in women and there are some epidemiological and biological similarities between canine and 
human mammary tumours. 
Materials and Methods  
The incidence rate (IR) of MT in female dogs, living in Venice and Vicenza provinces (Northestern 
Italy), during 2005-2013 were calculated as annual rate per 100,000 animals. Tumours were classified 
according to the WHO International histological classification of tumours of domestic animals. Data 
about sex, breed, and age were employed in the determination of the structure of the canine 
population to obtain specific incidence rates. 
Results  
Overall 2744 mammary tumours were reported, accounting for 54% of all tumours in female dogs. 
The annual IR for malignant tumours was 150 (95%CI: 142.12 – 156.67). Keeping in consideration the 
spayed status, the 26% of cases were detected in neutered subjects. The mean age at diagnosis 
resulted significantly higher for neutered dogs (10.09 years) than for entire females (9.20 years). The 
Samoyed, Dobermann, Schnauzer and Yorkshire Terrier dogs resulted to be more incline to develop 
malignant neoplasms than the overall population average. 
Conclusions 
In Veneto region, breast cancer is the most frequent tumour in women, with an IR of 176 new cases 
per 100,000 females. It is worth noting that the IR observed in canine population is similar to that of 
humans, supporting the validity of canine MT as epidemiologic model for human breast cancer. 
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Introduction 
Squamous cell carcinoma is the most common skin tumor in cats affecting animals of all ages, being 
most frequently diagnosed in geriatric and clear coat cats. The clinical presentation can range from 
small superficial to deep infiltrative lesions. Therapeutic approaches include surgery, which may be 
followed by photodynamic (PDT) and/or cryotherapy, depending on the clinical stage at diagnosis. 
Materials and Methods  
The aims of this study were retrospectively evaluation of the clinical outcome, and therapeutic 
response in 32 cases of squamous cell carcinoma diagnosed in cats selected between 2008 and 2013. 
Results  
Of the 32 cases studied, 62.5 % (20/32) had stage 1 at diagnosis, and 37.5 % (12/20) had stage 2. Two 
cases (6.3 %) with regional lymph node metastasis were identified. Twelve out of 32 cases (37.5%) 
were subjected to photodynamic therapy. The median survival time (MST) for the sample studies was 
818 days. Regarding patients submitted to photodynamic therapy, MST was 940 days, a higher result 
compared to those who were not submitted to PDT (MST 744 days). 
Conclusions 
The results should be interpreted cautiously, given the existence of several variables, such as surgical 
margins and different chemotherapy protocols previously used. However, these results reveal the 
relevance of adjuvant therapies, alternative or even neoadjuvant to surgery and its contribution to 
the reduction of relapse. According to our results PDT revealed to be one of the best treatment 
options for cats with squamous cell carcinoma. However further prospective and randomized studies 
are required to confirm our results. 
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Introduction 
The Electrochemotherapy (ECT) is a technique for local control of neoplasm that has been gaining 
ground among the cancer treatments, because of its high rate of objective response to neoplasms of 
various histological types, beyond the simplicity of execution and low toxicity. We reported a case of 
SCC committing wide and deep one of the pelvic limbs of a dog and treated conservatively with 
multiple eletrochemotherapy sessions, resulting in complete remission. 
Materials and Methods  
The formation has 20cm in diameter, on the medial face of the left hind limb, extending from the 
inguinal region to the distal femur portion. Numerous other verrucous lesions, ranging from 0.3 cm 
to 2.5 cm in diameter, presented themselves throughout the abdominal region and extending to the 
medial face of the right hind limb, the region of distal femur. The inguinal lymph node was involved. 
In the begining of the treatment Clinical staging of the patient was T4N3M0. Other clinical signs were 
not observed. Eight ECT sessions were held over a period of 164 days, at intervals ranging 14-37 days. 
In each session, the animal underwent general anesthesia. Biopsies were performed in order to 
confirm the presence of tumor cells prior to the ECT. For this purpose, the technique of cryotomy 
was used. 
Results  
After the ECT sessions, the animal showed complete remission of the disease. Until the writing of this 
paper the animal was disease free, totaling 373 days. 
Conclusions 
The results indicate the potential of ECT as an excellent tool to SCC conservative control of advanced 
clinical stage
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Introduction 
Oxidative status is dependent of balance between oxidants and antioxidant defences. Oxidative 
stress impairs organic function and is associated to cellular senescence and death, and has been 
associated with various feline diseases. The aim of this study was to characterize the oxidative status 
in cats with spontaneous malignant mammary tumours. 
Materials and Methods  
Serum total antioxidant capacity (TAC) and paraoxonase-1 (PON-1) were determined in 20 female 
cats with malignant mammary tumours. Cats with history of previous tumours or with concomitant 
tumours or other diseases were excluded. Information on tumour type, histological grade, size, 
location, ulceration, vascular neoplastic infiltration, necrosis, metastases and survival time from 
diagnosis was assessed. Blood samples were collected before surgery in all cats, and whenever 
possible, serial samples collected on control visits. 
Results  
Studied population included 20 domestic short-haired cats with mammary carcinomas -  solid 
carcinomas (n=10), tubulopapillary carcinomas (n=8), one cribriform carcinoma and one 
carcinosarcoma.  
In the studied population, serum PON-1 ranged from 1.83-5.99 IU/ml, mean 3.72 IU/ml, standard 
deviation 1.07 IU/ml (reference range 3.0-4.3 IU/ml), and serum TAC ranged from 0.0-0.51 mmol/l, 
mean 0.36 mmol/l, standard deviation 0.17 mmol/l (reference range >0.35 mmol/l), at the time of 
surgery. 
The serum concentrations of TAC were significantly associated with presence of tumour ulceration 
(p=0.033) and vascular neoplastic infiltration (p=0.022). Development of thoracic metastases was 
significantly associated with a decrease of serum PON-1 (p=0.021).  
Conclusions 
This study suggests that development of tumour ulceration, vascular infiltration with neoplastic 
trombi and thoracic metastases in cats with malignant mammary tumours are associated with 
oxidative stress.
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Introduction  
Treating the oral as well as the skin malignant melanoma in canine patients is still one of the major 
challanges for veterinary clinicians. 
Materials and Methods  
Altogether 69 oral or skin malignant melanoma bearing dogs were referred into our Institute for 
postsurgical treatments. Treatment groups were: Group I (radiation + medical 22 dogs), Group II 
(radiation 20 dogs), Group III (medical 12 dogs, Group IV (alternatives 15 dogs). Recurrance time, 
survival time, side effects and owner-satisfaction were evaluated by treatment groups. 
Results  
Only 3 dogs were alive two years after initiating the postsurgical treatments all the 3 belong to Group 
I. Four dogs were anaeshtetized because of unrelated reasons and we lost 7 patients during the 
follow-ups. The median progression-free survival and the overall survival time was 495 and 560 days 
in Group I, 445 and 502 days in Group II, 414 and 461 days in Group III, and 128 and 210 days in 
Group IV, respectivelly.  Dogs tolerated well the local irradiations and systemic carboplatin 
treatments. There was only a single case in Group I, where local irradiations must be stopped after 
the 8th fraction because of mucosa ulceration and two further cases both in Group III, because of 
decreasing blood cell numbers and consequtive infections. 
Conclusions 
The median progression-free survival and overall survival time showed significantly lower data in 
Group IV compared to Group I and II but in case of Group III the difference proved to be non-
significant. Neither we could make statistical differences among the data of Groups I, II, and III. 
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Introduction 
Squamous cell carcinoma (SCC) is a common lingual neoplasia in dogs. Although surgical resection is 
recommended, sometimes this surgical treatment is not possible and radiotherapy and/or medical 
treatment could be the only treatment choice. Here we report a case of sublingual SCC that was 
treated with oral metronomic therapy with a very good long term response. 
Materials and Methods  
A 15 year old male mixed-breed dog was presented with a history of hiporexia and halitosis. An 
ulcerated solid sublingual mass was detected in the base of the tongue. Histopathological 
examination of the mass revealed infiltrative SCC. FNA of regional lymph nodes and thorax 
radiograph did not reveal any metastasis. Due to localization and extension of the tumor, surgical 
excision was declined by the owner and metronomic oral therapy (toceranib phophate 2.5 
mg/kg/48h + cyclophosphamide 10 mg/m2/48h + firocoxib 5 mg/kg/24h) was established. 
Results  
Three months after initiating therapy the mass was greatly reduced and there was no ulceration, the 
dog recovered his appetite and had no problems taking food. Currently, more than 1 year after 
diagnosis, the dog is still receiving this oral therapy, and is doing well, no signs of disease are shown. 
As side effects, only two episodes of diarrhoea that were resolved with symptomatic treatment and 
in one occasion with toceranib interruption for 1 week have been observed. 
Conclusions 
Continuous oral metronomic chemotherapy (receptor kinase inhibitor + low dose alkylating agent + 
COX2 inhibitor) can be very effective for treating dogs with oral SCC when surgical excision or 
radiotherapy are not feasible. 
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Introduction  
Feline mammary tumours are the third more common type of feline neoplasia. Conventional 
treatment for cats with mammary tumours is radical mastectomy with or without adjuvant 
doxorubicin, but to our knowledge there is no definitive evidence of clinical benefits of adjuvant 
chemotherapy. We report a case of a cat with a highly malignant mammary tumour treated with 
radical mastectomy plus toceranib phosphate and metronomic chemotherapy.  
Materials and Methods  
A twelve-year-old female cat was presented with multiple nodular lesions around a surgical scar of a 
previous mastectomy of the fourth left mammary gland. There was no evidence of distant metastasis 
on radiological or ultrasound examination. A radical mastectomy was performed and the tissue was 
submitted for anatomopathological examination. Tumour was histologically diagnosed as simple 
tubular-papillary carcinoma grade III with signs of vascular invasion. Three weeks after surgery, once 
the surgical wound was totally healed, the cat started antiangiogenic therapy with toceranib 
phosphate (3.33 mg/kg every 72 hours) and cyclophosphamide (10mg/m2 every 48 hours).  
Results  
After seven months of treatment and twelve months after the first surgery, no haematological 
abnormalities were detected and tolerance to both drugs was excellent. No evidence of local 
recurrence or distant metastasis was noted on the subsequent physical examinations and thoracic 
radiographs.   
 
Conclusions 
In this case, antiangiogenic therapy with toceranib phosphate and cyclophosphamide was a good 
adjuvant option to treat a feline patient after mammary carcinoma resection, resulting in the control 
of the disease with an excellent quality of life for the animal.  
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Introduction  
Electrochemotharapy is an alternative, not invasive treatment to control local neoplasia . It combines 
electroporation (The making of reversible porosity of cell membranes by short electric pulse) and 
chemotherapeutic agent as bleomycin, systemically administered. 
Materials and Methods  
The eyelid carcinoma may have metastatic potential and local invasiveness and &ldquo;en 
bloc&rdquo; excision with surgical reconstruction of eyelid is required. The adverse effects of surgery 
may be epiphora, corneal lesions, hair growth from the upper margin of the skin flap, recurrence of 
neoplasia. 
Results  
A 10 years old male natured cat was referred for lower eyelid mass. Cytological analysis was 
suggestive of medium/high grade carcinoma. The cat was staged with a complete blood cell count, 
serum biochemical profile and Tc totalbody. The neoplasia was treated by ECT in general anesthesia.  
The electric pulses was generated by Ciniporator , IGEA (8 square wave pulses 1000 V/cm for 100µs 
at 5kHz) using linear needle electrodes. The neoplasia  and its lymphnodes was electroporated 10 
minutes after the systemically administration of bleomycin (15 UI/m2). 
Conclusions 
A lower eyelid carcinoma was treated by ECT, without  pain or any complications afterwards.  After 
240 days, the cat continued in total remission with satisfactory cosmetic effect and preservetion of 
palpebral andexas. The ECT is a good alternative method to the surgery. It’ s a not invasive anticancer 
treatment with almost  no side effects and it  preserves the  eyelid and its adnexas
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Introduction  
Hemangiosarcoma (HSA) is a common malignant neoplasm of vascular endothelial cells. Most 
common affected sites are spleen, right atrium, liver, and skin. Bone, kidney, bladder, muscle and 
lung can also be primarily affected. Brain is rarely affected of metastastatic HSA. Intramuscular HSAs 
are characterized by an average survival of 172 days after diagnosis and only 25% dogs lived more 
than 1 year. 
Materials and Methods  
An 8-year-old female, neutered, boxer was presented to our hospital with an, ill defined, fluctuating 
mass at the cervical region with deep intramuscular cervical location. Exploratory surgery evidenced 
a non resectable, deeply infiltrated mass affecting most dorsal cervical muscles. Biopsy report came 
as highly aggressive grade III intramuscular HSA. Clinical stage was T3N0M0. Two courses of modified 
VAC protocol followed by antiangiogenic therapy (masitinib, cyclophosphamide, NSAID) were 
administered as adjuvant treatment. 
Results  
After 106 days of treatment without evidence of metastatic disease in chest radiographs or 
abdominal ultrasound, neurological symptoms were reported by owner. MRI confirmed brain lesions 
highly suggestive of metastatic disease. Dog was euthanized due to rapid deterioration. Necropsy did 
not show evidence of neoplastic disease at cervical region. Two round, friable, well demarcated, 
masses were observed in the cerebral hemispheres. Both lesions corresponded histologically with 
hemangiosarcoma. No other metastatic lesions were observed in the rest of the body. 
Conclusions 
Consecutive treatment with modified VAC protocol followed by antiangiogenic therapy produced a 
complete remission of the primary unresectable hemangiosarcoma and avoided tumor dissemination 
to target organs, without any effect in development of CNS metastasis. 
 
  
ESVONC, Vienna 2014 139 
Multiple hair follicular melanocytoma in a dog 
 
Alejandro Suárez-Bonnet1, Espinosa de los Monteros1, Michael Goldschmidt2, Maria Aguirre1, Oscar 
Quesada-Canales1, Marisa Andrada1, Pedro Herráez1 
 
1
Unit of Histology and Animal Pathology. Veterinary School. University of Las Palmas de Gran CanariaTrasmontańa s/n, 
35415,  
 Arucas, Spain, 
2
Laboratory of Pathology and Toxicology. Department of Pathobiology. University of Pennsylvania. School of Veterinary  
 Medicine, USA 
 
asuarez@becarios.ulpgc.es 
 
Introduction 
Melanocytic neoplasms are commonly diagnosed in dogs. Different classification systems have been 
used for canine melanocytic proliferations. In accordance with the World Health Organization 
classification system (Goldschmidt et al., 1998), the term ‘melanocytoma’ is used to encompass all 
variants of congenital and acquired benign neoplasms arising from melanocytes while ‘melanoma’ is 
used synonymously with malignant melanoma. Melanocytoma can arise from the melanocytes in the 
epidermis, dermis, or adnexa. Follicular melanoma (FM) is a rare, recently and scarcely described 
morphologic variant of melanoma in human beings, and to the author´s knowledge no previous 
reports of similar lesions in domestic animals have been made. 
Materials and Methods  
A 6-year-old, male, not spayed, hound dog was presented in November of 2011 with a pigmented 
plaque of 2.2 x 1.3 cm. The lesion was surgically removed, fixed in 10% buffered formalin, and 
submitted to histopathological analysis. 
Results  
Microscopical examination revealed a melanocytoma affecting deepest parts of multiples hair 
follicles without involvement of the follicular infundibulum nor overlying epidermis. Neoplastic 
melanocytes were well differentiated with an inconspicuous and clear cytoplasm, well defined nuclei 
and formed nest of cells that affect the external root sheath of the hair follicles. Mitotic figures were 
not noted. Immunohistochemical analysis was performed. After two years of follow up the patient 
remains alive and no recurrence of the primary lesion neither metastasis to lymph node or internal 
organs have developed. 
Conclusions 
Based on histological, immunohistochemical and clinical results a diagnosis of multiple hair follicular 
melanocytoma was made. 
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Introduction 
Ectopic thyroid carcinomas have been described in several studies with two main predilection sites 
emerging, the cranial mediastinum and the ventral laryngeal area. Despite surgical resection, in many 
cases these tumors are locally invasive and perioperative morbidity can be high. 
Materials and Methods  
A 10 years old female spayed boxer was referred to our service with a large, rounded, attached mass 
in the thoracic inlet. Respiratory distress and dysphagia was present. No other abnormalities were 
found on physical exam or lab tests. Chest radiographs and abdominal ultrasound showed no 
evidence of metastases. Mass aspiration produced 160 ml fluid, without evidence of malignant cells. 
FNA, tru-cut and surgical biopsies were subsequently taken, being all inconclusive. Iodinated contrast 
injection into the mass did not revealed signs of migration and cavity was well delimitated. Surgical 
resection was performed. Mass was firmly adhered to most cervical structures, but no infiltration 
was present. Surgical margins were invaded by tumor cells at some areas. No signs of vascular 
invasion were detected. Histopathologic diagnosis came as high grade thyroid ACA. 
Results  
Dog was started on metronomic cyclophosphamide (15 mg/kg daily) and meloxycam (0.05 mg/kg 
eod). Six months later owner decided stop therapy. After three months dog was presented with 
respiratory distress.Pleural effusion and significant abnormalities on blood work made owner elect 
euthanasia. Necropsy revealed metastatic disease in several organs. No evidence of recurrence was 
observed. 
Conclusions 
Metronomic therapy with cyclophosphamide and meloxycam showed activity over local control of 
recurrence but no apparent effects on metastasis prevention. 
 
 
 
 
 
  
ESVONC, Vienna 2014 141 
Future ESVONC Congresses 
 
2014 
 
 4 – 6 September ESVONC@ECVIM, Mainz, Germany 
 
2015  
 
 28 – 30 May  ESVONC Annual Congress, Krakow, Poland 
  
 
 
 
 
 
2015 
 
10 – 12 September ESVONC@ECVIM, Lisbon, Portugal 
 
2016  
 
3 - 6  March   3rd World Veterinary Cancer Congress,  Foz do Iguacu Brazil 
 
8-10 September  ESVONC@ECVIM, Gothenborg, Sweden 
   
 
 
  
ESVONC, Vienna 2014 142 
  
ESVONC, Vienna 2014 143 
  
ESVONC, Vienna 2014 144 
 
  
ESVONC, Vienna 2014 145 
 
